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Abstract 
Plasma Produced Reactive Oxygen and Nitrogen Species in Angiogenesis 
Krishna Priya Arjunan 
Alisa Morss Clyne, Ph.D. 
 
 
 
Angiogenesis, the growth of new blood vessels from existing vessels, plays a key 
role in physiological processes including development, growth, and wound healing. 
Insufficient angiogenesis contributes to impaired wound healing in diabetic patients and 
the elderly. Vascularization is also essential for the successful engineering of large, 
complex tissues and organs in vitro. Although successful tissue fabrication of a few 
hundred microns has been achieved, tissue engineering is limited by the inability to 
vascularize constructs to provide nutrients to the tissue core. 
Plasma medicine is a rapidly expanding interdisciplinary field combining 
engineering, physics, biochemistry and life sciences. Plasma, the fourth state of matter, is 
an ionized gas composed of charged particles (electrons, ions), excited atoms and 
molecules, radicals, and UV photons. Non-thermal dielectric barrier discharge (DBD) 
plasma, which primarily produces reactive oxygen species (ROS) has previously been 
used primarily to sterilize tissue and equipment, coagulate blood, or kill bacteria and 
cancerous cells. A nitric oxide (NO) producing pin-to-hole spark discharge (PHD) plasma 
has been reported to sterilize liquids and surfaces, including living tissue. 
Low doses of reactive oxygen and nitrogen species (ROS/RNS) contribute to 
angiogenesis. This study demonstrates the potential of plasma in delivering ROS/RNS 
into liquids and cells for wound or tissue engineering vascularization. ROS produced by a 
DBD plasma penetrated into both treatment liquid as well as into endothelial cells. These 
ROS then enhanced endothelial cell proliferation, migration and tube formation through 
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fibroblast growth factor-2 (FGF-2) release. Specifically, H2O2 and OH· were the primary 
ROS responsible for plasma-induced angiogenesis. In longer term studies, non-thermal 
DBD plasma induced FGF-2 release led to secondary intracellular ROS production, 
enhanced FGF-2 expression and subsequent enhanced FGF-2 release.  In a parallel study, 
a PHD plasma produced NO that enhanced endothelial cell proliferation and migration 
while maintaining cell viability.  
This research improves both our understanding of plasma and ROS/RNS effects 
on endothelial cells, and may facilitate the development of inexpensive, portable, medical 
devices for wound treatment. Thus, this dissertation contributes significantly to vascular 
biology, plasma medicine and health care. 
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CHAPTER 1: INTRODUCTION 
1.1 Thesis overview 
Angiogenesis, the growth of new blood vessels from existing vessels, plays a key 
role in a variety of physiological processes including development, growth, and wound 
healing [1]. Insufficient vascularization contributes to impaired wound healing in several 
disease conditions [2-7]. Non-healing as well as slow healing wounds reduce the quality 
of patient life, and have an enormous financial impact. The global wound care market 
was estimated at US$ 13 billion in the year 2001 with 15% annual growth rate [8]. In 
vitro, vascularization is essential for engineering complex, large tissues and organs such 
as bone, muscle, liver and heart. Although successful tissue fabrication on the scale of a 
few hundred microns has been achieved, tissue engineering is limited by the inability to 
adequately vascularize constructs [9-12]. 
Current therapeutic angiogenesis techniques lack the required clinical efficacy. 
While many angiogenic growth factors including vascular endothelial growth factor 
(VEGF) [13, 14] and fibroblast growth factor-2 (FGF-2) [15, 16] are critical to the 
angiogenic process, their success depends on precise timing, dose, and gradients [17-20]. 
Efforts to apply growth factors either in wounds or in tissue engineered constructs to 
induce angiogenesis have met with limited success [20-22]. Vascularization studies may 
rapidly advance tissue-engineering as well as therapeutic angiogenesis [23, 24]. 
Reactive oxygen species (ROS) and nitric oxide (NO) are known to promote 
vascularization. Several conflicting reports describe pro-and anti-angiogenic ROS effects 
[25-28].  Precise dosing of these species by ROS and NO donors is difficult to achieve 
due to their temperature and pH dependent release kinetics. Electrical plasma discharges 
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produces ROS and NO in air which can diffuse or react with liquid as well as enter the 
cells to generate a physiological response. 
This thesis investigates the potential of electrical plasma in delivering ROS/NO 
into liquids and cells for wound or tissue engineering vascularization. We hypothesize 
that ROS produced by a non-thermal dielectric barrier discharge (DBD) plasma induce 
angiogenesis in a dose-dependent manner via FGF-2 release. This FGF-2 release may 
also induce further intracellular ROS production and FGF-2 expression. We also 
hypothesize that NO produced by a pin-to-hole spark discharge (PHD) plasma induce 
angiogenesis in a dose-dependent manner. In support of these concepts, this thesis 
consists of a series of studies to understand the role of plasma-produced ROS and NO in 
promoting angiogenesis. This will improve both our understanding of plasma-produced 
ROS and NO effects on endothelial cells. These studies may facilitate the development of 
inexpensive, portable, medical devices for wound treatment and tissue-engineering 
application in the future. 
1.2 Clinical Motivation 
1.2.1 Wound healing 
Non-healing wounds are a major clinical issue affecting approximately 3 million 
patients in US alone [8]. Several factors contribute to impaired wound healing including 
malnutrition, old age, presence of foreign particles in the wound, diseases such as 
diabetes and immunosuppressive medications [29]. Available therapeutic wound care 
products include traditional dressings such as gauze, moist and antimicrobial wound 
dressings, as well as  bioactive dressings (chitosan, alginate and hydrogels), topical 
creams, skin substitutes, growth factor therapies and tissue-engineered products [29, 30]. 
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Wound healing is a complex process involving a series of events including blood 
coagulation, inflammation, angiogenesis, extracellular matrix deposition, re-
epithelialization, contraction and remodeling [31].The normal wound healing process can 
be divided into three phases: inflammatory, proliferative and remodeling. The 
inflammatory phase begins with blood coagulation. The blood clot serves as a barrier 
against bacteria, a matrix for invading cells and growth factor storage for long term 
healing process. Phagocytic cells which appear within a few minutes of injury digest the 
damaged tissue and destroy microorganisms. The inflammatory cells also produce 
cytokines and growth factors, which start the proliferative phase of wound healing, 
including angiogenesis. The proliferative phase starts with migration and proliferation of 
keratinocytes, fibroblasts, and endothelial cells at the wound edge into the wound area. 
Fibroblasts deposit extracellular matrix while endothelial cells proliferate to new blood 
vessels.  Granulated tissue is formed within 3-7 days following injury. 48-66% of the 
granulation tissue formed during wound healing is composed of vasculature [32]. It is 
also reported that the capillary density in skin wounds exceeds twice that of uninjured 
normal tissue [33, 34]. During the remodeling phase, wound contraction occurs. Collagen 
is deposited on the granulated tissue by fibroblasts. The newly formed capillaries 
replenish the tissue with oxygen and nutrients. As the wound matures, collagen is cross-
linked and organized into a scar. 
1.2.2 Ischemia 
Inadequate blood supply leads to several diseases such as ischemic heart disease 
(IHD), peripheral vascular diseases (PVD), stroke, neuropathy and restenosis. IHD is the 
leading cause of mortality in the United States. Approximately 20% of adults over the 
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age of 55 have peripheral artery diseases (PAD) [35] and the risk of losing a limb due to 
PAD increases with age.  In United States alone, about 10 million people suffer from 
PAD [36]. Some conventional treatments includes medical management, coronary and 
peripheral artery bypass surgery, percutaneous coronary intervention and percutaneous 
transluminal angioplasty (PTA) and stent placement. Unfortunately, a significant number 
of patients are not suitable for these treatments due to comorbidities such as cancer or 
calcified aorta, lack of available conduits, poor distal vessels and unsuitable anatomy due 
to diffuse arterial disease [37]. The procedures also have drawbacks such as neointimal 
hyperplasia, which is characterized by smooth muscle cell migration from the media into 
the intima. Hence, efforts to utilize angiogenesis or neo-vascularization as a therapeutic 
modality in these diseases are being carried out. 
1.2.3 Vascularization of tissue engineering scaffolds 
The demand for tissue-engineered organs to replace damaged or lost organ or 
organ function is enormous [23, 38]. Tissue fabrication of a few hundred microns in 
thickness has been successfully achieved. However, engineering of large and complex 
tissue structures require adequate nourishment to prevent cell death at the tissue core [9, 
39-41]. Several vascularization approaches have attempted to overcome this limitation 
[24, 42, 43]. One approach is to load the scaffold with growth factors such as FGF-2 and 
VEGF, the success of which depends on precise release timing and dose. Alternatively, 
the vasculature can be built using different fabrication techniques. In a MEMS-related 
approach, channels as narrow as 6 µm or as wide as 50 µm were molded in hydrogels 
using biodegradable microfluidics. 150 µm channels were then molded using needles 
[42] to enable anastomosis with the host vasculature upon implantation. Finally, the 
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vessels themselves were created by seeding endothelial cells in the engineered lumens. A 
vasculature can also be created by implanting scaffolds in vivo and allowing the host 
animal vasculature to infiltrate the scaffold. In a polysurgery technique, multiple layers of 
confluent cell sheets were stacked prior to implantation for vascularization [9]. 
Additional cell sheet layers can be stacked on the already vascularized graft, thus 
enabling engineering of thicker organs. 
1.3 Angiogenesis 
Angiogenesis is the process by which new blood vessels are formed from pre-
existing vasculature. The term angiogenesis was used for the first time in 1787 by a 
British surgeon, John Hunter [44]. Blood vessel formation involves a series of steps, 
including basement membrane degradation by cell secreted proteases and endothelial cell 
migration through the basement membrane. The endothelial cells then align, proliferate, 
and form a lumen [45]. Angiogenesis, which restores blood flow with nutrients and 
oxygen to a tissue, plays a key role in physiological processes such as growth, 
development and wound healing. It is also involved in several pathological processes 
including cancer and metastasis, psoriasis, rheumatoid arthritis, scleroderma, neovascular 
glaucoma and diabetic retinopathy. Angiogenesis is tightly controlled by a balance of 
pro- and anti-angiogenic regulatory molecules. Pro-angiogenic factors include growth 
factors such as VEGF and FGF-2 [17, 46]. These growth factors promote endothelial cell 
proliferation, migration, and tube formation in vitro and in vivo. Anti-angiogenic factors, 
such as the plasminogen fragment angiostatin and the collagen XVIII fragment 
endostatin, occur naturally to prevent excess vessel growth [47]. The extracellular matrix 
provides a balance of pro- and anti-angiogenic factors. As it breaks down, the matrix 
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releases growth factors that were bound to heparan sulfate proteoglycans. Concurrently, 
matrix protein fragments inhibit angiogenesis. This balance prevents angiogenesis from 
proceeding unchecked. 
1.3.1 Reactive species 
ROS as well as NO are known to play a major role in angiogenesis. Low ROS 
doses may act as second messengers in angiogenic signal transduction pathways, while 
NO regulates the activity of pro-angiogenic cytokines such as VEGF. ROS and NO dose 
is critical to determining their cellular response [48]. Low ROS/RNS doses may increase 
endothelial cell migration and proliferation through pro-angiogenic factor production [49-
51], while high ROS/RNS doses damage critical cellular components such as DNA, lipids 
and proteins leading to cell death [52-54]. Several conflicting reports describe pro-and 
anti-angiogenic effects of ROS and RNS in wound healing [25-28]. 
ROS are produced at the wound site to prevent wound infection, and they are 
required for initiating wound healing processes [55], especially angiogenesis [25]. At the 
same time, excessive ROS production or their impaired detoxification causes oxidative 
stress, which leads to chronic, non-healing wounds [56]. In wounds, leukocytes which 
appear within a few minutes of injury digest the damaged tissue and destroy the 
microorganisms via hydrogen peroxide (H2O2) and superoxide (O2
-
) release, which is 
referred to as “respiratory burst”. The NADPH oxidase enzymes, both phagocytic 
(PHOX) and non-phagocytic (NOX) are responsible for this enhanced ROS production 
[57]. While PHOX produce large ROS concentrations for preventing infection, NOX 
produces sustained low concentrations for intracellular angiogenic signaling. 
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ROS such as O2
-
 and H2O2 are produced in response to receptor activation by 
growth factors, cytokines and hormones [58]. These ROS activate multiple downstream 
signaling pathways such as Akt, MAPK, Src and eNOS leading to survival, proliferation 
and migration of endothelial cells [59-61]. ROS induces reversible protein oxidations. 
ROS play an important role in receptor tyrosine kinase (RTK) phosphorylation. They 
cause reversible inhibition of protein tyrosine phosphatases (PTPs) that negatively 
regulate RTKs, thus enhancing receptor autophosphorylation activating downstream 
signaling (Figure 1). Several studies have shown that H2O2 modulates protein 
phosphorylation on either serine-threonine or tyrosine residues [62-64] Exogenous H2O2 
has also been shown to mimic growth factors by inducing protein tyrosine 
phosphorylation and MAPK activation [65-67].  Rac 1 activation increases ROS to 
decrease cell-cell adhesion and promote cytoskeletal reorganization required for 
endothelial cell migration [68, 69]. Low ROS concentrations also induce transcription 
factors such as Ets-1 required for endothelial cell proliferation and tube formation [70]. 
Other transcription factors activated by low ROS concentrations include NF-κB, HIF-1α 
and AP-1 [71-73]. 
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Figure 1: Signaling pathways regulated by NADPH oxidase-derived ROS leading to angiogenesis. 
Growth factor binds to its receptor leading to translocation of GTPase Rac 1 into plasma membrane, 
stimulating ROS production by NADPH oxidases. These ROS inactivate negatively regulating 
protein tyrosine phosphatases (PTP-SH→PTP-SOH) enhancing receptor autophosphorylation. 
Multiple signaling pathways leading to angiogenesis are activated. 
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While the majority of NO synthesis takes place during the inflammatory phase of 
wound healing [74], lack of NO results in impaired wound angiogenesis in the 
proliferative phase. NO-mediated angiogenesis occurs through both cGMP-independent 
and cGMP-dependent pathways [75-77] as shown in Figure 2. The cGMP independent 
pathway is triggered through S-nitrosylation. NO acts on thiol (-SH) residues in protein 
kinases, G-proteins and phosphatases to produce S-nitrosothiol (SNO), which acts as a 
signaling molecule. SNO can occur through different mechanisms: by interacting directly 
with reduced thiol (RSH) to form a radical intermediate (RSNOH) followed by electron 
abstraction to form RSNO; through interaction with oxidants such as superoxide to form 
higher oxides of NO (NOx), such as nitrogen dioxide and peroxynitrite, followed by 
RSNO formation; or through metal centers via catalysis or formation of nitrosonium ion 
(NO
+
). S-nitrosylation of the protein Ras by NO leads to activation of kinases, Raf-1, 
MEK1 and ERK 1/2, which increase endothelial cell proliferation and migration [78]. Of 
the three PKC isoenzymes, NO activates or inhibits PKCα and PKCδ through S-
nitrosylation in a concentration dependent manner [26]. A low NO concentration 
activates PKCα while inhibiting PKCδ to enhance cell migration and proliferation [26, 
79]. 
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Figure 2: NO-mediated angiogenesis through cGMP independent and cGMP dependent pathways 
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Another major pathway in NO-mediated angiogenesis is the sGC- cGMP 
pathway. NO activates sGC by binding to its heme iron and increases the cGMP 
synthesis from GTP. This increased cGMP production activates cGMP-dependent protein 
kinases (PKG), which activate phosphoinositide-3-kinase (PI3K) and Raf-1, leading to 
Akt [80] and ERK 1/2 activation [78], respectively. This downstream PKG signaling 
results in enhanced endothelial cell proliferation and migration. cGMP may also activate 
Ras [78], and PKG forms a complex with Raf-1 leading to downstream ERK 1/2 
activation [80]. 
In chronic wounds, a high ROS concentration, mainly superoxide, may interact 
with NO and reduce its bioavailability, which in turn could lead to impaired 
angiogenesis. High ROS and NO concentrations over a long time period could exhaust 
the antioxidant mechanism and lead to toxic byproduct accumulation in the wound. 
Hence, a balance between ROS and bioavailable NO, both in terms of timing and levels, 
may be critical in wound healing [81]. 
1.3.2 Fibroblast growth factor-2 
Fibroblast growth factor-2 (FGF-2), also known as basic fibroblast growth factor 
(bFGF), was first identified as a 146-amino acid protein solated from the pituitary [82]. 
FGF-2 binds to extracellular matrix heparan sulfate proteoglycans (HSPG) such as 
perlecan, which act as long term storage sites [83, 84]. HSPGs also regulate growth factor 
bioavailability. FGF-2 binds to cells via both the low-affinity HSPGs as well as high 
affinity tyrosine kinase cell surface receptors. FGF-2 binding to FGF receptors causes 
receptor dimerization and autophosphorylation leading to complex signal transduction 
pathways. Soluble and cell-associated HSPGs play an important role in regulating the 
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FGF2/FGFR interaction, since HSPG/FGF2/FGFR complex formation is necessary for 
FGFR activation and further downstream signaling. [85]. 
FGF-2 is associated with cell survival, proliferation, migration and differentiation 
[86-88]. FGF-2 induces an angiogenic phenotype by triggering extracellular matrix 
degradation through urokinase plasminogen activator (uPA) and matrix metalloproteinase 
(MMP) upregulation [89]. FGF-2 also enhances β-integrin and cadherin expression to 
regulate cell-cell and cell-substrate adhesions required for vessel maturation into 
capillary-like structures with a lumen [90-93]. Both low (18.8 kDa) and high molecular 
weight (24 kDa) FGF-2 isoforms induce neovascularization in vitro and in vivo [94]. 
FGF-2 is particularly interesting because it does not have a recognized signal 
sequence for secretion. FGF-2 is released by injured cells, whether the injury is by 
ionizing radiation, pulsed electromagnetic field, mechanical forces, or elevated glucose 
[95-99]. FGF-2 released during cell injury promotes cell survival and also increases FGF-
2 expression in endothelial cells, smooth muscle cells and cardiac myocytes (Figure 3) 
[100-104]. Thus, cells that have suffered an injury prepare themselves against subsequent 
injuries by synthesizing additional FGF-2. FGF-2 may also induce expression of other 
angiogenic growth factors, such as VEGF, in endothelial cells [105]. 
 
Figure 3: FGF-2 induces its own expression. 
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1.3.3 Therapeutic angiogenesis 
Therapeutic angiogenesis, otherwise known as pro-angiogenic therapy, refers to 
clinical promotion of collateral blood vessel growth in ischemic tissue.  Several 
angiogenic growth factors and gene therapies are currently used in clinical trials. 
According to Kastrup, an optimal growth factor therapy should be able to locally 
accumulate or stimulate growth factor production at a therapeutic concentration for the 
required time period with minimal effects on non-targeted tissue [106]. Three approaches 
are currently used to deliver growth factors to achieve therapeutic angiogenesis: protein, 
gene and cell-based therapy. 
1.3.3.1 Protein therapy 
Angiogenic factors such as FGF-2, VEGF, Scatter factor/ Hepatocyte growth 
factor (SF/HGF), Angiopoietin-1/2 (Ang-1/Ang-2) and acidic FGF (aFGF) have been 
tested widely in animal models. A single intra-arterial bolus of 500-1000 µg VEGF led to 
significant collateral blood vessel development in a rabbit ischemic hind limb model 
[107].  aFGF and bFGF also promoted revascularization in persistent ischemia model 
[108, 109]. Combined VEGF and bFGF stimulated more and faster collateral 
development than either angiogenic factor acting alone [110]. Protein therapy advantages 
include finite temporal exposure, defined dose response, repeated administration, 
multiple growth factor combinations, and absence of inflammatory response [22, 111]. 
Successful animal studies encouraged using these growth factors in clinical trials. 
Preliminary clinical studies using heparin-alginate microcapsules for slow FGF2 release 
in patients undergoing coronary artery bypass grafting proved safe and technically 
feasible [112]. While a phase I study with intracoronary rhVEGF infusion showed 
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tolerance up to 0.050 µg/kg/min [113], the phase II double-blind, placebo-controlled 
study (VIVA) failed to show any improvement over placebo [114]. Phase I study with 
intracoronary rhFGF administration also proved to be safe [115], but the results of a 
phase II clinical trial (FIRST) were disappointing [116]. A major drawback of protein 
therapy is the short serum and tissue half-life of the growth factors, and hence the need 
for repeated and high dose administration. 
1.3.3.2 Gene therapy 
Gene therapy overcomes the problem of angiogenic protein instability by enabling 
sustained local angiogenic factor production. Gene therapy involves the insertion of 
genes encoding the growth factor into a patient’s cells with a viral vector. The cells then 
produce the angiogenic factor that promote angiogenesis. Gene transfer with plasmid 
DNA as well as adenoviral vectors has been used. An adenovirus vector expressing 
VEGF121cDNA induced collateral blood vessel development and increased myocardial 
function in a porcine ischemic myocardium model [117]. Similar success was achieved 
with HGF transfection into infarcted rat myocardium [118]. While VEGF165 transfection 
into the infarcted rat myocardium showed induced angiogenesis [119], the newly formed 
blood vessels were in hemangiomas, and no improvement in the regional flow was 
observed. Arterial VEGF165 transfer into the ischemic limb of a 71 year old patient 
improved blood supply [120], but also led to spider angioma and edema. However, a 
clinical trial involving VEGF gene transfer during angioplasty and stenting showed 
significant increase in myocardial infusion with no adverse effects [121]. Potential 
drawbacks of gene therapy include inconsistent gene expression levels, potential non-
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targeted cell delivery, foreign genetic material introduction and inflammatory responses, 
single administration, and unpredictable tissue half-life [22, 111]. 
1.3.3.3 Cell-based therapy 
Cell-based therapy is a relatively new approach which uses autologous cells that 
produce angiogenic growth factors to promote angiogenesis in ischemic tissue. This 
eliminates problems associated with introduction of foreign genetic material with gene 
transfer. Several cell types such as endothelial progenitor cells and marrow stromal cells 
are used. Successful cell-based therapy has been reported in animal studies as well as 
early clinical trials. Significant neointimal hyperplasia inhibition and rapid denuded 
arteries and prosthetic graft re-endothelialization were observed in a rabbit model with 
autologous endothelial progenitor cell implantation [122]. A clinical trial involving 
catheter-based intramyocardial implantation of autologous mononuclear bone marrow 
cells in patients with severe ischemia showed significant improvement over placebo in 
myocardial perfusion 3 months following the procedure [123]. The use of a catheter for 
delivering the cells eliminated complications associated with open heart surgery. A 
significant increase in transcutaneous oxygen pressure and decrease in pain was observed 
in patients with leg ischemia after intramuscular bone marrow–derived mononuclear cell 
injection [124]. Cell-based therapy has several limitations such as low cell survival rate, 
lack of techniques to track the implanted cells in clinical studies and poor understanding 
of the mechanism by which the cells improve ischemic condition. 
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1.4 Plasma Medicine 
1.4.1 Plasma 
Plasma, referred to as the fourth state of matter, is an ionized gas composed of 
charged particles (electrons, ions), excited atoms, molecules, radicals, and UV photons. 
Irving Langmuir first used the word “plasma” in 1928 to describe ionized gas “containing 
balanced charges of ions and electrons” [125]. Common naturally occurring plasmas are 
lightning, Aurora Borealis and the ionosphere. Man-made plasmas are widely used in 
applications such as plasma television, ozone production, synthetic fabric treatment, 
lasers, fluorescent lamps, electronics such as cell phones and computers, thermonuclear 
synthesis, protective coating for aircrafts and medicine [126-128]. An important plasma 
feature is its ability to produce a high concentration of chemically active energetic 
species which can be far from thermodynamic equilibrium, thus keeping the bulk plasma 
temperature close to room temperature. 
Plasmas are classified into thermal and non-thermal plasmas. The electric field 
transfers energy to electrons, which then collide with heavy particles to transfer a small 
portion of this energy. The electron temperature (Te) is initially higher (~11,000 K) than 
the gas temperature (Tg), i.e. Te>Tg. Given sufficient time in the absence of a cooling 
mechanism, collisions between electrons and heavy particles eventually cause the 
temperatures to reach equilibrium (Te = Tg). This quasi-equilibrium plasma is referred to 
as thermal plasma. Plasma in which the electron temperature is significantly higher than 
gas temperature (Te>>Tg) is called non-thermal plasma. In non-thermal plasmas, the gas 
temperature remains close to room temperature and therefore can be used to treat surfaces 
and tissues without causing measurable changes to surrounding areas. Non-thermal 
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plasmas can be generated at low or atmospheric pressure or in different kinds of pulsed 
discharge systems. 
1.4.2 Non-thermal dielectric barrier discharge plasma 
Non-thermal plasma devices, specifically dielectric barrier discharge (DBD) 
plasma, are used extensively in medicine due to their selectivity, portability, scalability, 
ease of operation, and low manufacturing and maintenance costs. DBD plasma is 
generated at atmospheric pressure in air when short duration, high voltage pulses are 
applied between two electrodes, with one electrode being insulated to prevent an increase 
in current [129, 130]. While high temperature electrons interact with gas molecules to 
create reactive species, since the overall gas temperature in a non-thermal plasma remains 
close to room temperature, it can be applied directly to cells and tissue without 
measurable damage [131]. Depending on the applied voltage, dielectric material and 
interelectrode distance, the DBD plasma characteristics in air vary, including electron 
density, reduced electric field, gas temperature, and active species concentration [130]. 
For living tissue treatment, a floating electrode DBD (FE-DBD) is employed where an 
insulated high voltage electrode acts as one electrode while the live tissue acts as the 
second electrode [132]. Non-thermal DBD plasma produces a variety of biologically 
active reactive species, in particular reactive oxygen species [130]. Non-thermal DBD 
plasma has a g-factor (ROS generated per electron volt or eV) between 0.3 and 0.5 [133]. 
Thus, for every plasma dose of 1 J/cm
2
, 1.88 – 3.13 × 1016 ROS are produced in gas 
phase. 
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1.4.3 Pin-to-hole spark discharge plasma 
Thermal plasmas are used in medicine for cauterization and as “plasma scalpels” 
that section tissue with instantaneous blood coagulation [134]. NO treatment from 
thermal plasmas has previously been shown to enhance wound and skin disease 
treatment. The ‘Plazon’ system, a rapidly quenched hot air plasma jet, can provide a 
relatively high NO concentration with a significant therapeutic effect [135-137]. This 
plasma device was used in two modes. In ‘hot mode’, the plasma jet was used to rapidly 
coagulate and sterilize wound surfaces, as well as to remove, dissect or desiccate dead 
tissue and pathologic growths. In ‘cold mode’, the NO-rich plasma gas flow (20–40 °C) 
was used to stimulate regenerative processes and wound healing. Additional NO plasma 
sources include a pulsed arc discharge, a high frequency discharge and an atmospheric 
pressure plasma jet [138-140]. An alternative NO-producing plasma, a pin-to-hole spark 
discharge (PHD), has also been reported to sterilize liquids and surfaces (including living 
tissue) and may stimulate wound healing [141-146]. The advantages of this plasma 
include that it is small and portable, uses a low-voltage power supply, operates in room 
air, can be applied directly to tissue without measurable damage and can deliver both 
ROS (e.g. hydrogen peroxide [147, 148]) and UV radiation [149]. However, this spark 
discharge and its cellular effects have never been characterized. 
1.4.4 Clinical applications of plasma 
Thermal plasmas such as the argon plasma coagulator have been widely used for 
blood coagulation as well as for pathological tissue removal [150-154]. However, high 
thermal plasma operating temperatures cause significant damage to the surrounding 
healthy tissue. In recent years, non-thermal plasma has emerged as a novel technology for 
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medical applications. Since gas temperature remains close to room temperature, these 
plasmas can be applied directly to cells and tissue without measurable damage [131]. 
Non-thermal plasma has primarily been used to coagulate blood, sterilize tissue and 
equipment, or kill bacteria and cancerous cells [132, 137, 155-159]. While non-thermal 
plasma research initially focused on plasma’s preventive effects, it was recently showed 
that an atmospheric pressure non-thermal dielectric barrier discharge (DBD) plasma 
promoted angiogenesis in vitro [133]. 
1.4.4.1 Blood coagulation 
Blood coagulation is required to establish hemostasis after injury. On an average 
it takes 5 minutes for a blood clot to occur in a healthy person, according to the Ivy 
method [160]. Non-thermal FE-DBD plasma promoted blood coagulation without 
causing any histological tissue damage [132, 161]. A blood clot was formed within 5 
seconds of treatment due to plasma enhancement of the natural blood clotting process. 
Recently, a portable handheld air plasma torch (APT) coagulated blood with 12 seconds 
of treatment [156]. This enhanced blood coagulation was attributed to reactive atomic 
oxygen (RAO) in APT. Further research is needed to establish the efficacy of FE-DBD 
and APT in treating bleeding disorders. 
1.4.4.2 Wound sterilization  
Both acute and chronic wounds, including surgical wounds, diabetic ulcers, and 
burns are prone to bacterial infection. Current wound treatment protocols involve 
expensive wound dressings or antibacterial ointments that do not deliver clinically 
significant results [162, 163].  Non-thermal plasma sterilizes wounds against diverse 
pathogens. Complete sterilization of 10
9
 cfu/ml skin flora on human skin samples was 
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achieved with 15 seconds of FE-DBD plasma treatment [132, 164]. A low pressure 
atmospheric pressure plasma torch, MicroPlaSter® caused a 6-log reduction in 
Escherichia coli bacterial concentration following 2 minutes treatment [165]. Non-
thermal plasma treatment could be a good alternative to current topical treatments. 
1.4.4.3 Medical equipment sterilization 
Medical equipment sterilization is typically achieved through thermal techniques 
(autoclave). A common method for thermolabile equipment sterilization is toxic gases 
such as ethylene oxide, ozone or chlorine, which are hazardous to the environment. UV 
radiation and chemically active neutral species such as N2 and O2 from a low-pressure 
glow discharge plasma effectively sterilized Bacillus subtilis spores on metal and glass 
surfaces [155]. For 3 × 10
-3
 W/cm
3
 input power density, UV radiation from plasma 
caused a 7-log (complete) reduction in spore concentration. Therefore, plasma could be 
used to effectively sterilize medical equipment. 
1.4.4.4 Wound healing 
Insufficient vascularization contributes to impaired wound healing in patients 
with diabetes [2], and systemic sclerosis [3], the elderly [4], and patients treated with 
immunosuppressive drugs [5], chemotherapy [6] and radiotherapy [7]. Non-thermal FE-
DBD plasma increases porcine aortic endothelial cell (PAEC) proliferation 2-fold 
compared to control samples 5 days following treatment with a low dose of 3.9 J/cm
2
 
[133]. A 2-fold increase in MCF10A mammalian breast epithelial cells was also achieved 
3 days after low dose (0.19 J/cm
2
) FE-DBD plasma treatment [166]. Both cases report 
ROS as the major factor responsible for enhanced cell proliferation. Since different cell 
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types are involved in wound healing, a plasma treatment dose for optimum wound 
healing needs to be identified. 
1.4.4.5 Dental cavity treatment 
In dentistry, cavities need to be cleaned and sterilized prior to filling. This is 
usually accomplished by mechanical drilling, ultrasonic or laser treatment, which causes 
great discomfort and pain to patients [167]. Non-thermal atmospheric pressure plasma 
offers a less painful and less destructive alternative to the conventional techniques. An 
atmospheric pressure plasma needle sterilized 90% of the bacteria with 39 seconds of 
treatment for a plasma voltage 120 mV, without causing significant heating of the dental 
pulp [157]. 
1.4.4.6 Cancer therapy 
Non-thermal atmospheric pressure DBD plasma at high doses has been shown to 
induce apoptosis in melanoma cancer cells in vitro [158]. Reactive oxygen species 
produced by DBD plasma are the major mechanism, causing significant DNA damage 
leading to apoptosis. In another study, FE-DBD plasma caused a 56% decrease in tumor 
volume of human U87 malignant gliomaxenografts in mice [168]. In both cases, non-
malignant cells were undamaged. These results indicate that non-thermal plasma can be 
used to selectively treat cancer cells. 
1.4.4.7 Skin diseases 
Non-thermal FE-DBD plasma is effective in treating skin diseases as well. 
Cutaneous Leishmaniasis, a parasitic disease caused by the Leishmania parasite and 
transmitted through sand fly bites, affects the skin and the mucous membrane. It is 
reported largely in military personnel returning from Persian Gulf. The sand fly injects 
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the infective promastigote into the host where it is phagocytized by macrophages and 
transform into amastigotes, which multiply and affect different tissues. Following FE-
DBD plasma treatment, 100% promastigote inactivation was achieved with only 20% of 
the macrophages inactivated [169]. 
1.4.4.8 Cell transfection 
Gene transfection into target cells via viral vectors forms the basis of gene 
therapy. A disadvantage of this method is complications arising from the virus-mediated 
adverse host responses. Temporary cell permeabilization to foreign materials may also 
benefit drug delivery processes. HeLa cell treatment with a non-thermal atmospheric 
pressure glow discharge torch (APGD-t) created pores in the cell membrane with a radius 
between 4.8 nm – 6.5 nm [170]. Two proposed mechanisms for pore creation were cell 
charging and lipid peroxidation by OH radicals. A transfection efficiency of up to 35% 
was observed with hrGFP-II-1 plasmids 24 hours after APGD-t treatment. Another group 
reported plasmid DNA introduction into HeLa-S3, HT-1080, MCF-7, SH-SY5Y and 
Jurkat cells following 1-3 seconds of exposure with an electric pulse-activated gas plasma 
generator [171]. A maximum transfection efficiency of 18.3 ± 3.4% was obtained for 0.5 
µg/µl DNA with 3 seconds of plasma exposure. 
1.4.4.9 Scaffold treatment 
Tissue engineering scaffolds are surface treated to improve cell-scaffold 
interaction at the early stage of tissue engineering. Non-thermal DBD plasma improved 
adhesion and enhanced proliferation of mouse osteoblasts on poly (ε-caprolactone) 
(PCL), a biocompatible polyester that has great potential in drug delivery and tissue 
engineering applications. This was attributed to decreased hydrophobicity as well as 
increased PCL solid surface energy and surface roughness by the oxygen-based DBD 
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plasma treatment [159]. 5 min plasma treatment caused a 90% increase in cell 
proliferation compared to untreated PCL samples. Plasma physically and chemically 
modified the polymer surface without changing the bulk polymer properties. 
1.5 Biologically relevant reactive oxygen and nitrogen species 
1.5.1 Reactive oxygen species (ROS) 
ROS are highly reactive molecules or free radicals derived from molecular 
oxygen (O2) (Figure 4). Oxygen reduction by two electrons forms H2O2, while the OH· 
radical is produced by tri-electron reduction of O2. O2
-
 is formed by adding one electron 
to O2, and O2(
1Δg) is the electronically excited state of O2 ((
3Σg
-
) 
3
O2) when the two 
unpaired electrons adopt antiparallel spins and occupy the same orbital thus creating an 
opportunity to accept electrons of either spin. 
 
Figure 4: Production of biologically relevant ROS/RNS 
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In cells, most ROS are formed as by-products of mitochondrial electron transport 
(Figure 4). Physiologic ROS levels can increase endothelial cell permeability, cell 
adhesion molecule surface expression, and cause endothelial cell dependent and 
independent vasodilation [172]. ROS may also enhance growth factor affinity to their 
receptors to initiate the angiogenesis signaling cascade [81]. The role of ROS in a 
multitude of pathologies, such as radiation injury, carcinogenesis, ischemia-reperfusion, 
atherosclerosis, neurodegenerative diseases and diabetic vascular disease, has been 
studied over the past few decades [53, 173]. In diabetic patients, elevated blood sugar 
leads to excess cellular ROS production [52, 174]. High ROS levels damage critical 
cellular components such as lipids, proteins and DNA leading to cell death [173]. 
Relevant ROS, their production inside cells and in plasma discharge, and their key 
biological roles are detailed below. 
1.5.1.1 Superoxide (O2
-
) 
In cells, the mitochondrial oxidation-reduction system generates superoxide (O2
-
). 
Specifically, enzymes such as NADH/NADPH oxidase (Nox), xanthine oxidase, 
lipooxygenase, mitochondrial oxidase and cyclooxygenase reduce molecular O2 during 
oxidative phosphorylation for ATP generation [175], as shown in Equation 1. 
Approximately 2% of the O2 reduced by mitochondria is converted into O2
-
. O2
- 
is also 
generated in vivo by phagocytic cells such as macrophages, monocytes, neutrophils, and 
eosinophils in response to presence of foreign bodies such as bacteria [176]. 
     
      
   (1) 
 
In atmospheric pressure DBD plasma, O2
-
 is produced when free electrons 
accelerated by high electric field ionize O2: 
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        (M – third body particle) (2) 
 
Due to its negative charge, O2
-
 cannot readily cross biological membranes. 
However, aqueous O2
-
 at low pH forms hydroperoxyl radical (HO2∙), which can enter the 
cell easily. Superoxide is removed from cells by a spontaneous dismutation reaction, 
shown in Equation 3, during which one O2
-
 gets converted to molecular oxygen while a 
second O2
-
 is converted to hydrogen peroxide (H2O2). The reaction rate constant is 8 × 
10
4
 M
-1
sec
-1
, and the reaction proceeds four orders of magnitude faster in the presence of 
the enzyme superoxide dismutase [177, 178]. 
  
      
                   (3) 
 
1.5.1.2 Hydrogen peroxide (H2O2) 
H2O2 is mainly produced by O2
-
 dismutation. It is also directly produced by 
several enzymes such as monoamine oxidases and glycolate [179]. H2O2 is a stable and 
long living species since there are no unpaired electrons present. Due to their small size 
and neutral charge, H2O2 molecules freely dissolve in solution and readily diffuse into 
cells through cell membrane aquaporins [180, 181]. 
In non-thermal plasma, hydroxyl radicals combine to form H2O2: 
               (4) 
 
At low concentrations, H2O2 takes part in intracellular signaling [182-186] while 
at concentrations, H2O2 is associated with DNA, lipid and protein damage [173, 179]. 
Hydrogen peroxide concentrations below 20 – 50 µM are considered to be less toxic to 
human cells [179]. The deleterious effect of H2O2 is attributed to its conversion into OH∙ 
radical. In the presence of iron or copper ions, H2O2 reacts with O2
-∙ to produce highly 
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reactive OH∙ as shown in Equation 5. Ultraviolet radiation also converts H2O2 into OH∙ 
radicals by homolytic fission of the O-O bond (Equation 6). 
  
       
             
→                       (5) 
    
  
→       (6) 
 
Two major intracellular H2O2 scavengers are glutathione peroxidase (GSH-Px) 
and catalase. GSH-Px removes H2O2 by oxidizing reduced glutathione (GSH) into 
glutathione disulfide (GS-SG) as shown in Equation 7. Catalase decomposes H2O2 into 
H2O and O2 (Equation 8) 
                       (7) 
                 (8) 
 
1.5.1.3 Hydroxyl radical (OH∙) 
Hydroxyl radicals are the most reactive of all ROS even though they have a short 
half-life [187]. OH∙ is formed in biological systems from H2O2, as described earlier in 
Equations 5 and 6. 
In plasma, the high electric field accelerates electrons and produces N2
+
 from N2 
(Equation 9). A charge transfer occurs from N2
+
 ions to H2O, and OH∙ radicals are 
produced when H2O
+
 interacts with H2O (Equations 10 and 11). 
           
       (9) 
  
                
  (10) 
   
               
  (11) 
 
Due to its high reactivity, OH∙ reacts non-specifically with any cell component 
(DNA, lipids, proteins, amino acids and sugars) causing loss of cell integrity and function 
[188, 189]. α-tocopherol effectively converts OH∙ by forming stable tocopheroxyl 
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radicals, which are then reduced by ascorbate and NADH/NADPH-dependent reductase 
enzymes into phenol [190]. 
1.5.1.4 Singlet oxygen (O2(
1∆g)) 
Molecular oxygen exists in the triplet state ((
3Σg
-
)
3
O2) with two unpaired electrons 
of parallel spin in separate orbitals. Singlet oxygen is the electronically excited state of 
oxygen when these electrons adopt antiparallel spins and occupy the same orbital, thus 
opening an opportunity to accept electrons of either spin [176]. Singlet oxygen is formed 
in cells by energy transfer from photochemically excited photosensitizers to triplet state 
molecular oxygen or during an inflammatory reaction. O2
-
 produced by NADPH oxidase 
(Equation 12) undergoes dismutation to form H2O2 and O2 (Equation 13). This H2O2 is in 
the singlet state if dismutation is spontaneous rather than catalyzed by superoxide 
dismutase. H2O2 produces hypochlorite in the presence of myeloperoxidase (Equation 14) 
which in turn reacts with H2O2 to yield O2(
1∆g) (Equation 15). 
                
              (12) 
    
                  (13) 
        
            (14) 
        
               (  
 
 ) (15) 
 
Singlet oxygen is produced in plasma by the interaction of highly energetic 
electrons with molecular oxygen. 
        
       (16) 
 
Singlet oxygen both impairs and activates several signaling processes. Singlet 
oxygen generation during inflammation helps fight infection [176]. It also interacts with 
DNA to produce 8-oxo-7,8-dihydro(deoxy)guanosine (8-oxo-(d)G) moieties which 
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trigger DNA repair [176]. At very high O2(
1∆g) concentration, single strand DNA as well 
as double strand breaks occur. Some of the amino acids most sensitive to singlet oxygen 
oxidation are tryptophan, cysteine, methionine and histidine. Cysteine oxidation by 
singlet oxygen inactivates several enzymes including tyrosine phosphatases resulting in 
the activation of signaling pathways such as p38/JNK and NFκB [176, 191, 192]. 
Tryptophan and tyrosine oxidation produces peptides that inhibit caspases, thus 
preventing apoptosis [193]. 
1.5.2 Reactive nitrogen species (RNS) 
1.5.2.1 Nitric oxide (NO), nitrite (NO2), nitrate (NO3
-
), and peroxynitrite (ONOO
-
) 
Nitric oxide (NO) is synthesized intracellularly during the conversion of L-
arginine into L-citrulline in the presence of O2 [194]. NO is a lipophilic free radical which 
is chemically unstable. It has a very short half-life of approximately 10 seconds. NO 
functions as a signaling molecule in a wide range of physiological reactions to maintain 
normal endothelial function and an antithrombotic environment. NO regulates vascular 
tone, endothelial permeability, smooth muscle cell proliferation, platelet aggregation, and 
leukocyte adhesion [195]. NO production in endothelial cells is increased in response to 
mechanical stimuli such as shear stress and cyclic strain; physiological stimuli such as 
acetylcholine and bradykinin; and changes in oxygen tension [196-200]. 
In a thermal plasma, NO is produced by the Zeldovich chain mechanism which 
occurs only at high temperatures (2000 °C). 
          (17) 
          (18) 
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In aqueous solutions, NO is readily converted primarily into nitrite (NO2
-
) [201]. 
Nitrite is formed by reacting NO with molecular oxygen (Equation 19). NO also reacts 
with superoxide by a near diffusion limited reaction [202] to produce peroxynitrite 
(ONOO
-
) when superoxide and NO are in near equimolar ratio (Equation 20). The 
reaction rate of nitric oxide with superoxide is 6 – 10 × 109 M-1sec-1 while the reaction 
rate of superoxide with superoxide dismutase (SOD) is only 2 × 10
9
 M
-1
sec
-1 
[203]. 
Hence, when NO and O2
-
 are produced in equal concentrations, such as in inflammation, 
ONOO
-
 formation occurs instead of O2
-
 scavenging. NO also reacts with oxyhemoglobin 
(HbO2) to form methemoglobin and nitrate (NO3
-
) as shown in Equation 21. 
            
  (19) 
      
           
  (20) 
                 
  (21) 
 
In plasma, NO2 produced by NO and ozone (O3) reacts with H2O to form NO2
-
 
and NO3
-
(Equation 22) 
             (22) 
                           (23) 
 
ONOO
-
 is a highly reactive and highly unstable molecule with a half-life of less 
than 1.9 seconds at pH 7.4 [204]. If oxidative stress does not exhaust the antioxidant 
mechanism inside the cell, ONOO
-
 formation will act as an ROS scavenging mechanism 
to reduce cell oxidative stress. At low concentrations, ONOO
-
 is converted to the 
harmless nitrate ion [81]. But when the ROS concentration is very high, ONOO
-
 will also 
be formed in high concentrations. At high concentrations (>30-50 nM), ONOO
-
 is 
converted into NO2· and OH· (symmetric cleavage) or NO2
+
 and OH
-
 (asymmetric 
cleavage) [81]. These reactive species further contribute to the oxidative as well as 
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nitroxidative stress. Peroxynitrite formation has two important biological consequences: 
loss of bioactive NO and direct cytotoxic effects, which include cell and tissue damage, 
enzyme inactivation, protein modification, and DNA oxidation and breakage [205]. 
When the damage induced by ONOO
-
 is irreparable by cellular repair mechanisms, cells 
will undergo either apoptosis or necrosis [205]. 
1.6  Thesis Organization 
This thesis examines the role of ROS/RNS produced by plasma discharge in 
angiogenesis. The specific aims of this work are 
 Chapter 2: Identify ROS/RNS produced by DBD and PHD plasma in liquids and 
cells. 
 Chapter 3: Determine the angiogenic effects (proliferation, migration, and tube 
formation) of DBD plasma on endothelial cells as well the key plasma ROS 
primarily responsible for these effects. 
 Chapter 4: Quantify the angiogenic effects (proliferation, migration, and tube 
formation) of PHD plasma on endothelial cells. 
 Chapter 5: Investigate the long term effects of plasma released FGF-2 (secondary 
ROS production, FGF-2 expression, and subsequent FGF-2 release) on 
endothelial cells. 
References 
1. Folkman, J., Angiogenesis. Annu. Rev. Med., 2006. 57: p. 1-18. 
 
2. Martin, A., M.R. Komada, and D.C. Sane, Abnormal Angiogenesis in Diabetes 
Mellitus. Medicinal Research Reviews, 2003. 23(2): p. 117-145. 
 
31 
 
3. Mulligan-Kehoe, M.J., et al., Antiangiogenic Plasma Activity in Patients With 
Systemic Sclerosis. Arthritis & Rheumatism, 2007. 56(10): p. 3448-3458. 
 
4. Reed, M.J., et al., Neovascularization in Aged Mice: Delayed Angiogenesis is 
Coincident With Decreases Levels of Transforming Growth Factor Beta1 and 
Type 1 Collagen. Am J Pathol, 1998. 152(1): p. 113-123. 
 
5. Schäfer, M. and S. Werner, Oxidative Stress in Normal and Impaired Wound  
Repair. Pharmacol Res., 2008. 58(2): p. 165-171. 
 
6. Bland, K.I., et al., Experimental and Clinical Observations of the Effects of 
Cytotoxic Chemotherapeutic Drugs on Wound Healing. Ann Surg., 1984. 199(6): 
p. 782-790. 
 
7. Tibbs, M.K., Wound Healing Following Radiation Therapy: A Review. 
Radiotherapy and Oncology, 1997. 42(2): p. 99-106. 
 
8. Market Analysis in Advanced Wound Care Biologics: World Market Analysis 
Chapter 6 Theta Reports August 2002, PJB Medical Publications Inc. 
 
9. Shimizu, T., et al., Polysurgery of Cell Sheet Grafts Overcomes Diffusion Limits 
to Produce Thick, Vascularized Myocardial Tissues. FASEB J., 2006. 20(6): p. 
708-710. 
 
10. Lovett, M., et al., Vascularization Strategies for Tissue Engineering. Tissue Eng 
Part B Rev., 2009. 15(3): p. 353-370. 
 
11. Rouwkema, J., N.C. Rivron, and C.A. vanBlitterswijk, Vascularizaton in Tissue 
Engineering. Trends Biotechnol., 2008. 26(8): p. 434-441. 
 
12. Mikos, A.G., et al., Engineering Complex Tissues. Tissue Eng., 2006. 12(12): p. 
3307-3339. 
 
13. Ferrara, N., H.-P. Gerber, and J. LeCouter, The Biology of VEGF and its 
Receptors. Nat Med, 2003. 9(6): p. 669-676. 
 
32 
 
14. Neufeld, G., et al., Vascular Endothelial Growth Factor (VEGF) and its 
Receptors. The FASEB Journal, 1999. 13(1): p. 9-22. 
 
15. Bikfalvi, A., et al., Biological Roles of Fibroblast Growth Factor-2. Endocrine 
Reviews, 1997. 18(1): p. 26-45. 
 
16. Presta, M., et al., Fibroblast Growth Factor/Fibroblast Growth Factor Receptor 
System in Angiogenesis. Cytokine & Growth Factor Reviews, 2005. 16(2): p. 159-
178. 
 
17. Edelman, E.R., et al., Controlled and Modulated Release of Basic Fibroblast 
Growth Factor. Biomaterials, 1991. 12(7): p. 619-626. 
 
18. Borselli, C., et al., Induction of Directional Sprouting Angiogenesis by Matrix 
Gradients. Journal of Biomedical Materials Research Part A, 2007. 80A(2): p. 
297-305. 
 
19. Dor, Y., et al., Conditional Switching of VEGF Provides New Insights into Adult 
Neovascularization and Pro-angiogenic Therapy. EMBO J., 2002. 21(8): p. 1939-
1947. 
 
20. Boodhwani, M., et al., The Future of Therapeutic Myocardial Angiogenesis. 
SHOCK, 2006. 26(4): p. 332-341. 
 
21. Robson, M.C., T.A. Mustoe, and T.K. Hunt, The Future of Recombinant Growth 
Factors in Wound Healing. The American Journal of Surgery, 1998. 176(2, 
Supplement 1): p. 80S-82S. 
 
22. Simons, M., et al., Clinical Trials in Coronary Angiogenesis: Issues, Problems, 
Consensus : An Expert Panel Summary. Circulation, 2000. 102(11): p. e73-86. 
 
23. Moon, J.J. and J.L. West, Vascularization of Engineered Tissues: Approaches to 
Promote Angiogenesis in Biomaterials. Current topics in medicinal chemistry, 
2008. 8: p. 300-310. 
 
33 
 
24. Zisch, A.H., M.P. Lutolf, and J.A. Hubbell, Biopolymeric Delivery Matrices for 
Angiogenic Growth Factors. Cardiovascular Pathology, 2003. 12: p. 295-310. 
 
25. Roy, S., et al., Dermal Wound Healing Is Subject to Redox Control. Molecular 
Therapy, 2006. 13: p. 211–220. 
 
26. Jones, M.K., et al., Dual Actions of Nitric Oxide on Angiogenesis: Possible Roles 
of PKC, ERK, and AP-1. Biochemical and Biophysical Research 
Communications, 2004. 318: p. 520-528. 
 
27. Wlaschek, M. and K. Scharffetter-Kochanek, Oxidative Stress in Chronic Venous 
Leg Ulcers. Wound Repair and Regeneration, 2005. 13(5): p. 452 - 461. 
 
28. Sen, C.K. and S. Roy, Redox Signals in Wound Healing. Biochimica et 
Biophysica Acta, 2008. 1780(11): p. 1348-1361. 
 
29. Boateng, J.S., et al., Wound Healing Dressings and Drug Delivery Systems: A 
Review. Journal of Pharmaceutical Sciences, 2008. 97(8): p. 2892-2923. 
 
30. Paul, W. and C.P. Sharma, Chitosan and Alginate Wound Dressings: A Short 
Review. Trends Biomater. Artif. Organs, 2004. 18(1): p. 18-23. 
 
31. Isenberg, J.S., et al., Nitric Oxide in Wound Healing. Microsurgery, 2005. 25(5): 
p. 442 - 451. 
 
32. Dyson, M., et al., Comparison of the Effects of Moist and Dry Conditions on 
Dermal Repair. J Investig Dermatol, 1988. 91(5): p. 434-439. 
 
33. Szpaderska, A.M., et al., Distinct Patterns of Angiogenesis in Oral and Skin 
Wounds. Journal of Dental Research, 2005. 84(4): p. 309-314. 
 
34. Swift, M.E., H.K. Kleinman, and L.A. DiPietro, Impaired Wound Repair and 
Delayed Angiogenesis in Aged Mice. Lab Invest, 1999. 79: p. 1479-1487. 
 
34 
 
35. Hankey, G.J., P.E. Norman, and J.W. Eikelboom, Medical Treatment of 
Peripheral Arterial Disease. JAMA: The Journal of the American Medical 
Association, 2006. 295(5): p. 547-553. 
 
36. Criqui, M.H., Peripheral Arterial Disease - Epidemiological Aspects. Vascular 
Medicine, 2001. 6(1 suppl): p. 3-7. 
 
37. Mukherjee, D., et al., Direct Myocardial Revascularization and Angiogenesis-
How Many Patients Might Be Eligible? The American Journal of Cardiology, 
1999. 84(5): p. 598-600. 
 
38. Baumgartner, I., et al., Constitutive Expression of phVEGF165 After 
Intramuscular Gene Transfer Promotes Collateral Vessel Development in 
Patients With Critical Limb Ischemia. Circulation, 1998. 97(12): p. 1114-1123. 
 
39. Lovett, M., et al., Vascularization strategies for tissue engineering. Tissue 
Engineering: Part B, 2009. 15(3). 
 
40. Rouwkema, J., R. Nicolas C, and C.A.v. Blitterswijk, Vascularizaton in tissue 
engineering. Trends in Biotechnology, 2008. 26(8): p. 434-441. 
 
41. Mikos, A.G., et al., Engineering complex tissues. Tissue Engineering, 2006. 
12(12). 
 
42. Chrobak, K.M., D.R. Potter, and J. Tien, Formation of perfused, functional 
microvasular tubes in vitro. Microvascular Research, 2006. 71: p. 185-196. 
 
43. Golden, A.P. and J. Tien, Fabrication of  Microfluidic Hydrogels Using Molded 
Gelatin as a Sacrificial Element. Lab Chip, 2007. 7: p. 720-725. 
 
44. Hall, A.P., The Role of Angiogenesis in Cancer. Comparative Clinical Pathology, 
2005. 13(3): p. 95-99. 
 
45. Methods in Enzymology Angiogenesis: In Vitro Systems, ed. D.A. Cheresh. Vol. 
443. 2008 San Diego: Academic press. 
 
35 
 
46. Elçin, Y.M., V. Dixit, and G. Gitnick, Extensive In Vivo Angiogenesis Following 
Controlled Release of Human Vascular Endothelial Cell Growth Factor: 
Implications for Tissue Engineering and Wound Healing. Artificial Organs, 2001. 
25(7): p. 558-565. 
 
47. Kalluri, R., Basement Membranes: Structure, Assembly and Role in Tumour 
Angiogenesis. Nat Rev Cancer, 2003. 3(6): p. 422-33. 
 
48. K.R.Martin and J.C.Barrett, Reactive Oxygen species as double-edged swords in 
cellular proceses: low- dose cell signaling versus high-dose toxicity. Human and 
Experimental Toxicology, 2002(21): p. 71-75. 
 
49. Frank, S., et al., Nitric Oxide Drives Skin Repair: Novel Functions of an 
Established Mediator. Kidney International, 2002. 61: p. 882-888. 
 
50. Rhee, S.G., et al., Hydrogen Peroxide: A Key Messenger That Modulates Protein 
Phosphorylation Through Cysteine Oxidation. Sci. STKE, 2000. 2000(53): p. pe1. 
 
51. Finkel, T., Redox-Dependent Signal Transduction. FEBS Letters, 2000. 476(1-2): 
p. 52-54. 
 
52. Adly, A.A.M., Oxidative Stress and Disease: An Updated Review. Research 
Journal of Immunology, 2010. 3(2): p. 129-145. 
 
53. Cross, C.E., et al., Oxygen Radicals and Human Disease. Annals of Internal 
Medicine, 1987. 107(4): p. 526-545. 
 
54. Davies, K.J.A., M.E. Delsignore, and S.W. Lin, Protein Damage and 
Degradation by Oxygen Radicals II. Modification of Amino Acids. J Biol Chem., 
1987. 262(20): p. 9902-9907. 
 
55. Nikolic, D.L., et al., Role of boundary conditions in an experimental model of 
epithelial wound healing. Am J Physiol Cell Physiol, 2006. 291: p. 68 - 75. 
 
56. Schäfer, M. and S. Werner, Oxidative stress in normal and impaired wound  
repair. Pharmacological Research, 2008. 58(2): p. 165-171. 
36 
 
 
57. Lambeth, J.D., NOX Enzymes and the Biology of Reactive Oxygen. Nat Rev 
Immunol, 2004. 4(3): p. 181-189. 
 
58. Finkel, T., Signal Transduction by Reactive Oxygen Species in Non-Phagocytic 
Cells. J. Leukoc. Biol., 1999. 65(3): p. 337-340. 
 
59. Ushio-Fukai, M. and R. Alexander, Reactive Oxygen Species as Mediators of 
Angiogenesis Signaling. Role of NAD(P)H oxidase. Molecular and Cellular 
Biochemistry, 2005. 264(1): p. 85-97. 
 
60. Stone, J.R. and T. Collins, The Role of Hydrogen Peroxide in Endothelial 
Proliferative Responses. Endothelium, 2002. 9(4): p. 231-238. 
 
61. Matsumoto, T. and L. Claesson-Welsh, VEGF Receptor Signal Transduction. Sci. 
STKE, 2001. 2001(112): p. re21-. 
 
62. Sundaresan, M., et al., Requirement for Generation of H2O2 for Platelet-Derived 
Growth Factor Signal Transduction. Science, 1995. 270(5234): p. 296-299. 
 
63. Bae, Y.S., et al., Epidermal Growth Factor (EGF)-induced Generation of 
Hydrogen Peroxide. Journal of Biological Chemistry, 1997. 272(1): p. 217-221. 
 
64. Fetrow, J.S., N. Siew, and J. Skolnick, Structure-based Functional Motif 
Identifies a Potential Disulfide Oxidoreductase Active Site in the Serine/threonine 
Protein Phosphatase-1 Subfamily. The FASEB Journal, 1999. 13(13): p. 1866-
1874. 
 
65. May, J.M. and C.d. Haen, Insulin-stimulated Intracellular Hydrogen Peroxide 
Production in Rat Epididymal Fat Cells. 1979. 
 
66. Irani, K., et al., Mitogenic Signaling Mediated by Oxidants in Ras-Transformed 
Fibroblasts. Science, 1997. 275(5306): p. 1649-1652. 
 
37 
 
67. Yoshizumi, M., et al., Src and Cas Mediate JNK Activation but Not ERK1/2 and 
p38 Kinases by Reactive Oxygen Species. Journal of Biological Chemistry, 2000. 
275(16): p. 11706-11712. 
 
68. van Wetering, S., et al., Reactive Oxygen Species Mediate Rac-induced Loss of 
Cell-Cell Adhesion in Primary Human Endothelial Cells. Journal of Cell Science, 
2002. 115(9): p. 1837-1846. 
 
69. Moldovan, L., et al., The Actin Cytoskeleton Reorganization Induced by Rac1 
Requires the Production of Superoxide. Antioxid Redox Signal, 1999. 1(1): p. 29-
43. 
 
70. Yasuda, M., et al., Stimulation of In Vitro Angiogenesis by Hydrogen Peroxide 
and the Relation with Ets-1 in Endothelial Cells. Life Sciences, 1998. 64(4): p. 
249-258. 
 
71. Schreck, R., P. Rieber, and P.A. Baeuerle, Reactive Oxygen Intermediates as 
Apparently Widely Used Messengers in the Activation of the NF-kappa B 
transcription factor and HIV-1. EMBO J., 1991. 10(8): p. 2247-2258. 
 
72. Wang, G.L., B.H. Jiang, and G.L. Semenza, Effect of Protein Kinase and 
Phosphatase Inhibitors on Expression of Hypoxia Inducible Factor 1. 
Biochemical and Biophysical Research Communications, 1995. 216(2): p. 669-
675. 
 
73. Chua, C.C., R.C. Hamdy, and B.H.L. Chua, Upregulation of Vascular Endothelial 
Growth Factor by H2O2 in Rat Heart Endothelial Cells. Free Radical Biology and 
Medicine, 1998. 25(8): p. 891-897. 
 
74. Witte, M.B. and A. Barbul, Role of Nitric Oxide in Wound Repair. The American 
Journal of Surgery, 2002. 183: p. 406-412. 
 
75. Lander, H.M., et al., A Molecular Redox Switch on p21
ras
. Structural Basis for the 
Nitric Oxide-p21
ras
 Interaction. The Journal of Biological Chemistry, 1997. 
272(7): p. 4323–4326. 
 
38 
 
76. Gow, A.J., et al., Biological Significance of Nitric Oxide-Mediated Protein 
Modifications. Am J Physiol Lung Cell Mol Physiol, 2004. 287(2): p. 262-268. 
 
77. Fukumura, D., S. Kashiwagi, and R.K. Jain, The Role of Nitric Oxide in Tumor 
Progression. Nature Reviews Cancer, 2006. 6: p. 521-534. 
 
78. Oliveira, C.J.R., et al., Nitric Oxide and cGMP Activate the Ras-MAP Kinase 
Pathway-Stimulating Protein Tyrosine Phosphorylation in Rabbit Aortic 
Endothelial Cells. Free Radical Biology & Medicine, 2003. 35(4): p. 381-396. 
 
79. Shizukuda, Y., et al., Vascular Endothelial Growth Factor–Induced Endothelial 
Cell Migration and Proliferation Depend on a Nitric Oxide–Mediated Decrease 
in Protein Kinase C Activity. Circulation Research, 1999. 85: p. 247-256. 
 
80. Zaragoza, C., et al., Activation of the Mitogen Activated Protein Kinase 
Extracellular Signal-Regulated Kinase 1 and 2 by the Nitric Oxide–cGMP–
cGMP-Dependent Protein Kinase Axis Regulates the Expression of Matrix 
Metalloproteinase 13 in Vascular Endothelial Cells. Molecular Pharmacology, 
2002. 62(4): p. 927-935. 
 
81. Soneja, A., M. Drews, and T. Malinski, Role of Nitric Oxide, Nitroxidative and 
Oxidative Stress in Wound Healing. Pharmacological Reports, 2005. 57: p. 108-
119. 
 
82. Bohlen, P., et al., Isolation and Partial Molecular Characterization of Pituitary 
Fibroblast Growth Factor. Proc.Natl.Acad.Sci.USA, 1984. 81: p. 5364-5368. 
 
83. Dowd, C.J., C.L. Cooney, and M.A. Nugent, Heparan Sulfate Mediates bFGF 
Transport through Basement Membrane by Diffusion with Rapid Reversible 
Binding. Journal of Biological Chemistry, 1999. 274(8): p. 5236-5244. 
 
84. Saksela, O., et al., Endothelial Cell-derived Heparan Sulfate Binds Basic 
Fibroblast Growth Factor and Protects it from Proteolytic Degradation. The 
Journal of Cell Biology, 1988. 107(2): p. 743-751. 
 
39 
 
85. Rusnati, M. and M. Presta, Interaction of Angiogenic Basic Fibroblast Growth 
Factor with Endothelial Cell Heparan Sulfate Proteoglycans. International 
Journal of Clinical & Laboratory Research, 1996. 26(1): p. 15-23. 
 
86. Cross, M.J. and L. Claesson-Welsh, FGF and VEGF Function in Angiogenesis: 
Signaling Pathways, Biological Responses and Therapeutic Inhibition. Trends 
Pharmacol Sci., 2001. 22(4). 
 
87. Nugent, M.A. and R.V. Iozzo, Fibroblast Growth Factor-2. Int J Biochem Cell 
Biol., 2000. 32(2): p. 115-120. 
 
88. Houchen, C.W., et al., FGF-2 Enhances Intestinal Stem Cell Survival and its 
Expression is Induced After Radiation Injury. Am J Physiol Gastrointest Liver 
Physiol., 1999. 276(1): p. G249-258. 
 
89. Taraboletti, G., et al., Shedding of the Matrix Metalloproteinases MMP-2, MMP-9 
and MT1-MMP as Membrane Vesicle-Associated Components by Edothelial 
Cells. Am J Pathol, 2002. 160(2): p. 673-680. 
 
90. Klein, S., et al., Basic Fibroblast Growth Factor Modulates Integrin Expression 
in Microvascular Endothelial Cells. Molecular Biology of the Cells, 1993. 4: p. 
973-982. 
 
91. Collo, G. and M. Pepper, Endothelial Cell Integrin Alpha5beta1 Expression is 
Modulated by Cytokines and During Migration In Vitro. J Cell Sci, 1999. 112(4): 
p. 569-578. 
 
92. Sepp, N.T., et al., Basic Fibroblast Growth Factor Increases Expression of the 
v3 Integrin Complex on Human Microvascular Endothelial Cells. J Investig 
Dermatol, 1994. 103(3): p. 295-299. 
 
93. Underwood, P.A., P.A. Bean, and J.R. Gamble, Rate of Endothelial Expansion is 
Controlled by Cell:Cell Adhesion. The International Journal of Biochemistry & 
Cell Biology, 2002. 34(1): p. 55-69. 
 
94. Gualandris, A., et al., Interaction of High-Molecular-Weight Basic Fibroblast 
Growth Factor with Endothelium: Biological Activity and Intracellular Fate of 
40 
 
Human Recombinant Mr 24,000 bFGF. Journal of Cellular Physiology, 1994. 
161(1): p. 149-159. 
 
95. Tepper, O.M., et al., Electromagnetic Fields Increase In Vitro and In Vivo 
Angiogenesis Through Endothelial Release of FGF-2. FASEB J., 2004. 18: p. 
1231-1233. 
 
96. Fuks, Z., et al., Basic Fibroblast Growth Factor Protects Endothelial Cells 
Against Radiation-Induced Programmed Cell Death In Vitro and In Vivo. Cancer 
Res., 1994. 54: p. 2582-2590. 
 
97. Haimovitz-Friedman, A., et al., Protein Kinase C Mediated Basic Fibroblast 
Growth Factor Protection of Endothelial Cells Against Radiation-Induced 
Apoptosis. Cancer Res., 1994. 54(10): p. 2591-2597. 
 
98. Morss, A.S. and E.R. Edelman, Glucose Modulates Basement Membrane 
Fibroblast Growth Factor-2 via Alterations in Endothelial Cell Permeability. J 
Biol Chem., 2007. 282(19): p. 14635-14644. 
 
99. Cheng, G.C., et al., Mechanical Strain Tightly Controls Fibroblast Growth 
Factor-2 Release from Cultured Human Vascular Smooth Muscle Cells. Circ 
Res., 1997. 80: p. 28-36. 
 
100. Ku, P.T. and P.A. D'Amore, Regulation of Basic Fibroblast Growth Factor 
(bFGF) Gene and Protein Expression Following its Release from Sublethally 
Injured Endothelial Cells. J Cell Biochem., 1995. 58(3): p. 328-343. 
 
101. Finklestein, S.P., et al., Increased Basic Fibroblast Growth Factor (bFGF) 
Immunoreactivity at the Site of Focal Brain Wounds. Brain Res., 1988. 460(2): p. 
253-259. 
 
102. Fischer, T.A., et al., Regulation of bFGF Expression and Ang II Secretion in 
Cardiac Myocytes and Microvascular Endothelial Cells. Am J Physiol Heart Circ 
Physiol., 1997. 272(2 ): p. H958-968. 
 
41 
 
103. Weich, H.A., et al., Transcriptional Regulation of Basic Fibroblast Growth 
Factor Gene Expression in Capillary Endothelial Cells. J Cell Biochem., 1991. 
47(2): p. 158-164. 
 
104. Jimenez, S.K., et al., Transcriptional Regulation of FGF-2 Gene Expression in 
Cardiac Myocytes. Cardiovas Res., 2004. 62(3): p. 548-557. 
 
105. Seghezzi, G., et al., Fibroblast Growth Factor-2 (FGF-2) Induces Vascular 
Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of 
Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis. J 
Cell Biol., 1998. 141(7): p. 1659-1673. 
 
106. Kastrup, J., Clinical Vascular Growth Factor Therapy for Neovascularization in 
Patients with Coronary Artery Disease, in Therapeutic Neovascularization: Quo 
Vadis?, E. Deindl and C. Kupatt, Editors. 2007, Springer: Dordrecht. 
 
107. Takeshita, S., et al., Therapeutic Angiogenesis. A Single Intraarterial Bolus of 
Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit 
Ischemic Hind Limb Model. J. Clin Invest, 1994. 93(2): p. 662-670. 
 
108. Pu, L., et al., Enhanced Revascularization of the Ischemic Limb by Angiogenic 
Therapy. Circulation, 1993. 88(1): p. 208-215. 
 
109. Baffour, R., et al., Enhanced Angiogenesis and Growth of Collaterals by In Vivo 
Administration of Recombinant Basic Fibroblast Growth Factor in a Rabbit 
Model of Acute Lower Limb Ischemia: Dose-Response Effect of Basic Fibroblast 
Growth Factor. J Vasc Surg., 1992. 16(2): p. 181-191. 
 
110. Asahara, T., et al., Synergistic Effect of Vascular Endothelial Growth Factor and 
Basic Fibroblast Growth Factor on Angiogenesis In Vivo. Circulation, 1995. 
92(9): p. 365-371. 
 
111. Post, M.J., et al., Therapeutic Angiogenesis in Cardiology Using Protein 
Formulations. Cardiovascular Research, 2001. 49(3): p. 522-531. 
 
42 
 
112. Sellke, F.W., et al., Therapeutic Angiogenesis With Basic Fibroblast Growth 
Factor: Technique and Early Results. The Annals of Thoracic Surgery, 1998. 
65(6): p. 1540-1544. 
 
113. Henry, T.D., et al., Intracoronary Administration of Recombinant Human 
Vascular Endothelial Growth Factor to Patients with Coronary Artery Disease. 
American Heart Journal, 2001. 142(5): p. 872-880. 
 
114. Henry, T.D., et al., The VIVA Trial: Vascular Endothelial Growth Factor in 
Ischemia for Vascular Angiogenesis. Circulation, 2003. 107(10): p. 1359-1365. 
 
115. Laham, R.J., et al., Intracoronary Basic Fibroblast Growth Factor (FGF-2) in 
Patients with Severe Ischemic Heart Disease: Results of a Phase I Open-Label 
Dose Escalation Study. Journal of the American College of Cardiology, 2000. 
36(7): p. 2132-2139. 
 
116. Simons, M., et al., Pharmacological Treatment of Coronary Artery Disease With 
Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, 
Controlled Clinical Trial. Circulation, 2002. 105(7): p. 788-793. 
 
117. Mack, C.A., et al., Biologic Bypass with the Use of Adenovirus-Mediated Gene 
Transfer of the Complementary Deoxyribonucleic Acid for Vascular Endothelial 
Growth Factor 121 Improves Myocardial Perfusion and Function in the Ischemic 
Porcine Heart. The Journal of thoracic and cardiovascular surgery, 1998. 115(1): 
p. 168-177. 
 
118. Aoki, M., et al., Angiogenesis Induced by Hepatocyte Growth Factor in Non-
infarcted Myocardium and Infarcted Myocardium: Up-regulation of Essential 
Transcription Factor for Angiogenesis, ets. Gene therapy, 2000. 7(5): p. 417-427. 
 
119. Schwarz, E.R., et al., Evaluation of the Effects of Intramyocardial Injection of 
DNA Expressing Vascular Endothelial Growth Factor (VEGF) in a Myocardial 
Infarction Model in the Rat-Angiogenesis and Angioma Formation. J Am Coll 
Cardiol, 2000. 35(5): p. 1323-1330. 
 
120. Isner, J.M., et al., Clinical Evidence of Angiogenesis After Arterial Gene Transfer 
of phVEGF165 in Patient with Ischaemic Limb. The Lancet, 1996. 348(9024): p. 
370-374. 
43 
 
 
121. Hedman, M., et al., Safety and Feasibility of Catheter-Based Local Intracoronary 
Vascular Endothelial Growth Factor Gene Transfer in the Prevention of 
Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic 
Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT). 
Circulation, 2003. 107(21): p. 2677-2683. 
 
122. Griese, D.P., et al., Isolation and Transplantation of Autologous Circulating 
Endothelial Cells Into Denuded Vessels and Prosthetic Grafts: Implications for 
Cell-Based Vascular Therapy. Circulation, 2003. 108(21): p. 2710-2715. 
 
123. Tse, H.-F., et al., Angiogenesis in Ischaemic Myocardium by Intramyocardial 
Autologous Bone Marow Mononuclear Cell Implantation. The Lancet, 2003. 
361(9351): p. 47-49. 
 
124. Tateishi-Yuyama, E., et al., Therapeutic Angiogenesis for Patients with Limb 
Ischaemia by Autologous Transplantation of Bone-marrow Cells: A Pilot Study 
and a Randomised Controlled Trial. The Lancet, 2002. 360(9331): p. 427-435. 
 
125. Langmuir, I., Oscillations in Ionized Gases. Proc. Natl. Acad. Sci, 1928. 14(8): p. 
627-637. 
 
126. Fridman, A., Plasma Chemistry. 2008, New York: Cambridge University Press. 
 
127. Kogelschatz, U., B. Eliasson, and W. Egli, From Ozone Generators to Flat 
Television Screens: History and Future Potential of Dielectric Barrier 
Discharges. Pure Appl. Chem, 1999. 71(10): p. 1819-1828. 
 
128. Kogelschatz, U., Dielectric-Barrier Discharges: Their History, Discharge 
Physics, and Industrial Applications. Plasma Chemistry and Plasma Processing, 
2003. 23(1): p. 1-46. 
 
129. Eliasson, B., W. Egli, and U. Kogelschatz, Modelling of Dielectric Barrier 
Discharge Chemistry. Pure Appl. Chem., 1994. 66(6): p. 1275-1286. 
 
44 
 
130. Kuchenbecker, M., et al., Characterization of DBD Plasma Source for 
Biomedical Applications. J. Phys. D: Appl. Phys, 2009. 42(4). 
 
131. Chirokov, A., A. Gutsol, and A. Fridman, Atmospheric Pressure Plasma of 
Dielectric Barrier Discharges. Pure Appl. Chem., 2005. 77(2): p. 487-495. 
 
132. Fridman, G., et al., Blood Coagulation and Living Tissue Sterilization by 
Floating-Electrode Dielectric Barrier Discharge in Air Plasma Chem. Plasma 
Process., 2006. 26: p. 425-442. 
 
133. Kalghatgi, S., et al., Endothelial Cell Proliferation is Enhanced by Low Dose 
Non-Thermal Plasma Through Fibroblast Growth Factor-2 Release. Annals of 
Biomedical Engineering, 2010. 38(3): p. 748-757. 
 
134. Vargo, J.J., Clinical Applications of the Argon Plasma Coagulator. 
Gastrointestinal endoscopy, 2004. 59(1): p. 81-88. 
 
135. Fridman, G., et al., Applied Plasma Medicine. Plasma Process. Polym., 2008. 
5(6): p. 503- 533. 
 
136. Shekhter, A.B., et al., Experimental and Clinical Validation of Plasmadynamic 
Therapy of Wounds with Nitric Oxide. Bulletin of Experimental Biology and 
Medicine, 1998. 126(2): p. 829-834. 
 
137. Shekhter, A.B., et al., Beneficial Effect of Gaseous Nitric Oxide on the Healing of 
Skin Wounds. Nitric Oxide Biol Chem., 2005. 12: p. 210-219. 
 
138. Namihira, T., et al., Temperature and Nitric Oxide Generation in a Pulsed Arc 
Discharge Plasma. PLasma Science and Technology, 2007. 9: p. 747. 
 
139. Kuhn, S., et al., Non-thermal Atmospheric Pressure HF Plasma Source: 
Generation of Nitric Oxide and Ozone for Bio-medical Applications. Plasma 
Sources Sci. Technol, 2010. 19: p. 015013. 
 
45 
 
140. Pipa, A.V., et al., Absolute Production Rate Measurements of Nitric Oxide by an 
Atmospheric Pressure Plasma Jet (APPJ). J. Phys. D: Appl. Phys, 2008. 41: p. 
194011. 
 
141. Gostev, V. Cold Plasma in Biological Investigations. in NATO Advanced Study 
Institute (ASI): Plasma Assisted Decontamination of Biological and Chemical 
Agents. 2007. Cesme, Turkey. 
 
142. Gostev, V. and D. Dobrynin. Medical Microplasmatron in 3rd International 
Workshop on Microplasmas 2006. Greifswald, Germany. 
 
143. Misyn, F., et al., Experimental Studying of Bactericidal Action of Cold Plasma, in 
Diagnostics and treatment of infectious diseases. 2000: Petrozavodsk, Russia. 
 
144. Misyn, F.A., et al., Experimental Investigation of Bactericidal Influence of 
‘‘Cold’’ Plasma and Its Interaction with Cornea, in Diagnostics and treatment of 
infectious diseases. 2000: Petrozavodsk, Russia. 
 
145. Misyn, F.A., et al., Experimental Curing of Bacterial Ulcerous Keratitis with 
“Cold” Plasma in Diagnostics and treatment of infectious diseases. 2000: 
Petrozavodsk, Russia. 
 
146. Misyn, F.A. and V.A. Gostev, ”Cold” Plasma Application for Curing of Eyelid 
Phlegmon in Diagnostics and treatment of infectious diseases. 2000: 
Petrozavodsk, Russia. 
 
147. Dobrynin, D., et al. Pin-to-hole spark discharge (PHD) plasma for biological and 
medical applications. in Proc. 37th Int. Conf. on Plasma Science. 2010. Norfolk, 
VA. 
 
148. Dobrynin, D., et al. RNS and ROS production and delivery into liquid and 
agarose media by microsecond spark discharge plasma. in 3rd Int. Conf. on 
Plasma Medicine 2010. 2010. Greifswald, Germany. 
 
149. Chakravarthy, K., et al., Cold Spark Discharge Plasma Treatment of 
Inflammatory Bowel Disease in an Animal Model of Ulcerative Colitis. 2011. 
1(1): p. 3-19. 
46 
 
 
150. Barlow, D.E., Endoscopic Applications of Electrosurgery: A Review of Basic 
Principles. Gastrointestinal endoscopy, 1982. 28(2): p. 73-76. 
 
151. Brand, C.U., et al., Application of Argon Plasma Coagulation in Skin Surgery. 
Dermatology, 1998. 197(2): p. 152-157. 
 
152. Colt, H.G. and S.W. Crawford, In Vitro Study of the Safety Limits of 
Bronchoscopic Argon Plasma Coagulation in the Presence of Airway Stents. 
Respirology, 2006. 11(5): p. 643-647. 
 
153. Raiser, J. and M. Zenker, Argon Plasma Coagulation for Open Surgical and 
Endoscopic Applications: State of the Art. J. Phys. D: Appl. Phys., 2006. 39: p. 
3520-3523. 
 
154. Robotis, J., P. Sechopoulos, and T. Rokkas, Argon Plasma Coagulation: Clinical 
Applications in Gastroenterology. Annals of Gastroenterology, 2003. 16(2): p. 
131-137. 
 
155. Soloshenko, I.A., et al., Sterilization of Medical Products in Low-Pressure Glow 
Discharges. Plasma Physics Reports, 2000. 26(9): p. 792-800. 
 
156. Kuo, S.P., et al., Contribution of a Portable Air Plasma Torch to Rapid Blood 
Coagulation as a Method of Preventing Bleeding. New J. Phys., 2009. 11: p. 
115016. 
 
157. Sladek, R.E.J., et al., Plasma Treatment of Dental Cavities: A Feasibility Study. 
IEEE Trans. Plasma Sci., 2004. 32(4 ): p. 1540-1543. 
 
158. Sensenig, R., et al., Non-thermal Plasma Induces Apoptosis in Melanoma Cells 
via Production of Intracellular Reactive Oxygen Species. Annals of Biomedical 
Engineering, 2011. 39(2): p. 674-687. 
 
159. Yildrim, E.D., et al., Effect of Dielectric Barrier Discharge Plasma on the 
Attachment and Proliferation of Osteoblasts Cultured Over Poly(ε-caprolactone) 
Scaffolds Plasma Process Polym., 2008. 5(4): p. 397. 
47 
 
 
160. Mielke, C.H., JR., et al., The Standardized Normal Ivy Bleeding Time and Its 
Prolongation by Aspirin. Blood, 1969. 34(2): p. 204-215. 
 
161. Kalghatgi, S., et al., Mechanism of Blood Coagulation by Nonthermal 
Atmospheric Pressure Dielectric Barrier Discharge Plasma. IEEE Trans. Plasma 
Sci., 2007. 35(5): p. 1559-1566. 
 
162. Demling, R.H., Burns: What are the Pharmacological Treatment Options? Expert 
Opinion on Pharmacotherapy, 2008. 9(11): p. 1895-1908. 
 
163. Nelson, E.A., et al., Systematic Review of Antimicrobial Treatments for Diabetic 
Foot Ulcers. Diabetic Medicine, 2006. 23(4): p. 348-359. 
 
164. Fridman, G., et al., Comparison of Direct and Indirect Effects of Non-Thermal 
Atmospheric-Pressure Plasma on Bacteria. Plasma Processes and Polymers, 
2007. 4(4): p. 370-375. 
 
165. Shimizu, T., et al., Characterization of Microwave Plasma Torch for 
Decontamination. Plasma Processes and Polymers, 2008. 5(6): p. 577-582. 
 
166. Kalghatgi, S., et al., Effects of Non-Thermal Plasma on Mammalian Cells. PLoS 
ONE, 2011. 6(1): p. e16270. 
 
167. Yip, H.K. and L.P. Samaranayake, Caries Removal Techniques and 
Instrumentation: A Review. Clinical Oral Investigations, 1998. 2(4): p. 148-154. 
 
168. Vandamme, M., et al., Response of Human Glioma U87 Xenografted on Mice to 
Non Thermal Plasma Treatment. Plasma Medicine, 2011. 1(1). 
 
169. Fridman, G., et al. Biomedical Applications of Non-Thermal Atmospheric 
Pressure Plasma. in 37th AIAA Plasmadynamics and Lasers Conference. 2006. 
San Francisco, CA. 
 
48 
 
170. Leduc, M., et al., Cell Permeabilization Using a Non-Thermal Plasma. New 
Journal of Physics, 2009. 11. 
 
171. Sakai, Y., et al., A Novel Transfection Method for Mammalian Cells Using Gas 
Plasma. Journal of Biotechnology, 2006. 121(3): p. 299-308. 
 
172. Ogita, H. and J. Liao, Endothelial function and oxidative stress. Endothelium, 
2004. 11(2): p. 123-32. 
 
173. Halliwell, B. and J.M.C. Gutteridge, Free Radicals in Biology and Medicine. 4 ed. 
2007, New York: Oxford University Press. 
 
174. Wolff, S.P. and R.T. Dean, Glucose Autoxidation and Protein Modification. The 
Potential Role of 'Autoxidative Glycosylation' in Diabetes. biochem J, 1987. 
245(1): p. 243-250. 
 
175. Hensley, K., et al., Reactive Oxygen Species, Cell Signaling, and Cell Injury. Free 
Radical Biology and Medicine, 2000. 28(10): p. 1456-1462. 
 
176. Klotz, L., K. Kroncke, and H. Sies, Singlet Oxygen-Induced Signaling Effects in 
Mammalian Cells. Photochemical & Photobiological Sciences, 2003. 2(2): p. 88-
94. 
 
177. Halliwell, B., Reactive Oxygen Species in Living Systems: Source, Biochemistry, 
and Role in Human Disease. The American Journal of Medicine, 1991. 91(3, 
Supplement 3): p. S14-S22. 
 
178. Fridovich, I., Superoxide Radical - An Endogenous Toxicant. Annual Review of 
Pharmacology and Toxicology, 1983. 23: p. 239-257. 
 
179. Halliwell, B., M.V. Clement, and L.H. Long, Hydrogen Peroxide in the Human 
Body. FEBS Letters, 2000. 486(1): p. 10-13. 
 
180. Bienert, G.P., et al., Specific Aquaporins Facilitate the Diffusion of Hydrogen 
Peroxide Across Membranes. Journal of Biological Chemistry, 2007. 282(2): p. 
1183-1192. 
49 
 
 
181. Bienert, G.P., J.K. Schjoerring, and T.P. Jahn, Membrane Transport of Hydrogen 
Peroxide. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2006. 1758(8): 
p. 994-1003. 
 
182. Sen, C. and L. Packer, Antioxidant and Redox Regulation of Gene Transcription. 
The FASEB Journal, 1996. 10(7): p. 709-720. 
 
183. Dalton, T.P., S. Howard G, and A. Puga, Regulation of Gene Expression by 
Reactive Oxygen. Annual Review of Pharmacology and Toxicology, 1999. 39: p. 
67-101. 
 
184. Schreck, R., P. Rieber, and P.A. Baeuerle, Reactive Oxygen Intermediates As 
Apparently Widely Used Messengers in the Activation of the NF-kB Transcription 
Factor and HIV-1. The EMBO Journal, 1991. 10(8): p. 2247-2258. 
 
185. Wang, X., et al., The Cellular Response to Oxidative Stress: Influences of 
Mitogen-Activated Protein Kinase Signalling Pathways on Cell Survival. 
Biochem J, 1998. 333(Pt 2): p. 291-300. 
 
186. Griendling, K.K. and D.G. Harrison, Dual Role of Reactive Oxygen Species in 
Vascular Growth. Circ Res, 1999. 85(6): p. 562-563. 
 
187. Bielski, B.H.J. and D.E. Cabelli, ChemInform Abstract: Superoxide and Hydroxyl 
Radical Chemistry in Aqueous Solution. Active Oxygen in Chemistry, ed. C.S. 
Foote. 1996, Glasgow, NZ: Chapman & Hall. 
 
188. Halliwell, B., Oxygen and Nitrogen are Pro-carcinogens. Damage to DNA by 
Reactive Oxygen, Chlorine and Nitrogen Species: Measurement, Mechanism and 
the Effects of Nutrition. Mutation Research/Genetic Toxicology and 
Environmental Mutagenesis, 1999. 443(1-2): p. 37-52. 
 
189. Stadtman, E.R. and B.S. Berlett, Fenton Chemistry. Amino Acid Oxidation. 
Journal of Biological Chemistry, 1991. 266(26): p. 17201-17211. 
 
50 
 
190. Buettner, G.R., The Pecking Order of Free Radicals and Antioxidants: Lipid 
Peroxidation, -Tocopherol, and Ascorbate. Archives of Biochemistry and 
Biophysics, 1993. 300(2): p. 535-543. 
 
191. Herrlich, P. and F.D. Böhmer, Redox Regulation of Signal Transduction in 
Mammalian Cells. Biochemical Pharmacology, 2000. 59(1): p. 35-41. 
 
192. Chiarugi, P. and P. Cirri, Redox Regulation of Protein Tyrosine Phosphatases 
During Receptor Tyrosine Kinase Signal Transduction. Trends in Biochemical 
Sciences, 2003. 28(9): p. 509-514. 
 
193. Hampton, M.B., P.E. Morgan, and M.J. Davies, Inactivation of Cellular Caspases 
by Peptide-Derived Tryptophan and Tyrosine Peroxides. FEBS Letters, 2002. 
527(1): p. 289-292. 
 
194. Palmer, R.M.J., D.S. Ashton, and S. Moncada, Vascular Endothelial Cells 
Synthesize Nitric Oxide from L-arginine. Nature, 1988. 333(6174): p. 664-666. 
 
195. Kojda, G. and D. Harrison, Interactions Between NO and Reactive Oxygen 
Species: Pathophysiological Importance in Atherosclerosis, Hypertension, 
Diabetes and Heart Failure. Cardiovascular Research, 1999. 43: p. 562-571. 
 
196. Awolesi, M.A., W.C. Sessa, and B.E. Sumpio, Cyclic Strain Upregulates Nitric 
Oxide Synthase in Cultured Bovine Aortic Endothelial Cells. J. Clin. Invest, 1995. 
96: p. 1449-1454. 
 
197. Fermor, B., et al., The Influence of Oxygen Tension on the Induction of Nitric 
Oxide and Prostaglandin E2 by Mechanical Stress in Articular Cartilage. 
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society, 2005. 
13(10): p. 935-941. 
 
198. Kellogg, D.L., et al., Acetylcholine-induced Vasodilation is Mediated by Nitric 
Oxide and Prostaglandins in Human Skin. Journal of Applied Physiology, 2005. 
98(2): p. 629-632. 
 
199. Sesti, S., et al., Effect of Bradykinin on Nitric Oxide Production, Urea Synthesis 
and Viability of Rat Hepatocyte Cultures. BMC Physiology, 2005. 5(2). 
51 
 
 
200. Boo, Y.C., et al., Shear Stress Stimulates Phosphorylation of Endothelial Nitric-
oxide Synthase at Ser1179 by Akt-independent Mechanisms. Journal of Biological 
Chemistry, 2002. 277(5): p. 3388-3396. 
 
201. Ignarro, L.J., Biosynthesis and Metabolism of Endothelium-Derived Nitric Oxide. 
Annual Review of Pharmacology and Toxicology, 1990. 30: p. 535-560. 
 
202. Gross, S.S. and M.S. Wolin, Nitric Oxide: Pathophysiological Mechanisms. 
Annu. Rev. Physiol, 1995. 57: p. 737-769. 
 
203. Estévez, A.G. and J. Jordán, Nitric oxide and superoxide, a deadly cocktail. 
Annals of the New York Academy of Sciences, 2002. 962: p. 207-211. 
 
204. Pacher, P., J.S. Beckman, and L. Liaudet, Nitric Oxide and Peroxynitrite in 
Health and Disease. Physiol Rev, 2007. 87: p. 315-424. 
 
205. Voetsch, B., R.C. Jin, and J. Loscalzo, Nitric Oxide Insufficiency and 
Atherothrombosis. Histochemistry and Cell Biology, 2004. 122(4): p. 353-367. 
  
52 
 
CHAPTER 2: REACTIVE OXYGEN AND NITROGEN SPECIES 
PRODUCED BY DBD AND PHD PLASMA IN LIQUID AND CELLS 
2.1 Introduction 
In recent years, plasma has emerged as a novel technology for medical 
applications [1, 2]. In a thermal plasma, the heavy particle and electron temperatures 
reach equilibrium making the gas hot (Tg = Te). Thermal plasmas such as the argon 
plasma coagulator have been widely used clinically for blood coagulation as well as for 
removal of pathological tissue [3-7]. However, high thermal plasma operating 
temperatures cause significant damage to the surrounding healthy tissue. In non-thermal 
(or non-equilibrium) plasma, high temperature electrons interact with gas molecules to 
create reactive species, but overall gas temperature remains close to room temperature 
(Tg << Te). Therefore, these plasmas can be applied directly to cells and tissue without 
measurable damage [8]. Non-thermal plasmas have been used primarily to sterilize tissue 
and equipment, coagulate blood, or kill bacteria and cancerous cells [9-15]. 
In spite of the high temperature, thermal plasmas which produce nitric oxide (NO) 
in high concentrations have significant therapeutic effects [2, 16, 17]. NO from thermal 
plasmas has previously been shown to heal wounds and skin diseases. The ‘‘Plazon’’ 
system, a rapidly quenched hot air plasma jet, provides a relatively high NO 
concentration with significant therapeutic effect [18-20]. This plasma device was used in 
two modes. In ‘‘hot mode,’’ the plasma jet was used to rapidly coagulate and sterilize 
wound surfaces, as well as to remove, dissect, or desiccate dead tissue and pathologic 
growths. In ‘‘cold mode,’’ the NO-rich plasma gas flow (20–40°C) was used to stimulate 
regenerative processes and wound healing. A pin-to-hole spark discharge (PHD), which 
produces primarily NO, has also been reported to sterilize liquids and surfaces (including 
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living tissue), treat gastroenterological diseases [21] and may also stimulate wound 
healing [22-27]. 
PHD plasma produces nitric oxide (NO) through the Zeldovich chain mechanism 
(Equations 1a and 1b). The reaction of oxygen and nitrogen requires high temperature, 
thus PHD plasma NO production takes place at ~2300K. Noble gases, air or water can be 
used as the plasma generating matter. In gas phase, PHD plasma produces electrons, ions, 
excited hydrogen and oxygen atoms, and excited water molecules [28]. PHD plasma also 
produces ROS, ultraviolet radiation and visible light. 
          (1a) 
          (1b) 
 
H2O2 is formed by water vapor in the air flow around the discharge cell, as well as 
by ion interaction with the liquid. Hydroxyl radicals (OH∙) are produced in significant 
concentrations in thermal plasma by the reaction between excited nitrogen (N2
*
) and 
water vapor (H2O) (Equation 2). Since thermal plasmas produce negligible ozone 
concentrations, NO availability is higher than in non-thermal plasmas. 
  
               (2) 
 
While non-thermal plasma research initially focused on plasma’s preventive 
effects, it was recently demonstrated that non-thermal plasma induces physiologic effects 
as well. Specifically, a non-thermal atmospheric pressure dielectric barrier discharge 
(DBD) plasma induced FGF-2 release leading to increased cell proliferation in vitro [29]. 
DBD plasma produces a variety of biologically active reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) in gas phase, including hydrogen peroxide 
(H2O2), hydroxyl radical (OH·), superoxide (O2
-
), singlet oxygen (O2(
1Δg)), ozone (O3) 
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nitric oxide (NO) and peroxynitrite (ONOO
-
) [30, 31]. ROS are highly reactive molecules 
or free radicals derived from molecular oxygen (O2) [32, 33], while RNS are produced by 
the interaction of NO with ROS. Oxygen reduction by two electrons forms H2O2, while 
the OH· radical is produced by tri-electron reduction of molecular oxygen. O2
-
 is formed 
by adding one electron to oxygen, and O2(
1Δg) is the electronically excited state of 
molecular oxygen ((
3Σg
-
) 
3
O2) when the two unpaired electrons adopt antiparallel spins 
and occupy the same orbital thus creating an opportunity to accept electrons of either 
spin. NO reacts with O2
-
 and O3 to produce ONOO
-
 and NO2
-
, respectively. The major 
DBD plasma reactions which create biologically relevant ROS and RNS are shown in 
Tables 1 and 2, respectively. 
Table 1. DBD plasma production of biologically relevant ROS 
ROS Formula Plasma reactions 
Hydrogen peroxide                     
Hydroxyl radical     
           
       a) 
  
                
  
   
               
  
Superoxide   
             
    
Singlet oxygen    
             
       
a)
(M – Third body particle) 
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Table 2. DBD plasma production of biologically relevant RNS 
ROS Formula Plasma reactions 
Nitric oxide                
                 
 
Peroxynitrite ONOO-      
        
 
Nitrite    
               
                           
Many of the plasma-produced ROS/RNS are also created in cells and perform 
biological functions. Endothelial cells produce H2O2 and O2
-
 at low concentrations to 
increase cell proliferation, migration and tube formation through pro-angiogenic factor 
production [34-38]. At low concentrations, H2O2 takes part in intracellular signaling 
while high H2O2 concentrations are associated with DNA, lipid and protein damage [33, 
39-44]. Due to its high reactivity, OH∙ reacts non-specifically with many cell components 
namely DNA, lipids, proteins, amino acids and sugars, leading to loss of cell integrity and 
function [45, 46]. O2(
1∆g) produced during inflammation helps fight infection, and it also 
triggers DNA repair processes by interacting with DNA to produce 8-oxo-7,8-
dihydro(deoxy)guanosine (8-oxo-(d)G) moieties [47]. NO promotes cell survival and 
angiogenesis, both in vivo and in vitro [48-52]. ONOO
-
 reacts directly with amino acids 
such as cysteine, tryptophan and methionine [53], and NO2
-
 may take part directly in 
intracellular signaling [54]. 
Plasma has been shown to promote wound healing. We believe that this enhanced 
wound healing may be related to angiogenesis. However, as a first step towards studying 
plasma-induced angiogenesis, plasma-produced reactive species must be characterized. 
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Therefore, ROS and RNS produced by both DBD and PHD plasmas in liquids and cells 
were measured. 
2.2 Materials and methods 
2.2.1 Cell culture 
Porcine aortic endothelial cells (PAEC) were cultured in low glucose Dulbecco’s 
modified Eagle’s medium (DMEM, Mediatech) supplemented with 5% fetal bovine 
serum (Hyclone), 1% penicillin-streptomycin, and 1% L-glutamine (Invitrogen). Cells 
between passages 4 and 9 were maintained in a humidified incubator at 37°C and 5% 
CO2 with medium change every two days. 
2.2.2 Plasma treatment 
2.2.2.1 Non-thermal atmospheric pressure DBD plasma 
Non-thermal DBD plasma was generated by applying alternating polarity pulsed 
voltage (1.5 kHz, 20 kVpeak-to-peak) between an insulated high voltage electrode and 
the cell sample [29, 55] (Figures 5a and 5b). A variable voltage and current power supply 
(Quinta) was connected to a 25.4 mm diameter copper electrode with a 1 mm thick quartz 
insulating dielectric covering its bottom surface. The insulating dielectric prevented 
current flow between the electrodes, creating plasma with high reactive species 
concentrations but minimal gas heating. The discharge gap between the quartz dielectric 
and the cell sample was fixed at 2 mm. The voltage and current were measured using a 
voltage probe (North Star PVM-4, 100 MHz bandwidth) and a current probe (Pearsons 
Model 2878), respectively (Figure 5c). The signals were recorded with an oscilloscope 
(TDS 5052B, Tektronix Inc). The pulse waveform had a 1.65 µs width and a 5 V/ns rise 
time. Discharge power density was calculated to be 0.84 W/cm
2
 (1.5 kHz) using 
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MATLAB (Mathworks). The plasma treatment dose in J/cm
2
 was calculated by 
multiplying the plasma discharge power density with the plasma treatment duration. Cells 
in glass bottom dishes (14 mm microwells, MatTek) or on 18 mm coverslips (VWR) 
were directly treated with DBD plasma in the presence of 100 µl serum-free medium 
(SFM) to prevent sample drying. Plasma was produced between the insulated high 
voltage electrode and the cell sample, which acted as the other electrode. 
 
Figure 5: Non-thermal DBD plasma (a) schematic, 1: High-voltage wire, 2: Ultem insulation, 3: 
Copper electrode core, 4: Quartz (dielectric), 5: Cell culture media, 6: Grounded base, 7: Endothelial 
cells, 8: Plasma; (b) device; and (c) voltage and current waveforms 
2.2.2.2 Pin-to-hole spark discharge plasma 
A PHD plasma operated in spark mode was ignited in pin-hole electrode 
configuration, where the central needle-like electrode (1.5 mm diameter) was powered 
from the positive output of a high voltage power supply. The outer electrode (7 mm 
diameter) was grounded. The spark discharge had the following characteristics: voltage 4 
kV, pulse duration ~ 20 µs, frequency 1 – 7 Hz, energy per pulse ~1.8 J, plasma diameter 
3 – 5 mm, gas temperature 300 – 330 K. To reduce cell exposure to ultraviolet radiation 
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and ROS produced by the spark discharge, the device was equipped with a curved, 50 
mm Tygon tube extension attached to the cathode. 
 
Figure 6: Pin-to-Hole spark Discharge (PHD) plasma system (a) schematic and (b) in operation. 
Phosphate buffered saline (PBS) and endothelial cells were plasma treated with 
either the straight or curved tube extension. All NO measurements were done in PBS (pH 
7.4). 4,5-diaminofluorescein (DAF-2) and 4,5-diaminofluorescein diacetate (DAF-2 DA) 
were purchased from Cayman Chemicals. Diethylamine NONOate (DEA NONOate, 
Cayman Chemicals) was used as NO donor. 
2.2.3 ROS/RNS measurement in liquid and cells 
Direct ROS detection is difficult in vitro due to their short-life and high reactivity. 
In this study, we used a set of fluorescent probes to indirectly assay ROS in liquid and 
cells. These probes fluoresce after reacting with ROS and are often specific to 
extracellular or intracellular species. While these probes do present some challenges due 
to concerns about their specificity and sensitivity as well as the effects of varied culture 
conditions, with careful control and analysis they provide quantitative ROS data [56]. 
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2.2.3.1 Cumulative ROS/RNS in liquid 
Cumulative ROS/RNS in liquid following plasma treatment were quantified with 
2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA, Cayman chemicals), which 
fluoresces following reaction with ROS/RNS such as H2O2, OH∙, O2 (
1Δg), ROO
-
, NO, 
ONOO
-
,organic hydroperoxides and NO2
-
 [57, 58]. The probe was activated by removing 
the acetate groups using an alkaline solution as described [59]. Specifically, 1 mM 
DCFH-DA in ethanol was added to 0.01 N sodium hydroxide (NaOH, Sigma) for 30 min 
at room temperature in the dark. The resultant DCFH solution was then neutralized with 
25 mM sodium phosphate buffer (pH 7.2, Alfa Aesar) and stored on ice until use. Fresh 
DCFH was prepared for each experiment and used the same day. To measure DBD 
plasma-produced ROS/RNS, 150 µl PBS or SFM containing 20 µM DCFH with or 
without the scavengers was added to a glass bottom dish and plasma treated (0 – 9.24 
J/cm
2
). 100 µl of the treated liquid was then transferred to a 96-well plate. To determine 
the presence of individual species, samples were plasma treated in the presence of 
specific species scavengers. Catalase (1000 U/ml), DMSO (500 µM) and carboxy-PTIO 
(200 µM) were used to scavenge H2O2, OH· and NO respectively. To measure PHD 
plasma-produced ROS/RNS, 100 µl PBS containing 20 µM DCFH in 96-well plate was 
plasma treated (0 – 120 pulses). Fluorescence was measured at ex/em: 488/525 nm using 
an Infinite 200 Tecan microplate reader. 
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Figure 7: The non-fluorescent DCFH-DA undergoes de-esterification in the presence of alkaline 
solution to form non-fluorescent DCFH. Upon reacting with ROS/RNS, it is converted into 
fluorescent DCF. 
2.2.3.2 Cumulative ROS/RNS in cells 
Intracellular ROS/RNS was assessed using the Image-iT LIVE Green ROS 
Detection Kit (Invitrogen). The assay is based on 5-(and 6)-carboxy-2’, 7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a fluorogenic marker for 
ROS/RNS in live cells [57, 58]. Carboxy-H2DCFDA is internalized by cells and 
metabolized by intracellular esterases to carboxy-DCFH, which then reacts with 
ROS/RNS to form the fluorescent carboxy-DCF. 
 
Figure 8: The cell permeable carboxy-H2DCFDA dye is cleaved by cellular esterases into non-
fluorescent carboxy-DCFH, which is converted into fluorescent carboxy-DCF upon reacting with 
ROS/RNS 
100,000 PAEC were seeded in 50 mm glass bottom dishes and cultured for 2 days 
to confluence. Following either DBD plasma (0 – 8.4 J/cm2) or PHD plasma (0-120 
pulses) treatment, cells were labeled for ROS according to the manufacturer’s protocol. 
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Briefly, cells were incubated with 25 µM carboxy-H2DCFDA in warm HEPES buffer (20 
mM Hepes, 137 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 2 mM CaCl2, 1 mM MgCl2 and 
10 mM glucose, pH 7.4) for 30 min at 37°C. tert-butylhydroperoxide (tBHP, Invitrogen), 
which induces intracellular ROS production, was the positive control. After washing 
three times with warm buffer, the samples were imaged using an Olympus IX81 inverted 
confocal microscope at ex/em: 488/520 nm. 
2.2.3.3 Hydrogen peroxide (H2O2) 
Hydrogen peroxide in liquid was assessed using the Amplex Red Hydrogen 
Peroxide/ Peroxidase Assay kit (Invitrogen). Amplex red (10-acetyl-3,7-
dihydroxyphenoxazine), is a colorless, non-fluorescent derivative of dihydroresorufin. 
H2O2 reacts with horseradish peroxidase (HRP) to form peroxy radicals which oxidize 
Amplex red into fluorescent resorufin (3H-phenoxazine-3-one,7-hydroxy) [60]. 
 
Figure 9: H2O2 is converted into peroxy radical in the presence of HRP enzyme, which oxidizes 
Amplex red into fluorescent resorufin. 
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To measure DBD plasma produced H2O2, 200 µl PBS or SFM was added to a 
glass bottom dish and plasma treated (0 – 12.6 J/cm2). Catalase (1000 U/ml) was used as 
the H2O2 scavenger. 50 µl of the treated liquid was transferred to a 96-well plate. A 
working solution containing Amplex red reagent (100 µM) and HRP (0.2 U/ml) in 1X 
reaction buffer was added to the samples. Following incubation in the dark at room 
temperature for 30 min, fluorescence was measured at ex/em: 530/590 nm using the 
microplate reader. Fluorescence was converted to H2O2 concentration using a prepared 
H2O2 standard curve. 
Intracellular H2O2 was measured indirectly since no direct assay exists. H2O2 
crosses cell membrane through aquaporins to achieve equilibrium between intracellular 
and extracellular liquids [61]. We therefore measured extracellular H2O2 concentration to 
indirectly assess intracellular concentration. Confluent PAEC on 18 mm glass cover slips 
were treated with DBD plasma (0 – 9.24 J/cm2) in 100 µl SFM, and incubated with 400 
µl of Amplex red reagent (50 µM) and HRP (0.1 U/ml) for 30 min at 37 °C. 50 µl of the 
reaction buffer was then added to a 96-well plate and fluorescence was measured at 
ex/em: 530/590 nm using a microplate reader. Fluorescence was converted to H2O2 
concentration using a standard curve prepared using known H2O2 concentrations. 
2.2.3.4 Hydroxyl radical and peroxynitrite (OH∙ and ONOO-) 
3’-p-(hydroxyphenyl fluorescein (HPF, Invitrogen), a cell-permeable fluorescent 
probe, was used for OH· radical and ONOO
-
 detection in liquids and cells [62, 63]. Upon 
reacting with OH· and ONOO
-
, non-fluorescent HPF is O-dearylated to form fluorescent 
fluorescein. HPF is insensitive to other reactive species such as NO, O2 (
1Δg), alkyl 
peroxide, hypochlorite ion (ClO
-
, O2
- 
and H2O2 and light-induced autoxidation. 
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Figure 10: The fluorescence intensity of hydroxyphenyl fluorescein is increased upon reacting with 
highly reactive oxygen species (hROS) OH∙ and ONOO-. 
For detection in liquid, 10 µM HPF in 200 µl PBS or SFM was directly treated 
with DBD plasma (0 – 9.24 J/cm2). 100 µl of each sample was transferred to a 96-well 
plate and fluorescence intensity measured (ex/em: 492/525 nm). OH· and ONOO
- 
were 
measured in cells by preincubating confluent PAEC with HPF (10 µM) for 30 min at 
37°C. After washing, cells were plasma treated (0 – 8.4 J/cm2) and imaged by confocal 
microscopy (ex/em: 488/520 nm). Dimethylsulfoxide (DMSO, 5-20% v/v) and mannitol 
(10 µM) were the OH· scavengers in liquid. Since DMSO is toxic to cells at 
concentrations >0.1%, only mannitol was used in cells. 
2.2.3.5 Superoxide (O2
-
) 
Tempo-9AC (4-((9-acridinecarbonyl)amino)-2,2,6,6-tetramethylpiperidin-1-oxyl, 
Invitrogen) was used to measure superoxide in liquid and cells. It contains a nitroxide 
moiety which quenches its fluorescence. The fluorescence is restored when the probe 
traps a superoxide molecule. For detection in liquid, 10 µM Tempo-9AC in 200 µl PBS 
or SFM was directly treated with DBD plasma (0 – 9.24 J/cm2). Fluorescence was 
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measured in 100 µl of sample in a 96-well plate at ex/em:  358/461 using a microplate 
reader. Ascorbic acid (Vitamin C, 10 µM) was used as O2
-
 scavenger. 
 
Figure 11: Molecular structure of superoxide detection probe, Tempo-9AC 
For superoxide measurement in cells, confluent PAEC in glass bottom dishes (4 × 
10
5
 cells) were preincubated with Tempo-9AC (10 µM) in warm HEPES buffer (20 mM 
Hepes, 137 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 2 mM CaCl2, 1 mM MgCl2 and 10 
mM glucose, pH 7.4) for 30 min at 37°C. After washing, cells were plasma treated (0 – 
8.4 J/cm
2
) in the presence or absence of the superoxide scavenger ascorbic acid (10 µM), 
and imaged by confocal microscopy at ex/em: 405/461 nm. 
2.2.3.6 Singlet oxygen (O2(
1∆g) 
Trans-1(2’-methoxyvinyl)pyrene (t-MVP, Invitrogen) was used to detect singlet 
oxygen in liquids and cells. Upon reacting with singlet oxygen, t-MVP is converted to 1-
pyrenecarboxaldehyde (ex/em: 366/460 nm) [64]. 200 µl PBS or SFM containing 10 µM 
t-MVP was treated directly with DBD plasma (0 – 9.24 J/cm2). Fluorescence was 
measured in 100 µl of the sample at ex/em: 366/460 nm using a microplate reader. 
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Figure 12: Trans-1-(2'-methoxyvinyl)pyrene reacts with singlet oxygen yielding a dioxetane 
intermediate which decomposes to 1-pyrenecarboxaldehyde. 
 
For singlet oxygen measurement in cells, confluent PAEC were incubated with 
tMVP (10 µM) for 30 min at 37 °C. After washing, cells were plasma treated, trypsinized 
and added to a 96-well plate. Fluorescence was measured at ex/em: 366/460 nm using a 
microplate reader. 
2.2.3.7 Nitrite (NO2
-
) 
Nitrite concentration in plasma-treated liquid was measured using a Griess 
reagent kit (Invitrogen). In the Griess assay, the reagent sulfanilic acid reacts with NO2
-
 
to form a diazonium salt, which is then coupled to a second reagent N-(1-
naphthyl)ethylenediamine to form an azo dye. This azo dye can be 
spectrophotometrically detected by measuring absorbance at 548 nm. 
 
Figure 13: The reagent sulfanilic acid reacts with NO2
-
 to form a diazonium salt. The diazonium salt 
then reacts with N-(1-naphthyl)ethylenediamine to form an azo dye which can then be 
spectrophometrically detected. 
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200 µl PBS or SFM was directly treated with DBD plasma (0 – 12.6 J/cm2). 150 
µl of the treated liquid was incubated with the Griess reagent in a 96-well plate in the 
dark at room temperature for 30 min. Absorbance was measured at 548 nm using a 
microplate reader and converted to NO2
-
 concentration using a sodium nitrite standard 
curve. 
2.2.3.8 Nitric oxide (NO) 
The fluorescent dye DAF-2 is widely used for quantitative NO measurement in 
liquids and biological tissues. DAF-2 does not interact with ROS/RNS such as nitrates 
(NO3
-
) and nitrites (NO2
-
), superoxide (O2
-
), hydrogen peroxide (H2O2), or peroxynitrite 
(ONOO
-
) [65]. DAF-2 detects NO by reacting with an active intermediate, N2O3, formed 
during oxidation of NO to nitrite, yielding a fluorescent compound DAF-2 triazole (DAF-
2T) [65]. 
All reagents were freshly prepared prior to each experiment. 100 µl PBS 
containing 1 µM DAF-2 was added to a 96-well plate (Corning).  The solution was 
treated with PHD plasma for 0 – 240 pulses, using either the straight or curved tube 
extension. Fluorescence was measured at ex/em: 485/538 nm using an Infinite 200 Tecan 
microplate reader. Fluorescence was converted to NO concentration using a standard 
curve developed using the NO donor, DEA NONOate. DEA NONOate dissociates with a 
half-life of 2 minutes at 37°C to liberate 1.5 moles of NO per molecule NONOate [66]. 
To obtain the standard curve, DEA NONOate (0 – 1000 nM) dissolved in 0.01 N NaOH 
was incubated with DAF-2 (1 µM) for 30 min at 37°C and fluorescence measured using 
the microplate reader as described. 
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The cell permeant version of DAF-2, DAF-2 diacetate, was used to measure NO 
concentration in an endothelial cell monolayer. DAF-2 DA is a non-fluorescent cell 
permeable molecule, which upon entry into the cell is cleaved by cellular esterases into 
the less permeable DAF-2 [65]. PAEC were seeded near confluence in a 96-well plate 
(30,000 cells/well) and incubated for 24 h. Prior to plasma treatment, cells were loaded 
with DAF-2 DA (10 µM) for 45 min. The wells were washed once and 100 µl PBS was 
added. The cells were treated with PHD plasma for 0 - 240 pulses, using the curved tube 
extension. To obtain the standard curve, cells pre-loaded with DAF-2DA were incubated 
with DEA NONOate (0 – 1000 nM) for 30 min. Fluorescence was measured at ex/em: 
485/538 nm in a microplate reader. 
 
Figure 14: DAF-2DA detection due is cleaved by cellular esterases into non-fluorescent DAF-2 
molecule, which is converted into the fluorescent molecule DAF-2T in the presence of NO and O2. 
DAF-2T (fluorescent compound) stability was tested by plasma treating samples 
(60 pulses) and measuring fluorescence at regular intervals up to 30 min after treatment. 
The measured fluorescence was stable for up to 15 min, after which a 7% decrease was 
observed at 30 min (Figure 15). Hence, all plasma treatments and fluorescence 
measurements were carried out in less than 15 min for repeatability. 
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Figure 15: DAF-2T was stable for up to 15 min. PHD plasma treated samples (60 pulses) were 
monitored at regular intervals for up to 30 min by measuring fluorescence at ex/em: 485/538 nm. 
2.2.4 pH and temperature measurement 
pH of DBD plasma treated liquids was measured using a pH microelectrode 
(model HI 1083B, Hanna instruments) for small volume (<100 µl) measurements, 
connected to HI 221 pH meter. 200 µl PBS or SFM was plasma treated in glass bottom 
dishes. 100 µl treated liquid was then transferred to a 96-well plate. The pH measurement 
was obtained by inserting the electrode in the well. Similar DBD plasmas have gas and 
surface temperature of around 47°C [67, 68]. In our research, the cell medium 
temperature was critical. Therefore, we measured the temperature change of PBS or SFM 
due to plasma. A thermistor probe (YSI 427) connected to a meter (YSI #43TA, Yellow 
Springs Instruments) was placed in 200 µl PBS or SFM immediately after plasma 
treatment.  
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2.2.5 Statistical analysis 
Statistical analysis was performed using Prism software (GraphPad). Data are 
expressed as mean ± SD. Comparisons between two groups were analyzed by Student’s t-
test, and trends were analyzed by ANOVA.  
2.3 Results 
2.3.1 DBD Plasma: Total ROS/RNS in liquid 
Previous plasma studies theoretically calculated that a plasma dose of 1 J/cm
2
 
produced 1.88 – 3.13 × 1016 ROS/RNS in gas phase [29]. We measured plasma-produced 
ROS/RNS in the liquid phase. In both plasma-treated PBS and SFM, the ROS 
concentration increased with plasma dose (Figure 16). ROS levels increased rapidly at 
low treatment doses and more slowly at higher treatment doses, likely because higher 
plasma doses saturated the fluorescent ROS dye. Cumulative ROS/RNS concentration 
was consistently 25 – 35% higher in plasma-treated SFM compared to PBS. 
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Figure 16: ROS/RNS were produced by DBD plasma in liquid. Cumulative ROS/RNS in PBS and 
SFM was detected using DCFH (ex/em: 488/525 nm). p<0.001  for PBS and SFM by ANOVA, and 
p<0.0001 between PBS and SFM. 
DCFH detects multiple ROS and RNS. To determine the presence of individual 
species, liquids were plasma treated in the presence of specific scavengers for OH∙ (500 
µM DMSO), H2O2 (1000 U/ml catalase) and NO (200 µM carboxy-PTIO).  Each 
scavenger decreased DCFH fluorescence in plasma-treated PBS. For 4.2 J/cm
2
 DBD 
plasma, DMSO, catalase and carboxy-PTIO decreased DCFH fluorescence in PBS by 14, 
46 and 55%, respectively (Figure 17). With DMSO and catalase, DCFH fluorescence 
increased in a dose-dependent manner with plasma treatment. However, in the presence 
of carboxy-PTIO DCFH fluorescence increased initially but then remained constant. A 
similar trend was observed in plasma-treated SFM in the presence of scavengers. For 4.2 
J/cm
2
 DBD plasma dose, DMSO, catalase and carboxy-PTIO decreased DCFH 
fluorescence in PBS by 10, 31 and 48%, respectively (Figure 18). 
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Figure 17: Total ROS produced by DBD plasma in PBS decreased with specific scavengers. ROS 
were measured using DCFH (ex/em: 488/525 nm) in the presence of DMSO (OH∙ scavenger), catalase 
(H2O2 scavenger), carboxy-PTIO (NO scavenger) p<0.001 for PBS, PBS+DMSO and PBS+catalase. 
 
Figure 18: Total ROS produced by DBD plasma in SFM decreased with specific scavengers. ROS 
were measured using DCFH (ex/em: 488/525 nm) in the presence of DMSO (OH∙ scavenger), catalase 
(H2O2 scavenger), carboxy-PTIO (NO scavenger) p<0.001 for SFM, SFM+DMSO and SFM+catalase. 
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2.3.2 DBD Plasma: Total ROS/RNS in cells 
Plasma-produced ROS/RNS, as well as products from the reaction of plasma 
ROS/RNS with SFM, can either diffuse through the cell membrane into the cytosol or 
react with the cell membrane to produce intracellular ROS/RNS. We therefore quantified 
intracellular reactive species by loading cells with the fluorescent ROS/RNS marker 
carboxy-H2DCFDA. Plasma treatment induced a dose-dependent increase in intracellular 
oxidative stress immediately after treatment.  A plasma dose of 4.2 J/cm
2
 led to a 14% 
increase in intracellular ROS compared to untreated control cells, and a higher dose of 
8.4 J/cm
2
 produced an 8% further increase (Figure 19). The change in intracellular 
ROS/RNS over time following plasma treatment was then quantified for both the plasma 
doses. Plasma induced intracellular ROS peaked by 1 hour after treatment for 4.2 J/cm
2
, 
and then returned to near baseline levels by 3 hours after treatment (Figure 20 and 21). 
For 8.4 J/cm
2
, the sudden increase in ROS/RNS with plasma treatment decreased within 
1 hour, but cells maintained a slightly higher oxidative state than control for up to 3 hours 
(Figure 20 and 21). 
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Figure 19: DBD plasma-produced ROS/RNS went in cells. Intracellular ROS/RNS were measured 
via carboxy-H2DCFDA (ex/em: 488/520 nm). PAEC were incubated with carboxy-H2DCFDA for 30 
min at 37°C, plasma treated for 0 – 8.4 J/cm2, and imaged by confocal microscopy. Fluorescence was 
quantified using Image J. † p<0.001 compared to no plasma 
 
Figure 20: Intracellular ROS over time following DBD plasma. PAEC were treated with 4.2 or 8.4 
J/cm
2
 plasma and incubated with carboxy-H2DCFDA for 30 min at 37°C, imaged by confocal 
microscopy. Fluorescence was quantified using Image J. † p<0.001 compared to control no plasma. 
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Figure 21: Sample ROS images taken by confocal microcopy and quantified using Image J. Scale bar 
is 100 µm. 
2.3.3 Hydrogen peroxide (H2O2) 
2.3.3.1 DBD plasma: H2O2 in liquid 
In both DBD plasma-treated PBS and SFM, the H2O2 concentration increased 
with plasma dose. Interestingly, H2O2 concentration was 1.8 – 2 times higher in PBS 
compared to SFM for all treatment doses (Figure 22). For 200 µl treated with 4.2 J/cm2 
plasma, ~18 µM H2O2 was detected in PBS compared to ~ 8 µM in SFM. The H2O2 
scavenger catalase (1000 U/ml) decreased H2O2 concentration in plasma-treated PBS and 
SFM by 61% and 70%, respectively.  
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Figure 22: DBD plasma produced more hydrogen peroxide (H2O2) in PBS than in SFM. H2O2 
concentration in 200 µl PBS or SFM treated with plasma was measured using Amplex red (ex/em: 
530/590 nm). Fluorescence was converted to concentration using an H2O2 standard curve. Catalase 
(1000 U/ml) was the H2O2 scavenger. p<0.001 by ANOVA. 
2.3.3.2 DBD plasma: H2O2 in cells 
Since there is no probe to accurately determine intracellular H2O2, an indirect 
method was used. Extracellular H2O2 concentration was measured as an approximation of 
intracellular H2O2 concentration, since H2O2 reaches equilibrium across the cell 
membrane [61]. Extracellular H2O2 increased up to 5.88 J/cm
2
 plasma and achieved 
saturation at ~2 µM. For 4.2 J/cm2 plasma, ~1.81 µM H2O2 was detected extracellularly, 
which was 2.6 times greater than that measured in control samples (Figure 23). 
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Figure 23: Extracellular H2O2 concentration was used to approximate intracellular H2O2, since H2O2 
equilibrates across the cell membrane. Confluent PAEC were plasma treated in 100 µl SFM and 
incubated with Amplex red reagent. Fluorescence was measured in 100 µl of solution. p<0.0001 by 
ANOVA. 
2.3.4 Hydroxyl radical and peroxynitrite (OH∙ and ONOO-) 
2.3.4.1 DBD plasma: OH∙ and ONOO- in liquid 
HPF fluorescence increased linearly in both PBS and SFM. In contrast with H2O2, 
HPF fluorescent intensity in SFM was ~20% higher than in PBS (Figure 24). The OH· 
radical scavenger mannitol decreased HPF fluorescent intensity in PBS and SFM by 30% 
and 21%, respectively. Since HPF detects both OH· and ONOO
-
, DMSO was added to 
PBS at increasing concentrations to scavenge OH· and separate the ONOO
-
 signal. For 
4.2 J/cm
2
 plasma, 5, 10 and 20% DMSO decreased HPF fluorescent intensity by ~33, 42 
and 61%, respectively (Figure 25). So ~39% of the HPF fluorescent intensity was related 
to ONOO
-
.  
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Figure 24: DBD plasma produced hydroxyl radical/peroxynitrite (OH·/ONOO
-
) in a dose-dependent 
manner in liquid. OH·/ONOO
-
 in 200 µl plasma treated PBS or SFM was measured using 10 µM 
HPF (ex/em: 492/ 525 nm). p<0.0001 for increase in OH·/ONOO
-
 with plasma, p<0.05 for PBS vs. 
SFM, p<0.05 for mannitol addition. 
 
Figure 25: DBD plasma produced hydroxyl radical/peroxynitrite (OH·/ONOO
-
) in a dose-dependent 
manner in liquid. OH·/ONOO
-
 in 200 µl plasma treated PBS or SFM was measured using 10 µM 
HPF (ex/em: 492/ 525 nm). DMSO (OH· scavenger) was used to separate the ONOO
-
 signal. p<0.01 
for PBS vs. 5% or 10% DMSO, p<0.001 for PBS vs. 20% DMSO. 
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2.3.4.2 DBD plasma: OH∙ and ONOO- in cells 
Since HPF is cell permeable, it was used to detect OH·/ONOO
-
 in plasma treated 
endothelial cells. For 4.2 J/cm
2
 and 8.4 J/cm
2
 plasma, fluorescent intensity increased 1.2 
and 1.7 fold, respectively (Figure 26, representative cell images in Figure 28). 
Intracellular HPF fluorescence decreased 26% for 4.2 J/cm
2
 plasma with the OH· 
scavenger mannitol (Figure 27, representative images in Figure 28). This accounted for 
~54% of plasma-induced HPF fluorescence. The rest of the fluorescence was likely due 
to ONOO
-
. DMSO was not used in cell studies, since concentrations above 0.1% are 
cytotoxic. 
 
Figure 26: DBD plasma produced hydroxyl radical/peroxynitrite (OH·/ONOO
-
) in a dose-dependent 
manner in cells. Confluent endothelial cells were incubated with 10 µM HPF, plasma treated, and 
imaged by confocal microscopy to measure intracellular OH·/ONOO
-, *p<0.05 and †p<0.01 
compared to control 
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Figure 27: Mannitol decreased DBD plasma-produced hydroxyl radical/peroxynitrite (OH·/ONOO
-
) 
in cells. Confluent endothelial cells were incubated with 10 µM HPF, plasma treated in the presence 
of mannitol, and imaged by confocal microscopy to measure intracellular OH·/ONOO
-
. 
 
Figure 28: Sample confocal microscopy images of HPF fluorescence in plasma-treated endothelial 
cells.  
80 
 
2.3.5 Superoxide (O2
-
) 
2.3.5.1 DBD plasma: O2
-
 in liquid 
Tempo-9AC fluorescence increased linearly in plasma treated liquid, although 
SFM had lower fluorescence than PBS (Figure 29). For 4.2 J/cm
2
 plasma, the 
fluorescence intensity in PBS was ~2.9 times higher than in SFM.  10 µM ascorbic acid 
decreased PBS fluorescence intensity by ~57%, while in SFM it decreased fluorescence 
by only ~ 28%.  
 
Figure 29: Superoxide (O2
-
) was produced by DBD plasma in liquid. (a) O2
-
 in 200 µl PBS or SFM 
treated with plasma was measured using Tempo-9AC (ex/em: 358/461 nm). Ascorbic acid (10 µM) 
was the O2
-
 scavenger. p<0.01 for PBS vs. SFM and ascorbic acid effects. 
2.3.5.2 DBD plasma: O2
-
 in cells 
Since Tempo-9AC is cell permeable, it was also used to detect intracellular O2
-·
. 
Cells were pre-incubated with the probe before plasma treatment since superoxide is a 
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short-lived species. No significant increase in intracellular O2
-
 was observed with plasma 
treatment doses up to 8.4 J/cm
2
 (Figure 30, representative images in Figure 31).   
 
Figure 30: DBD plasma-produced superoxide (O2
-
) was not measured in cells. Confluent PAEC were 
incubated with Tempo-9AC (ex/em: 405/461 nm), plasma treated, and imaged by confocal 
microscopy . 
 
Figure 31: Sample confocal microscopy images of superoxide (O2
-
) in cells.  
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2.3.6 DBD plasma: Singlet oxygen (O2(
1∆g)) in liquid and cells 
The probe tMVP reacts with singlet oxygen to form 1-pyrenecarboxaldehye. 
However, no fluorescence increase was observed in either PBS or SFM with plasma 
treatment (Figure 32).  O2(
1Δg) in plasma-treated endothelial cells also did not change 
with plasma.  
 
Figure 32: Singlet oxygen (O2 (
1Δg)) was not detected in either plasma-treated PBS or SFM. O2(
1Δg) 
was measured in 200 µl of liquid using 10 µM tMVP (ex/em: 377/460 nm). 
2.3.7 DBD plasma: Nitrite (NO2
-
) in liquid  
NO2
-
 in plasma-treated liquid increased linearly with plasma (Figure 33). NO2
-
 
concentration was not significantly different in PBS vs. SFM. For 4.2 J/cm
2
 plasma, 92 
µM NO2
-
 was detected in PBS and 74 µM in SFM. However, due to assay sensitivity 
limitations, this was not statistically significantly different. 
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Figure 33: Nitrite (NO2
-
) increased linearly with plasma in both PBS and SFM. NO2
-
 was measured 
200 µl liquid using a Griess assay reagent kit. Absorbance (548 nm) was converted into concentration 
using a sodium nitrite standard curve. 
2.3.8 PHD plasma: Total ROS/RNS in liquid and cells 
PHD plasma produces NO and multiple ROS in gas phase. We measured plasma-
produced ROS/RNS in the liquid phase. In PHD plasma-treated PBS, the ROS/RNS 
concentration increased with plasma dose (Figure 34). Interaction of PHD plasma-
produced ROS/RNS was quantified by loading cells with the fluorescent ROS/RNS 
marker carboxy-H2DCFDA. Plasma treatment induced a dose-dependent increase in 
intracellular oxidative stress immediately after treatment.  A plasma treatment of 240 
pulses led to a 3 fold increase in intracellular ROS compared to untreated control cells 
(Figure 35, representative images in Figure 36). 
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Figure 34: ROS/RNS were produced by PHD plasma in liquid. Cumulative ROS/RNS in PBS was 
detected using DCFH (ex/em: 488/525 nm). p<0.0001 by ANOVA 
 
Figure 35: PHD plasma-produced ROS/RNS were measured in cells using carboxy-H2DCFDA 
(ex/em: 488/520 nm). PAEC were incubated with carboxy-H2DCFDA for 30 min at 37°C prior to 
plasma treatment. p<0.0001 by ANOVA 
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Figure 36: Sample confocal microcopy images of intracellular ROS/RNS levels following PHD 
plasma treatment. Scale bar is 100 µm. 
 
2.3.9 Nitric oxide (NO) and nitrite (NO2
-
) 
2.3.9.1 PHD plasma: NO and NO2
-
 in PBS 
NO is small, lipophilic, and has a short half-life of approximately 10 seconds. It 
diffuses freely across biological membranes into the cytoplasm. We therefore determined 
NO concentrations in liquid, and cells following PHD plasma treatment. In gas phase, 
NO concentration rapidly increased with PHD plasma treatment and reached a stable 
level of 1980±50 ppm NO by around 50 seconds [21]. In PBS, a linear increase in NO 
concentration was observed for treatment of up to 240 pulses with the straight tube and 
curved tube, as measured by DAF-2 dye. 1400 - 1600 nM NO was detected in PBS, with 
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the straight tube, for a treatment of 240 pulses at 1 Hz (240 sec) (Figure 37). For the 
curved tube configuration, ~ 900 nM NO was detected in PBS for the same treatment 
duration. Since the dye interacts with organic medium, NO measurement was done only 
in PBS. 
 
Figure 37: NO concentration in plasma treated PBS increased linearly with straight tube and curved 
tube configurations, as measured by DAF-2 dye. p<0.0001 by ANOVA for straight tube and curved 
tube, p<0.001 straight vs. curved tube. 
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NO2
-
 concentration in PBS treated with PHD plasma (curved tube configuration) 
increased in a dose-dependent manner (Figure 38). For 240 pulses, ~ 10 µM NO2
-
 was 
detected in PBS. 
 
Figure 38: NO2
-
 increased in a dose-dependent manner with PHD plasma treatment in PBS. NO2
-
 was 
measured in 200 µl liquid using a Griess assay. Absorbance (548 nm) was converted into 
concentration using a sodium nitrite standard curve. p<0.0001 by ANOVA 
2.3.9.2 PHD plasma: NO in cells 
PHD plasma treatment of cells employing the straight tube configuration showed 
increased intracellular NO concentration with treatment time. ~150 nM NO was detected 
in endothelial cells immediately following 240 plasma pulses (Figure 39). Based on NO 
concentration in liquid, approximately 11% of NO from plasma-treated PBS diffused 
through the cell membrane into the cytoplasm after 240 pulses. 
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Figure 39: NO in PHD plasma treated cells increased linearly with the curved tube configuration, as 
measured by DAF-2. p<0.0001 by ANOVA 
2.3.10 Plasma effect on liquid pH 
No significant change in pH was detected in PBS and SFM following plasma 
treatment up to 9.24 J/cm
2
. For the highest treatment dose of 9.24 J/cm
2
, the pH dropped 
from 7.76 to 7.2 in PBS, while in SFM it increased from 7.6 to 7.78 (Figure 40). 
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Figure 40: pH remained unchanged in PBS and SFM with DBD plasma treatment. pH change in 200 
µl of PBS or SFM was measured by a micro pH electrode immediately after treatment. p<0.0001 for 
PBS and SFM 
2.3.10 Plasma effect on liquid temperature 
A 1°C temperature change could affect cells if it raises the cell temperature above 
37°C. Therefore we measured the final liquid temperature after DBD plasma treatment 
for PBS and SFM that was heated to 37°C in a water bath, just as we did for all 
experiments. Even though PBS and SFM were warmed to 37°C, the liquid temperature 
dropped rapidly when 200 µl fluid was placed on a room temperature glass coverslip and 
exposed to room temperature air. As a result, even for a high plasma dose of 134.4 J/cm
2
, 
the plasma treated liquid temperature did not increase above 28.5 °C (Figure 41). 
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Figure 41: Temperature increase of PBS treated with DBD plasma treatment. p<0.0001 by ANOVA 
2.4 Discussion 
A thorough analysis of the reactive species produced by plasma is necessary to 
understand plasma effects on cells. We showed that non-thermal plasma DBD treatment 
produced ROS/RNS in liquid and cells. H2O2 and OH∙ increased in a dose-dependent 
manner in DBD plasma-treated liquid and cells, whereas O2
-
 was measured only in liquid. 
O2(
1Δg) was below detectable limits in both plasma-treated liquid and cells. Interestingly, 
we also detected several reactive nitrogen species, ONOO
-
 and NO2
-
, in DBD plasma 
treated samples. PHD plasma also produced ROS/RNS in liquids and cells. NO and NO2
-
 
concentration increased in liquid in a dose-dependent manner, while a linear increase in 
NO was also detected in cells. This study improves our understanding of plasma-
produced reactive species in liquid and cells which can be used to develop plasma 
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devices that deliver precise doses of specific ROS or RNS for wound healing and tissue 
engineering scaffold vascularization. 
2.4.1 DBD plasma 
DBD plasma produces ROS in gas phase, and these ROS then diffuse into liquid 
where they may react with organic matter. We measured higher ROS/RNS levels in 
plasma-treated SFM as compared to PBS. We believe this occurred because plasma 
ROS/RNS reacted with medium components such as amino acids, which were not present 
in PBS. Since many ROS/RNS are short lived, plasma ROS/RNS effects on cells may be 
extended through these ROS/RNS interactions with organic medium components (Figure 
42). 
 
Figure 42: The effects of plasma ROS/RNS may be amplified by various interactions including ROS-
ROS, ROS-liquid and ROS-cell interactions 
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Different intracellular ROS trends were observed following treatment with low 
plasma dose (4.2 J/cm
2
) vs. high plasma dose (8.4 J/cm
2
). In both cases, ROS levels 
reached a similar peak value. However, intracellular ROS increased more sharply for the 
high plasma dose than for the lower dose. The sharp rise in intracellular ROS may trigger 
the cell antioxidant mechanisms. Several antioxidant mechanisms exist within a cell to 
neutralize ROS [69-71]. Enzymes such as superoxide dismutase convert superoxide into 
hydrogen peroxide, which can then be disposed of by the enzyme glutathione (GSH) 
peroxidase. Catalase and vitamin E are two other major antioxidants inside the cell. In 
most oxidative stress related diseases, high ROS cause cellular damage likely by 
overwhelming the antioxidant mechanisms and repair systems [72]. However, for low 
plasma dose, ROS levels continued to rise up to 1 hour following plasma treatment 
before declining to basal levels.  The slow rise in ROS may also prevent the antioxidants 
in the cell from actively scavenging them. 
Specific ROS levels in DBD plasma-treated PBS were often different than in 
SFM. H2O2 and O2
-
 concentrations were higher in PBS, whereas OH∙ was higher in SFM. 
Ferric ions in the SFM could generate OH∙ radicals from the Haber-Weiss reaction 
between H2O2 and O2
-
  (Equations 3a and 3b) [73]. This would decrease H2O2 and O2
-
 
and increase OH∙ in SFM compared to PBS. 
        
          (3a) 
            
                 (Fenton reaction) (3b) 
 
Bishop et al showed that cell culture medium scavenged H2O2 and O2
-
 while 
increasing the OH∙ radical concentration compared to salt solution due to its iron content 
[74]. 
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Intracellular H2O2 and OH∙ increased with DBD plasma, however no change in 
O2
-
 was detected. Reactivity, size, and charge determine ROS diffusion through liquid 
and cells. H2O2 is a long living species with a half-life of several minutes, while O2
-
 has a 
microsecond half-life and OH∙ has a nanosecond half-life (which would be even shorter if 
the reaction were not diffusion limited) [73]. Since H2O2 is relatively stable, small, and 
uncharged, it can diffuse through cell membrane aquaporins and be converted to the 
highly reactive OH∙ radical inside the cell [75-77]. Despite being highly reactive, OH∙ 
effects on cells are enhanced and extended through interactions with organic liquid 
components. SFM used in cell plasma treatment contained  amino acids which are readily 
oxidized to organic hydroperoxides (ROOH) by OH∙ radicals through the following 
reactions [78-81]. 
              (4a) 
           (4b) 
                  (4c) 
 
where R and R΄ are organic groups. OH∙ reacts with cellular components such as lipids, 
proteins and DNA [82]. Organic hydroperoxides, which do not diffuse freely into the 
cells due to their large size, damage the cell membrane through lipid peroxidation [83]. 
Both H2O2 and OH∙ radicals can also cause carbonylation of medium amino acids such as 
lysine, arginine, proline and threonine [81, 84, 85]. Protein carbonylation leads to protein 
inactivation, which can either contribute to pathological processes or in the case of 
Annexin-1 promote cell survival [84, 85]. O2
-, although it is more stable than OH∙ and 
small, cannot readily diffuse through the cell membrane due to its negative charge. The 
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absence of increase in intracellular O2
-
 with plasma treatment in our experiments may be 
attributed to scavenging by superoxide dismutase and culture medium. 
When cells are exposed to exogenous H2O2, equilibrium is attained rapidly 
between extracellular and intracellular H2O2 concentrations since H2O2 diffuses freely 
through the cell membrane [61]. We took advantage of this equilibrium by using 
extracellular H2O2 as a measure of intracellular H2O2. However, cells maintain an H2O2 
gradient across the cell membrane, with intracellular concentration lower than 
extracellular H2O2 [61]. Antunes et al showed that an exogenous application of a bolus of 
50 µM H2O2 to Jurkat cells resulted in a maximal equilibrium intracellular H2O2 
concentration of only 7 µM [61]. Therefore, our measured extracellular H2O2 
concentration is not the same as the intracellular H2O2 concentration but rather serves as 
an index of change in H2O2 concentration with plasma treatment. 
Singlet oxygen was not detected in liquid or cells even at high plasma doses. 
DBD plasma produces O2(
1∆g) at a density of 10
14
 – 1016 molecules.cm-3 [86, 87]. The 
short half-life (microseconds) of this species makes it difficult to measure [73]. Even 
though another study using a similar plasma device showed increase in O2(
1∆g) in 
plasma-treated PBS using the probe singlet oxygen sensor green, we did not measure any 
increase in tMVP fluorescence [88]. This could be attributed to differences in treatment 
volume, liquid depth and dye sensitivity between the two studies. In the presence of 
O2(
1∆g), tMVP produces a luminescent signal and converts to 1-pyrenecarboxaldehyde. 
Since we did not detect any luminescent signal, we employed the technique used by 
Bulina et al which included fluorescent detection of 1-pyrenecarboxaldehyde [64]. But 
this technique also showed no increase. This lack of signal could be either due to the 
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absence of significant singlet oxygen production with our treatment method or poor 
sensitivity of tMVP dye. The SFM blank consistently had a higher fluorescent intensity at 
the characteristic tMVP excitation/emission wavelengths compared to PBS blank. 
Interestingly, we also measured significant amounts of reactive nitrogen species 
(RNS), including peroxynitrite and nitrite in liquid and cells treated with DBD plasma. 
DBD plasma-produced NO immediately reacts with either O3 or O2
-
, making it extremely 
difficult to measure directly. Instead, we detected ONOO
-
, which is produced by the 
reaction between NO and O2
-
 [53, 89], and NO2
-
, which is derived from NO and ONOO
-
 
[53, 90]. ONOO
-
 may diffuse freely across phospholipid membranes or pass through 
anion channels [89, 91]. Even though ONOO
-
 has a permeability coefficient comparable 
to that of water, due to the rather short  half-life (milliseconds) at pH 7.4 and 37 °C, it 
diffuses only ~100 µm in physiological buffers [73, 92]. In our experiments, the liquid 
height above the cell monolayer was ~650 µm, which could have limited ONOO
-
 entry 
into cells to ONOO
-
 produced in close proximity to cells. Plasma-produced RNS are 
important because ONOO
-
 reacts directly with amino acids such as cysteine, tryptophan 
and methionine present in SFM and NO2
-
 may take part directly in intracellular signaling 
[53, 54]. 
Once ROS enter cells, they can either damage intracellular components [82] or 
promote or inhibit intracellular signaling pathways [93, 94]. Cells may also activate 
antioxidant mechanisms such as glutathione, catalase, ascorbate, superoxide dismutase 
etc., which may remove the ROS influx and maintain cell redox state [69].We observed 
that the intracellular ROS increase immediately after plasma treatment decreased to 
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control values within 3 hours. This could be in part due to ROS removal by cellular anti-
oxidant mechanisms. 
While this study identified several ROS and RNS in liquid and cells, it is not 
without limitations. We quantified H2O2 and NO2
-
 concentrations with H2O2 and sodium 
nitrite standard curves, but the lack of stock ROS or donors limited our study to 
measuring change in probe fluorescence. We also used SFM in our studies, since serum is 
difficult to characterize and has anti-oxidant properties [74, 95]. Since serum would be 
present in a wound environment, serum and fluid thickness effects on plasma treatment 
should be determined. 
2.4.2 PHD plasma 
In gas phase, NO levels rapidly increased with PHD plasma treatment and 
reached a stable level of 1980 ± 50 ppm NO in ~50 pulses [21, 96]. While NO saturated 
after 50 pulses in gas phase, the NO concentration in liquid and cells continued to rise up 
to 240 pulses. This effect may be related to the difference in NO diffusion time in air and 
liquids. While NO diffusion in gas is rather fast, it is slow in water (Dgas=0.3cm
2
/s vs. 
DH2O=2×10
-5
cm
2
/s). Also, in order for the plasma produced NO to reach the liquid 
surface, it has to travel through a 50 mm tygon tube. To reach the cells from the liquid 
surface, NO has to travel another 3 mm and 1 mm in 96-well and 24-well plate, 
respectively. The difference in liquid NO concentration between straight and curved tube 
is most likely due to NO interaction with the curved tube surface. The low NO 
concentrations detected in cells compared to that in PBS may be due to the short NO half-
life in liquid. 
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We measured DBD plasma and PHD plasma-produced biologically relevant 
reactive oxygen and nitrogen species in liquids and cells, namely H2O2, OH·, O2
-
, 
ONOO
-
, and NO2
-
. This study will help create plasma devices that can be used to deliver 
precise ROS/RNS doses for biological treatments. Specific ROS or RNS in controlled 
doses can be achieved by controlling plasma discharge properties, including electron 
density, temperature, and gas composition. For example, hydroxyl radicals can be 
increased by raising gas moisture. This preliminary study will help to identify the role of 
specific plasma-produced ROS or RNS in generating physiological responses, 
specifically angiogenesis in wound healing. 
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CHAPTER 3: EFFECTS OF DBD PLASMA TREATMENT ON 
ENDOTHELIAL CELLS 
3.1 Introduction 
Angiogenesis, the growth of new blood vessels from existing vessels, plays a key 
role in a variety of physiological processes including development, growth, and wound 
healing [1]. Insufficient vascularization contributes to impaired wound healing in patients 
with diabetes [2] and systemic sclerosis [3], the elderly [4], and patients treated with 
immunosuppressive drugs [5], chemotherapy [6] and radiotherapy [7]. In vitro, 
vascularization is essential for engineering complex, large tissues and organs such as 
bone, muscle, liver and heart. Although successful tissue fabrication on the scale of a few 
hundred microns has been achieved, tissue engineering is limited by the inability to 
adequately vascularize constructs to provide nutrients to the tissue core [8-11]. 
Over the past few decades, many growth factors that stimulate angiogenesis have 
been discovered, including vascular endothelial growth factor (VEGF) [12, 13] and 
fibroblast growth factor-2 (FGF-2) [14, 15]. These growth factors are the standard by 
which other angiogenic therapies are measured in either in vivo assays (e.g. Matrigel 
plug, corneal implant) [16-19] or in vitro assays (e.g. cell proliferation, Boyden chamber 
migration, collagen gel tube formation) [20-24]. While these growth factors are critical to 
the angiogenic process, their success depends on timing, dose, and gradients [25-28]. 
Efforts to apply growth factors in wounds or in tissue engineered constructs to induce 
angiogenesis have met with limited success [28-30]. 
FGF-2, a pro-angiogenic molecule that binds to heparan sulfate proteoglycans as 
well as cell surface tyrosine kinase receptors, is associated with cell survival, 
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proliferation, and migration [31-33]. FGF-2 is particularly interesting because it does not 
have a recognized signal sequence for secretion. FGF-2 is known to be released by 
injured cells, whether the injury is by ionizing radiation, pulsed electromagnetic field, 
mechanical forces, or elevated glucose [34-38]. FGF-2 released during cell injury 
promotes cell survival and also increases FGF-2 expression in endothelial cells, smooth 
muscle cells and cardiac myocytes [39-43]. Thus, cells that have suffered an injury 
prepare themselves against subsequent injuries by synthesizing additional FGF-2. FGF-2 
may also induce expression of other angiogenic growth factors, such as VEGF, in 
endothelial cells [44]. 
In the previous chapter, we demonstrated that non-thermal DBD plasma increased 
ROS concentration in both phosphate buffered saline (PBS) and serum-free medium 
(SFM) in a dose-dependent manner, with a higher concentration observed in SFM 
compared to PBS. We also measured DBD plasma-produced biologically relevant 
reactive oxygen and nitrogen species in liquids and cells, namely H2O2, OH·, O2
-
, 
ONOO
-
, and NO2
-
. These reactive oxygen species (ROS) contribute to angiogenesis and 
angiogenic signaling [45]. While in an early wound high ROS levels mediate 
inflammation [46] and may inhibit angiogenesis, later low ROS levels initiate wound 
healing partially through angiogenesis [47-49]. Low dose ROS may increase endothelial 
cell migration, proliferation and tube formation in vitro and in vivo through growth factor 
related mechanisms. ROS can enhance production of pro-angiogenic factors such as 
VEGF and FGF-2 [48, 50-52], as well as other mitogens such as insulin-like growth 
factor-1 (IGF-1) [53] and transforming growth factor-α (TGF-α) [54]. Low ROS doses 
may enhance growth factor binding to receptors, induce receptor tyrosine kinase 
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phosphorylation, or act as messengers in downstream signaling along growth factor 
pathways [45, 55-58]. Finally, ROS can damage the cell membrane leading to FGF-2 
release, which then has proliferative and survival effects on adjacent cells [37, 59]. 
Previous work showed that DBD plasma promoted cell proliferation through 
FGF-2 release [60]. However, it was not clear which plasma-produced ROS were 
responsible for FGF-2 release and angiogenic effects. Also, the effects of plasma induced 
FGF-2 release on the next steps in angiogenesis - cell migration and tube formation - 
were not measured. We hypothesized that plasma-induced FGF-2 release occurs through 
sub-lethal membrane damage, caused primarily by H2O2 and OH∙ radicals.  In this 
chapter, we quantify the effects of cell-released FGF-2 on endothelial cell proliferation, 
migration, and tube formation and use species specific scavengers to determine which 
ROS are primarily involved in plasma-induced angiogenesis. 
3.2 Experimental procedure 
3.2.1 Cell culture, materials and plasma treatment 
Porcine aortic endothelial cells (PAEC) were cultured as previously described. 
Non-thermal DBD plasma with the same characteristics as described in Chapter 2 was 
used for all treatments. Cells in glass bottom dishes (14 mm microwells, MatTek) or on 
18 mm coverslips (VWR) were directly treated with plasma in the presence of 100 µl 
serum-free medium to prevent sample drying. Plasma was produced between the 
insulated high voltage electrode and the cell sample, which acted as the other electrode. 
Recombinant human FGF-2 was from Peprotech, and the neutralizing FGF-2 antibody 
was from Upstate Biotechnology. An intracellular ROS scavenger, 10 mM N-acetyl 
cysteine (NAC, Sigma) and an extracellular ROS scavenger, 50 mM sodium pyruvate 
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(SP, Sigma), were used to block plasma-produced ROS. 10 µM mannitol (M, Sigma), 
1000 U/ml catalase (C, Sigma), 10 µM sodium azide (SA, Sigma) and 10 µM ascorbic 
acid (AA, Sigma) were used to scavenge OH∙, H2O2, O2(
1∆g) and O2
-
, respectively. 
3.2.2 Proliferation assay 
Endothelial cell proliferation in response to plasma treatment was measured by 
cell counts. 10,000 cells were seeded on 18 mm glass coverslips and incubated for 24 
hours at 37°C. Cells were then treated with plasma (0 – 8.4 J/cm2, day 0) and returned to 
the incubator. Medium was changed on days 2 and 4. On days 1, 3 and 5 after plasma 
treatment, PAEC were washed with PBS, trypsinized and counted using a Coulter 
counter. Cell proliferation was defined as fold change in attached cell number on day 5 
compared to day 1. 
To measure which plasma ROS were responsible for cell proliferation, cells were 
then treated with plasma (4.2 J.cm
-2
) in the presence or absence of mannitol (10 µM) and 
catalase (1000 U/ml) and returned to the incubator (Day 0), and cell were counted as 
previously described. 
3.2.3 2D migration assay  
 
Figure 43: Cells seeded in a circle on gridded coverslip migrate outwards with time 
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Endothelial cell migration in response to plasma treatment was measured using a 
2D migration assay [61, 62]. 30,000 cells were seeded inside 4 mm cloning rings on 
gridded cover slips placed in 6-well plates. A 5 mm glass bead was placed on top of the 
ring to provide tight contact with the coverslip, and samples were placed in an incubator. 
After 3 hours, the bead and ring were removed, and unattached cells were washed away 
with PBS. This process produced a confluent circle of attached PAEC. Cell samples were 
then treated with 4.2 J/cm
2
 plasma, since this dose showed maximal cell response in our 
previous work [60]. Untreated samples were the negative control, and FGF-2 (10 ng/ml) 
was the positive control. Images were captured at 0, 24, 48 and 72 hours after treatment 
in each direction (0, 90, 180 and 270°) using a Nikon Eclipse TS100 inverted phase 
contrast microscope equipped with a Nikon DS-Fi1 CCD camera. Migration distance, 
defined as the difference between cell migration fronts at 0 and 72 hours, was analyzed 
using Image J. After 72 hours, cells were trypsinized and counted using a Coulter counter 
to determine cell number. 
3.2.4 Modified Boyden chamber 3D migration assay 
3D migration was quantified using the QCM cell invasion assay kit (Millipore). In 
this assay, cells migrate through a collagen coated Transwell membrane with 8 µm pores 
and attach to the membrane bottom surface as depicted in figure 2. Migrated cells are 
then fluorescently quantified by staining DNA following cell lysis. 1×10
5
 PAEC in 100 
µl serum-free medium were plasma treated and then added to the upper Boyden chamber 
compartment. Cells were plasma treated prior to being added to the Boyden chamber 
because the DBD plasma electrode was too large for direct cell treatment in the Boyden 
chamber. 150 µl DMEM with 10% FBS was added to the lower compartment. FGF-2 (10 
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ng/ml) was used as positive control and cells without plasma treatment as negative 
control. Samples were incubated at 37°C for 24 hours. 
 
Figure 44: Cells seeded on top of a modified Boyden chamber migrate through a collagen coated 
membrane towards the chemoattractant added to the lower compartment and attach to the 
membrane bottom surface 
Cells that migrated through the membrane were quantified according to the 
manufacturer’s protocol. Briefly, residual cells from the upper compartment were 
removed using a cotton swab. After rinsing the inserts with PBS, cells on the membrane 
bottom surface were removed by incubating inserts in cell detachment solution for 30 
min at 37°C. The detached cells were incubated in lysis buffer/CyQuant dye solution for 
15 min at room temperature, to stain the DNA. 150 µl cell lysis solution was then 
transferred to a 96-well plate and fluorescence was measured at ex/em: 480/520 nm using 
a microplate reader. Fluorescence was converted to cell number using a standard curve. 
3.2.5 Tube formation assay 
An in vitro tube formation assay was performed as described [63]. Briefly, 4 
mg/ml rat tail type I collagen (BD Biosciences) was mixed with plasma treated PAEC 
(4.2 J/cm
2
, 3×10
5
 cells) in serum-free medium. 200 µl cell-collagen mixture was 
immediately added to a 24-well plate and incubated for 1 hour at 37°C. Supplemented 
medium was then added, and medium was replaced every day without disturbing the 
tubes. Phase contrast microscopy images were taken at 0, 24, 48 and 72 hours. Tube 
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formation was quantified using Image J [64]. Tube formation was assessed by measuring 
the tube length from a branch point or between branch points. Eight tube lengths were 
measured in each image, with three images per treatment condition. At 96 hours, samples 
were incubated with 2 µM calcein in Hepes buffer (20 mM Hepes, 137 mM NaCl, 5 mM 
KCl, 1 mM KH2PO4, 2 mM CaCl2, 1 mM MgCl2 and 10 mM glucose, pH 7.4) at room 
temperature for 30 minutes in the dark. Z-stack images were taken by confocal 
microscopy. 
3.2.6 FGF-2 release 
Confluent endothelial cells on coverslips were treated with plasma (4.2 J/cm
2
) in 
the presence or absence of ascorbic acid (10 µM, O2
-
 scavenger), mannitol (10 µM, OH· 
scavenger), catalase (1000 U/ml, H2O2 scavenger) or sodium azide (10 µM, O2(
1Δg) 
scavenger). Following treatment, cells were incubated in SFM for 3 hours at 37°C. FGF-2 
release peaked at this time in our previous studies [60, 65]. Conditioned medium was 
then assayed for FGF-2 by FGF ELISA (R&D Systems). 
3.2.7 Cell viability – sparsely seeded vs. densely seeded vs. cells in suspension 
Kalghatgi et al observed that one day post plasma treatment, the attached cell 
number in plasma treated samples was less compared to control samples [60]. These 
experiments were carried out on sparsely seeded cells that were allowed to attach for 24 
hours. A cell viability study was carried out with sparsely seeded, densely seeded and 
suspended cells. For sparsely seeded samples, 30,000 cells were seeded on 18 mm glass 
coverslips and incubated for 2 hours at 37°C. For densely seeded samples, 30,000 cells 
were seeded inside 4 mm cloning rings on 18 mm cover slips in a 12-well plate and 
incubated for 2 hours at 37°C. Sparsely and densely seeded cells were plasma treated (4.2 
115 
 
J/cm
2
) in 50 µl serum-free media followed by addition of 2 ml complete medium. For 
cells in suspension, 30,000 cells suspended in 50 µl serum-free medium were added to a 
coverslip, treated with plasma (4.2 J/cm
2
) and placed in a 12-well plate followed by 
addition of 2 ml complete medium. Samples were incubated for 24 hours at 37°C, 
trypsinized and counted using a Coulter counter. 
3.2.8 Statistical analysis 
Statistical analysis was performed with Prism software (Graphpad). Data are 
expressed as mean ± SD. Comparisons between two groups were analyzed using 
Student’s t-test, and comparisons between more than 2 groups were analyzed by 
ANOVA. 
3.3 Results 
3.3.1 Plasma-induced endothelial cell proliferation 
We previously demonstrated that plasma increased endothelial cell proliferation 
through FGF-2 release [60]. We now show that plasma-produced ROS are critical to 
enhanced cell proliferation. Cell proliferation increased in a dose-dependent manner up to 
4.2 J/cm
2
 plasma, and then decreased at higher plasma doses (Figure 45). Cells treated 
with 4.2 J/cm
2
 plasma on day one had ten times as many cells on day five, whereas 
control cells had only six times as many cells. Cells incubated with a 10 ng/ml FGF-2 
bolus on day one had twelve times as many cells on day five. An FGF-2 neutralizing 
antibody (Figure 45), the intracellular ROS scavenger N-acetyl cysteine, and the 
extracellular ROS scavenger sodium pyruvate (Figure 46) abrogated the plasma-induced 
enhancement in cell proliferation. 
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Figure 45: DBD plasma enhanced endothelial cell proliferation through FGF-2 release. PAEC were 
counted 1, 3 and 5 days after plasma treatment. A neutralizing antibody blocked FGF-2 effects. Data 
are represented as fold change in cell number on day 5 compared to day 1. † p<0.001 and # p<0.05 
compared to control. *p<0.0001 compared to plasma. 
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Figure 46: DBD plasma treatment enhanced endothelial cell proliferation through ROS-induced 
FGF-2 release. PAEC were counted 1, 3 and 5 days after plasma treatment. 10 mM N-acetyl cysteine 
(NAC) or 50 mM sodium pyruvate (SP) blocked intracellular and extracellular ROS, respectively. 
Data are represented as fold change in cell number on day 5 compared to day 1. † p<0.001 and # 
p<0.05 compared to control. *p<0.0001 compared to plasma.  
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3.3.2 Plasma-induced endothelial cell migration 
Since maximum cell proliferation was observed for 4.2 J/cm
2
 plasma, 2D cell 
migration was measured at this plasma dose. Endothelial cell 2D migration increased 
with plasma as early as 24 hours after treatment compared to untreated control (390 µm 
vs. 190 µm), and the difference was maintained up to 72 hours after plasma treatment 
(902 µm vs. 624 µm). Exogenous FGF-2 significantly increased endothelial cell 
migration compared to control (1709 µm vs. 624 µm). To elucidate whether enhanced 
cell migration was attributed to ROS-induced FGF-2 release, cells were plasma treated in 
the presence of an FGF-2 neutralizing antibody, N-acetyl cysteine, or sodium pyruvate. 
FGF-2 blockade decreased PAEC migration distance by 23% (Figure 47). Similarly, both 
N-acetyl cysteine and sodium pyruvate inhibited plasma-induced cell migration by 14% 
and 22%, respectively (Figure 48). Figure 49 shows phase contract images of migrating 
plasma-treated cells 0, 24, 48 and 72 hours after treatment. No significant difference in 
cell counts was observed between control and plasma treated samples at 72 hours, 
suggesting that these differences were primarily related to cell migration rather than 
proliferation. 
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Figure 47: Low dose DBD plasma treatment enhanced 2D endothelial cell migration, which was 
abrogated by FGF-2 neutralizing antibody. PAEC 2D migration after 4.2 J/cm
2
 plasma was assessed 
with an FGF-2 neutralizing antibody. †p<0.001 compared to control. *p<0.01, †† p<0.001.  
 
Figure 48: Low dose DBD plasma enhanced 2D endothelial cell migration, which was abrogated by 
ROS blockade. PAEC 2D migration after 4.2 J/cm
2
 plasma was assessed with N-acetyl cysteine 
(NAC) and sodium pyruvate (SP) to block intracellular and extracellular ROS, respectively. *p<0.01, 
†p<0.001. 
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Figure 49: Sample phase contrast microscopy images of migrating plasma treated cells in the cage 
assay. Scale bar 200 µm. 
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3D cell migration, which provides additional physiological relevance compared to 
the 2D migration assay, also increased with plasma treatment. 24 hours after plasma 
treatment (4.2 J/cm
2
), the PAEC number that migrated through a modified Boyden 
chamber increased significantly. 10 ng/ml FGF-2, used as positive control, increased 
migrated PAEC number by 13%. An FGF-2 neutralizing antibody reduced plasma-
induced migration by 7% (Figure 50), while sodium pyruvate caused a 22% reduction 
(Figure 51). 
 
Figure 50: 3D endothelial cell migration was enhanced by low dose plasma treatment via FGF-2 
release. Plasma treated PAEC were added to the upper compartment of a Boyden chamber, with or 
without a neutralizing FGF-2 antibody, and migrated cells on the well bottom were measured. 
*p<0.01 compared to control. †p<0.01 compared to plasma 
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Figure 51: 3D endothelial cell migration was enhanced by low dose plasma treatment via ROS-
induced FGF-2 release. Plasma treated PAEC were added to the upper compartment of a Boyden 
chamber and migrated cells on the well bottom were measured. To block the ROS effects, cells were 
plasma treated in the presence of extracellular ROS scavenger sodium pyruvate. #p<0.05 compared 
to control, + p < 0.05 compared to plasma. 
3.3.3 Plasma-induced endothelial cell tube formation 
Finally, since both endothelial cell proliferation and migration increased 
significantly with plasma treatment, endothelial cell tube formation following plasma 
treatment was tested. Preliminary tube formation studies showed significant tube 
formation in cells treated with 10 ng/ml FGF-2 compared to untreated samples up to 72 
hours (Figure 52). 
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Figure 52: Cells treated with and without FGF-2 were mixed with collagen gel and polymerized. 
Tube formation was observed in FGF-2 treated samples compared to control starting 24 hours Scale 
bar is 100 µm. 
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Cells treated with 4.2 J/cm
2
 plasma formed an extensive tube network 24 hours 
after plasma treatment, while untreated samples formed only tube segments (Figures 53 
and 54). The average tube length in plasma treated samples was 121 ± 22 µm, 
approximately 2.6 times longer than the average tube length in control samples (Figure 
54). Samples treated with positive control FGF-2 had an average tube length of 134 ± 16 
µm. The FGF-2 neutralizing antibody reduced tube length by 70% (37 ± 8µm). Similarly, 
a 67% decrease in tube length occurred after plasma treatment in the presence of the ROS 
scavenger sodium pyruvate. A phase contrast microscopy image taken with a 4X 
objective showed tube networks within the collagen gel (Figure 55). 
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Figure 53: Endothelial cell tube formation was enhanced by plasma treatment. PAEC were plasma 
treated (4.2 J/cm
2
) and polymerized in a collagen gel. (a) Phase contrast images of tube formation at 
24 hours. 
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Figure 54: Endothelial cell tube formation was enhanced by plasma treatment. PAEC were plasma 
treated (4.2 J/cm
2
) and polymerized in a collagen gel. Tube length was quantified using Image J. 
†p<0.001 compared to control, +p<0.0001 compared to plasma. 
 
Figure 55: Phase contrast image showing extensive tube formation by plasma treated cells deep in the 
collagen gel. 
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In vitro tube formation assay in collagen gel is usually accompanied by lumen 
formation [66]. Confocal microscopy images of plasma (4.2 J/cm
2
) treated samples 
showed extensive tube networks with a lumen-like structure (~10 µm in diameter, Figure 
56). 
 
Figure 56: Z-stack confocal microscopy images of calcein stained cells showed tubes with a lumen (10 
µm). 
3.3.4 Specific ROS in plasma-induced FGF-2 release and subsequent cell 
proliferation 
We demonstrated that plasma ROS induced FGF-2 release, which enhanced 
endothelial cell proliferation, migration, and tube formation. However, we did not know 
which plasma-produced ROS caused this effect. Since FGF-2 release peaked 3 hours 
following plasma treatment, we measured plasma-induced FGF-2 release at this 
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timepoint. Blocking O2
-
 (with 10 µM ascorbic acid) and O2 (
1Δg) (with 10 µM sodium 
azide) caused only 38% and 30% reduction in FGF-2 release, respectively [60]. FGF-2 
release from plasma-treated PAEC decreased by 72% and 75% upon blocking OH∙ (with 
10 µM mannitol) and H2O2 (with 1000 U/ml catalase), respectively (Figure 57). 
Endothelial cells treated with 4.2 J/cm
2
 plasma showed 1.8 times more cells than control 
samples five days after plasma treatment. OH∙ scavenging reduced cell proliferation 
almost 30%, while H2O2 scavenging caused an additional 15% reduction (Figure 58). 
 
Figure 57: Plasma-induced FGF-2 release was reduced upon blocking hydroxyl radical (OH·) and 
hydrogen peroxide (H2O2). Confluent PAEC were treated with 4.2 J/cm
2
plasma dose in the presence 
of 10 µM sodium azide (SA, O2
-
 scavenger), 10 µM ascorbic acid (AA, O2(
1Δg) scavenger), 10 µM 
mannitol (M, OH· scavenger) or 1000 U/ml catalase (C, H2O2 scavenger). FGF-2 was measured in 
conditioned medium 3 hours after treatment using an FGF ELISA. †p<0.01 compared to control, 
#p<0.01 compared to plasma. 
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Figure 58: Plasma-induced cell proliferation was reduced upon blocking OH· and H2O2. 
Subconfluent PAEC were treated with 4.2 J/cm
2
 plasma in the presence of mannitol or catalase. Data 
are represented as fold change in cell number on day 5 compared to day 1. *p<0.05 compared to 
control, **p<0.05 compared to plasma. 
3.3.5 Effect of seeding density on cell viability after plasma 
In sparsely seeded, densely seeded and suspended cells conditions, attached cell 
number in plasma (4.2 J/cm
2
) treated samples was less compared to control samples. In 
control samples, 90% of sparse and densely seeded cells survived 24 hours after seeding. 
However, only 56% of suspended cells remained. This cell loss limits the ability to judge 
the effect of plasma on suspended cells. In cells that were plasma treated, sparsely seeded 
cells showed a 61% decrease in attached cell number 24 hours after plasma treatment 
(Figure 59). Densely seeded cells only experienced a 12% decrease in cell number. These 
data suggest that cell viability post-plasma treatment depended on cell density. 
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Figure 59: Densely seeded cells have higher viability following plasma compared to sparsely seeded 
and suspended cells 
3.4. Discussion 
Vascularization is critical to a variety of processes, including wound healing and 
tissue engineering. Low ROS doses have previously been shown to promote 
vascularization through angiogenic growth factor mechanisms [45, 67]. Non-thermal 
plasma is known to produce a variety of ROS in the gas phase, and we previously 
demonstrated that non-thermal plasma enhanced endothelial cell proliferation through 
FGF-2 release [60]. We now show that ROS produced by plasma also enhance 
endothelial cell migration and tube formation through FGF-2 release and this increase 
was abrogated by a neutralizing FGF-2 antibody as well as intracellular and extracellular 
ROS scavengers. We also demonstrated that H2O2 and OH∙ are the primary plasma ROS 
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responsible for the angiogenic effect. These data suggest that plasma may be a useful tool 
for promoting vascularization. 
Sub-lethal cell membrane damage by plasma leads to FGF-2 release from 
endothelial cells [60]. Since FGF-2 lacks a classic signaling sequence, it is only known to 
be released when the plasma membrane is damaged [68]. Cell membrane disruption and 
FGF-2 release are induced in vivo by mechanical forces such as gastrointestinal tract 
movement, blood flow through aorta and muscular movements [69, 70], and in vitro 
during cell culture by trypsinization [69]. In our previous work, FGF-2 release peaked 3 
hours after plasma treatment and decreased to half the maximum value within another 3 
hours [60]. Released FGF-2 could promote damaged cell survival, proliferation, and 
FGF-2 mRNA and protein expression [37, 59, 71]. Since ROS are known to enhance 
FGF-2 affinity to its receptor, the presence of plasma-produced ROS could accelerate 
binding of released FGF-2 [57]. 
In this study, FGF-2 released following plasma treatment not only induced cell 
proliferation, but it also induced cell migration and tube formation. In typical migration 
assays, a growth factor gradient is used to induce directional migration. In both our 2D 
and 3D migration assays, cell FGF-2 release occurred in all directions, therefore our 
migration results may not be as high as if a growth factor gradient were induced. We 
additionally observed a decrease in cell migration when either a neutralizing FGF-2 
antibody or an ROS scavenger was added to both plasma-treated and control cells. Both 
FGF-2 and ROS are constitutively present in medium and cells, therefore blockade of 
these factors would be expected to affect even untreated samples. 
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H2O2 and OH∙ scavengers significantly reduced plasma-induced FGF-2 release 
and subsequent cell proliferation, confirming that these are the critical ROS for plasma-
induced angiogenesis. H2O2 and OH∙ can cause sub-lethal cell membrane damage and 
subsequent FGF-2 release [60]. Brunk et al showed that a 30 min exposure to 250 µM 
H2O2 induced non-lethal, reversible and reparable membrane disruption in cells [72]. 
Both large and small molecules move freely across these membrane disruptions which 
may range in size from 1 nm to greater than 1 µm [73]. A non-thermal atmospheric 
pressure glow discharge torch (APGD-t) permeabilized HeLa cells by creating temporary 
6.5 nm pores, and OH∙ was proposed to be the key ROS [74]. Since OH∙ is converted to 
H2O2 and vice versa, it is not clear whether only one or both species are important for the 
observed physiological effects. Both OH∙ and H2O2 are likely responsible for sub-lethal 
membrane damage leading to FGF-2 release. 
Non-thermal plasma has many advantages over other methods of applying ROS to 
stimulate vascularization. Plasma is a safe, cheap and portable technology compared to 
other mechanisms of inducing ROS or releasing FGF-2, such as electrical stimulation 
[75], pulsed electromagnetic fields [34] and ionizing radiation [76]. Unlike these 
technologies, non-thermal plasma does not cause measurable damage to surrounding 
tissue. Since plasma devices are small and portable, they can be used in hospitals, disaster 
areas, and in the military. Plasma devices can also be scaled to meet specific treatment 
requirements and modified to produce specific reactive species [77]. As shown in our 
previous work, in the event that direct plasma treatment is not possible, conditioned 
medium from plasma treated cells containing growth factors can also be used for 
promoting angiogenesis [60]. 
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While plasma can be used to apply ROS to wounds or tissue engineering 
structures and thereby promote vascularization, it is unlikely that plasma alone will be 
able to produce efficient angiogenesis. Angiogenesis is a complex physiological process 
involving several angiogenic factors, which must be released at specific times and in 
specific concentration gradients. Hence, it might not be possible to achieve angiogenesis 
of clinical significance by the application of one treatment technique but rather a 
combination of multiple treatment techniques. Growth factor therapy for promoting 
angiogenesis has been rather disappointing in clinical studies, even though it showed 
great promise in animal studies [28, 78]. This could be attributed to the inability to 
maintain a sufficient growth factor concentrations long enough to generate a response due 
to difficulties in delivery methods and precise dosing [78]. Non-thermal plasma enables 
localized ROS application in precise doses, which may be optimized to release sufficient 
concentration of growth factors, specifically FGF-2. Thus plasma may be used as an 
adjuvant to conventional vascularization techniques. Adding plasma-treated cells in tissue 
engineering scaffolds may accelerate the vascularization process, and plasma may help 
promote angiogenesis in wounds, leading to faster healing. 
Our goal was to understand plasma-induced FGF-2 release in endothelial cell 
proliferation, migration and tube formation. However, these studies are not without 
limitations. The ROS dye DCFH reacts with a wide variety of ROS, thus we are not 
certain which plasma-produced ROS induce the angiogenic response. Complexity is 
further enhanced since plasma-produced ROS interact with each other as well as air and 
liquid components to produce additional reactive species. Other angiogenic factors may 
also be upregulated by plasma treatment, and these could also play a role in plasma-
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induced vascularization. The 2D cell monolayer model employed in our research for 
plasma treatment is significantly different from in vivo conditions. We also used serum-
free medium in our studies, since serum is difficult to characterize and may have anti-
oxidant properties [79]. Since serum would be present in a wound environment, specific 
serum and fluid thickness effects on plasma treatment should be determined. 
We now show that plasma technology, specifically non-thermal DBD plasma, 
could be used to stimulate angiogenesis. By using specific ROS scavengers, we showed 
that both H2O2 and OH· induce angiogenesis via FGF-2 release through sub-lethal cell 
membrane damage. Plasma dose can be varied by changing the treatment time, and 
plasma composition can be modified by changing the electrical parameters. Plasma 
treatment could be used to promote tissue engineering scaffold vascularization as well as 
accelerate wound healing via enhanced angiogenesis. For tissue engineering scaffolds, 
cells could be treated with plasma prior to seeding them in the scaffold. For wound 
healing, plasma ROS could be used initially at higher doses to sterilize the wound and 
later at lower doses to promote healing. This novel tool could make ROS a practical, 
physiological method to create new blood vessels either in vitro or in vivo. 
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CHAPTER 4: EFFECTS OF PIN-TO-HOLE SPARK DISCHARGE PLASMA ON 
ENDOTHELIAL CELLS 
4.1 Introduction 
Nitric oxide (NO) is a short-lived (half-life 3-30 s) bioactive gas critical to 
inflammatory and vascular processes. As a signaling molecule, NO participates in a wide 
range of physiological reactions to maintain normal endothelial function and an 
antithrombotic environment. Specifically, NO regulates vascular tone, endothelial 
permeability, smooth muscle cell proliferation, platelet aggregation, and leukocyte 
adhesion [1]. NO is highly soluble in organic solvents [2] and rapidly diffuses into the 
cells due to its lipophilic nature. 
NO is generated in cells when NADPH-dependent enzymes called nitric oxide 
synthases (NOS) convert of the amino acid L-Arginine into L-citrulline in the presence of 
oxygen. Constitutively expressed neuronal NOS (nNOS) and endothelial NOS (eNOS) in 
neurons and endothelial cells produce NO in nanomolar concentrations (low), while 
inducible NOS (iNOS) activated during inflammation produces micromolar NO 
concentrations (high). During early stages of wound healing, inflammatory cells such as 
neutrophils and macrophages produce high NO levels to fight infection [3]. As the wound 
heals, endothelial cells, fibroblasts and keratinocytes produce lower sustained amounts of 
NO to stimulate angiogenesis and new tissue formation. 
NO promotes endothelial cell survival and angiogenesis, both in vivo and in vitro. 
The role of NO in in vivo angiogenesis was first identified by Pipili-Synetos et al using a 
chick embryo chorioallantoic membrane in vivo model [4]. Multiple signaling pathways 
have been reported for NO-mediated angiogenesis, both cGMP-dependent and cGMP-
independent [5-7] (detailed in Chapter 1). VEGF-stimulated angiogenesis proceeds 
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through NO production [8], and both exogenous and endogenous NO enhance FGF-2 
expression [9-11]. NO also stabilizes hypoxia inducible factor-1α (HIF-1α), which, in 
turn, upregulates VEGF production [12]. Finally, NO mediates αvβ3 integrin expression 
which facilitates cell migration [13]. 
The therapeutic potential of NO gas was recognized in 1991 [14], and since then 
has been used for the treatment of pulmonary hypertension in adults [15, 16] and in 
neonates [17, 18]. A major drawback associated with medical grade NO is its storage 
protected from oxidation. NO donor drugs opened up new ways of treating tissue 
ischemia by promoting both vasodilation and neovascularization. In spite of the 
enormous potential of NO, only two NO donor drug types are in current clinical use, 
namely sodium nitroprusside and organic nitrates (e.g. Glyceryl trinitrate) [19]. To 
promote wound healing in NO-deficient wounds such as diabetic ulcers, various local 
topical NO delivery systems have been developed [20-23]. However, the success of these 
treatments was limited by short NO half-life, rapid or inconsistent NO release over a 
limited timeframe, and NO donor instability [20, 24, 25]. Any NO therapy for wound 
healing should have simple administration with minimal side effects. Ideally, the 
approach should address both the wound inflammatory and healing stages. 
In recent years, thermal plasmas which produce NO in high concentrations have 
been shown to enhance wound and skin disease treatment. A rapidly quenched hot air 
plasma jet system, the ‘Plazon’, provides a relatively high NO concentration with 
significant therapeutic effect [26-28]. In ‘hot mode’, Plazon was used to rapidly coagulate 
and sterilize wound surfaces, while removing dead tissue. In ‘cold mode’, the NO-rich 
plasma gas flow (20–40°C) was used to stimulate regenerative processes and wound 
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healing. An additional NO producing plasma, a pin-to-hole spark discharge (PHD), has 
also been reported to sterilize liquids and surfaces (including living tissue) and may also 
stimulate wound healing [29-34].  However, the effects of this spark discharge at a 
cellular level have never been characterized. 
Here we present a study of the PHD plasma which produces local, topical NO for 
biological therapy. Previously, we measured the PHD plasma NO delivery into liquid and 
cells. We hypothesized that the PHD plasma-produced NO promote angiogenesis. In this 
study we further investigated plasma NO effects on cell viability and intracellular 
signaling. We also quantified effects of plasma NO on endothelial cell proliferation, 
migration and tube formation. This study will help develop a novel plasma device that 
delivers NO for therapeutic use in wound healing and tissue vascularization. 
4.2 Materials and methods 
4.2.1 Endothelial cell culture and plasma treatment 
Porcine aortic endothelial cells (PAEC) were cultured as described previously in 
Chapter 2. 3-isobutyl-1-methylxanthine (IBMX) and cGMP Enzyme Immunoassay (EIA) 
kit were purchased from Cayman Chemicals. Diethylamine NONOate (DEA NONOate, 
Cayman Chemicals) and sodium nitroprusside (SNP, Sigma) were used as NO donors. 
Sodium pyruvate (SP, Sigma) was used as the ROS scavenger. PAEC were plasma 
treated with either the straight or curved tube extension. Cell viability assays were done 
in both PBS and serum-free medium. The cGMP assay was carried out in serum-free 
medium. 
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4.2.2 Cell viability 
Cell viability following plasma treatment was measured via cell counts and a 
Live/Dead assay (Invitrogen). PAEC were seeded near confluence in a 24-well plate 
(200,000 cells/well) and incubated for 24 hours. Supplemented medium in the wells was 
replaced with 200 µl serum-free medium or PBS, and samples were treated with plasma 
for 0 – 240 pulses using the 50 mm curved tube extension. Following plasma treatment, 
PAEC were returned to supplemented medium and incubated at 37°C for 3 or 24 hours. 5 
mM SNP was used as the positive control. Cells were washed once in PBS to remove 
detached cells, trypsinized and counted using a Coulter counter (Beckman Coulter). 
For the Live/Dead assay, PAEC were seeded near confluence in a 96-well plate 
(30,000 cells/well) and incubated for 24 hours. 100 µl serum-free medium was added to 
each well, after which cells were treated with plasma for 0 – 240 pulses using the 50 mm 
straight or curved tube extension and incubated for 24 hours. Cells were then washed to 
remove detached cells, labeled with 2 µM calcein AM and 4 µM ethidium homodimer-1 
(EthD-1) and incubated for 45 min at room temperature. Live cells convert non-
fluorescent cell permeant calcein AM into highly fluorescent calcein by intracellular 
esterase activity. EthD-1 binds to nucleic acids in membrane damaged cells to undergo a 
40-fold increase in fluorescence, and is excluded by cells with intact membranes. Thus 
calcein is retained by live cells and produces green fluorescence (ex/em: 485/530 nm), 
while EthD-1 produces red fluorescence in dead cells (ex/em: 530/645 nm). Fluorescence 
was measured using the microplate reader. 
For Live/Dead imaging using a fluorescent microscope, PAEC were seeded near 
confluence in a 24-well plate (200,000 cells/well) and incubated for 24 hours. 
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Supplemented medium in the wells was replaced with 200 µl serum-free medium, and 
samples were treated with plasma for 0 – 240 pulses, using the 50 mm curved extension. 
Cells were then labeled with calcein AM and EthD-1 as described previously and imaged 
by fluorescent microscopy (Olympus) with a digital high performance CCD camera 
(Diagnostic Instruments). 
4.2.3 NO intracellular cGMP induction 
NO diffuses freely through biological membranes into the cytoplasm [35], where 
it stimulates soluble guanylyl cyclase (sGC) to convert guanosine triphosphate (GTP) 
into 3, 5-cyclic guanosine monophosphate (cGMP) [36]. Many NO biological effects are 
mediated through the second messenger, cGMP. Hence, the cGMP assay is widely used 
for the indirect NO measurement. Guanylyl cyclase can be activated by nanomolar 
concentrations of intracellular NO [37]. 
NO induced cGMP accumulation was measured using a cGMP competitive EIA. 
In this assay, a constant cGMP tracer concentration competes with free cGMP in the 
sample for cGMP-specific binding sites in the well. The sample cGMP concentration is 
therefore inversely proportional to the bound cGMP tracer amount (measured well color). 
PAEC were seeded near confluence in a 24-well plate (200,000 cells/well) and incubated 
for 24 hours. Prior to plasma treatment, cells were incubated with IBMX (0.5 mM) for 30 
min at 37°C, to prevent cGMP degradation by phosphodiesterases [38]. Cell medium was 
then replaced with 200 µl serum-free medium containing IBMX and plasma treated for 0-
240 pulses, employing the curved tube extension. Media was aspirated and 0.1 N HCl 
was added to each well. The cells were then scraped off the surface, samples were 
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centrifuged at 1000g for 10 min, and the supernatant was assayed as per manufacturer’s 
instructions. 
4.2.4 Proliferation assay 
Since cell counts and live/dead assay showed no significant cell death for 0 – 60 
plasma pulses with a curved tube extension, cells were treated at these doses for 
quantifying plasma NO angiogenic effects. 5,000 cells seeded in 24-well plates were 
treated with plasma for 0 – 60 pulses and endothelial cell proliferation was measured by 
cell counts as described previously in Chapter 3. 
4.2.5 2D migration assay 
Endothelial cell migration in response to plasma treatment was measured using a 
2D migration assay [39, 40] as previously described in Chapter 4. A confluent circle of 
attached PAEC (30,000 cells) were treated for 0 – 60 pulses. 
4.2.6 Tube formation assay 
An in vitro tube formation assay was performed as described previously [41]. 
Briefly, 4 mg/ml rat tail type I collagen (BD Biosciences) was mixed with Plasma treated 
PAEC (0 – 60 pulses, 3×105 cells) were mixed with collagen and analyzed for tube 
formation. 
4.2.7 Statistical analysis 
Statistical analysis was performed using Prism software (Graphpad). Data are 
expressed as mean ± SD. Comparisons between two groups were analyzed by Student’s t-
test, and trend over time was analyzed by one-way and two-way ANOVA. 
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4.3 Results 
4.3.1 Cell viability with plasma treatment 
Cell viability after plasma treatment was measured to ensure that PHD plasma 
was non-toxic to cells. For cell counts, PAEC were treated with plasma in both PBS and 
serum-free media, employing the curved tube configuration. For both fluids, no 
significant cell loss was observed 24 hours after plasma treatment up to 240 plasma 
pulses (Figure 60). A Live/Dead assay was carried out to confirm the results from cell 
counts. Approximately 20% cell loss was observed for a treatment of 240 pulses in 
serum-free media in the straight tube configuration. No significant cell loss was observed 
for low treatment doses (Figure 61). For similar treatment conditions employing the 
curved tube extension, no significant cell loss was observed even at 240 pulses (Figure 
62). 
 
Figure 60: Endothelial cell viability was maintained following PHD plasma treatment. Viable 
endothelial cell number 24 h post PHD plasma treatment was measured by cell count. p<0.05 for 
PBS. 
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Figure 61: Endothelial cell viability was maintained following PHD plasma treatment. Viable 
endothelial cell number 24 h post plasma treatment was measured using Live/Dead assay. *p < 0.05 
compared with control, #p < 0.001 comparing straight and curved tube for 240 pulse plasma 
treatment 
 
Figure 62: Sample Live/Dead assay images show cells that are alive (green) or dead (red). Scale bar is 
200μm. 
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4.3.2 Intracellular cGMP in response to plasma-derived NO 
NO biological activity was measured indirectly in cells by determining cGMP 
concentration. cGMP inside endothelial cells following plasma treatment was measured 
up to 240 pulses, using the curved tube extension. A linear increase in cGMP was 
observed with plasma dose (Figure 63). The endothelial cGMP concentration for the 
highest plasma treatment of 240 pulses increased approximately 4 times compared to 
control. To determine the influence of plasma-produced ROS on cGMP, the assay was 
carried out in the presence of ROS scavenger sodium pyruvate. While plasma-induced 
cGMP concentration decreased with the addition of sodium pyruvate, the cGMP level 
continued to increase linearly with plasma dose. 
 
Figure 63: cGMP concentration increased linearly in response to plasma treatment. Plasma-induced 
cGMP decreased overall with the ROS scavenger sodium pyruvate (10 mM); however, levels 
continued to increase linearly with plasma dose. *p < 0.05 compared with control without sodium 
pyruvate, +p < 0.05 compared with control with sodium pyruvate and #p < 0.001. 
152 
 
4.3.3 Endothelial cell proliferation 
Increased cell proliferation was observed with PHD plasma treatment starting 
from day 3 after treatment. A rapid increase in cell proliferation was observed for 5 
pulses followed by a slow increase for up to 60 pulses. Samples treated with the highest 
plasma dose of 60 pulses had 2.7 times as many cells on day five as on day one, while 
control samples had only 2.5 times. 
 
Figure 64: PHD plasma treatment enhanced endothelial cell proliferation. PAEC were counted 1, 3 
and 5 days after plasma treatment. Data are represented as fold change in cell number on day 5 
compared to day 1. *p<0.01, #p<0.05 compared to control. 
4.3.4 2D endothelial cell migration 
Endothelial cell 2D migration increased with plasma as early as 24 hours after 
treatment compared to untreated control for 15 pulses (290 µm vs. 403 µm) and 60 pulses 
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(290 µm vs. 374 µm). Significant cell migration was observed at 48 hours for all plasma 
treatments compared to plasma and this difference was maintained up to 72 hours after 
plasma treatment (789 µm, 757 µm and 795 µm for 15, 30 and 60 pulses respectively 
compared to control (603 µm)). 
 
Figure 65: PHD plasma treatment enhanced 2D endothelial cell migration. (a) PAEC migration after 
plasma treatment was assessed using a cage assay. Migration distance was assessed by phase contrast 
microscopy 0, 24, 48 and 72 hours after treatment. *p<0.01, **p<0.001, #p<0.05 compared to control. 
4.3.5 Tube formation 
No tube formation was observed in any of the plasma treated samples for up to 72 
hours. 
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4.4 Discussion 
NO is a key molecule involved in inflammation, vasodilation and vascularization. 
Low NO doses promote vascularization directly as well as through growth factor-related 
mechanisms. A pin-to-hole spark discharge plasma produces local, topical NO for 
biological therapy. Previously, we measured NO delivery from PHD plasma into liquid 
and endothelial cells. We now show that plasma-derived NO and PHD plasma treatment 
are relatively non-toxic to endothelial cells. PHD plasma treatment also promoted 
endothelial cell proliferation, migration and tube formation. These data suggest that PHD 
plasma treatment may be a useful tool for promoting vascularization. 
Differences in cell viability between the straight and curved tube configurations 
were likely related to residual PHD plasma UV reaching and killing the cells in the 
straight tube extension. PHD plasma radiates intensively in the UV range [42]. Hence, 
even 5 seconds of direct PHD plasma treatment can cause significant endothelial cell 
death. Human cells experience DNA damage by UV doses of 0.5 – 50 mJ/cm2 [43]. UV 
radiations of 90 and 140 µW/cm2, respectively, were measured in PHD plasma with and 
without air flow [42]. Fatal DNA damage could be induced in cells with just 5 sec of 
direct treatment. By employing the curved tube, UV radiation damage was reduced. 
Alternatively, the increased cell death may also have been related to NO dose, since more 
NO was detected in liquid with the straight tube extension. 
No tube formation was observed in PHD plasma treated samples. This could be 
attributed to the slow increase in PHD plasma induced cell proliferation and migration. 
Incubating the plasma treated samples for longer time points might show increased tube 
formation. 
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Multiple signaling pathways have been suggested for NO-mediated angiogenesis, 
both cGMP dependent and cGMP independent. cGMP production by NO activates 
cGMP-dependent protein kinases (PKG), which activates phosphoinositide-3-kinase 
(PI3K) and Raf-1, leading to Akt [44] and ERK 1/2 activation [45], respectively. The 
cGMP independent pathway is triggered through S-nitrosylation. S-nitrosylation of the 
protein Ras by NO leads to activation of kinases, Raf-1, MEK1 and ERK 1/2, which 
increase endothelial cell proliferation and migration [45]. Of the three isoenzymes of 
PKC, NO activates or inhibits PKCα and PKCδ through S-nitrosylation in a 
concentration dependent manner [46]. A low NO concentration activates PKCα while 
inhibiting PKCδ to enhance cell migration and proliferation [46, 47]. NO may also 
modulate the production and activity of angiogenic factors such as FGF-2 to promote 
angiogenesis [10]. 
Besides producing NO and ultraviolet radiation, PHD plasma also produces H2O2 
[42]. H2O2 is known to increase NO-stimulated cGMP production [48]. H2O2 in low 
concentrations increases intracellular cGMP level [49]. While PHD plasma-induced 
cGMP concentration decreased with the sodium pyruvate, the cGMP level continued to 
increase linearly with plasma dose suggesting that NO produced by the PHD plasma 
resulted in endothelial cell cGMP production. 
PHD plasma H2O2 production is also of interest in wound healing applications. In 
early wound healing, H2O2 activates cell surface tissue factor to restore hemostasis and 
modulates both leukocyte adhesion and motility in inflammation [50-52]. ROS are also 
important in wound re-vascularization, since H2O2 induces vascular endothelial growth 
factor expression and is critical in its signaling [53, 54]. Finally, in late wound healing, 
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H2O2 promotes re-epithelialization by activating matrix metalloproteinases and 
promoting epithelial cell motility [55]. Thus, a plasma device that can deliver defined 
doses of H2O2 and NO individually or in combination may be useful throughout the 
wound healing process. Simultaneous delivery of both NO and H2O2 may also induce 
apoptosis in cancerous cells [56], inactivate bacteria [57], and form biologically 
important singlet oxygen [58, 59]. 
Our goal was to understand the effects of PHD plasma produced NO on 
endothelial cell proliferation, migration and tube formation. But these studies are not 
without limitations. We observed minor electrode degradation due to the high plasma 
discharge current and temperature, which deposited iron nanoparticles on the tube walls. 
Further analysis has to be done to understand their impact on cell and tissue function 
during treatment, and precautions have to be taken to avoid any negative impacts. We 
also used serum-free medium in our studies, since serum is difficult to characterize and 
may have anti-oxidant properties [60]. Since serum would be present in a wound 
environment, specific serum and fluid thickness effects on plasma delivery of species 
should be determined. 
In summary, we showed that a microsecond spark discharge ignited in a pin-to-
hole electrode geometry can be safely applied to cells without causing measurable 
viability loss, even though the discharge was designed to be thermal to produce a 
significant amount of NO. PHD plasma employed with the curved tube extension also 
increased endothelial cell proliferation and migration. This plasma may therefore be used 
as a novel method for delivering NO locally and directly to wound sites to promote 
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wound healing. The different treatment configurations and consequent variation in 
delivered reactive species provide additional applications for this discharge. 
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CHAPTER 5: LONG TERM PLASMA EFFECTS DUE TO FGF-2 RELEASE 
5.1 Introduction 
Through the previous chapters in this thesis we showed that FGF-2 release 
induced by DBD plasma-produced OH∙ and H2O2 promoted angiogenesis in vitro. 
However, to develop a plasma wound treatment regime consisting of multiple plasma 
treatments over time, it is imperative to understand long term plasma effects due to FGF-
2 release. 
FGF-2 binds to the tyrosine kinase FGF receptor (FGFR), which causes receptor 
dimerization and autophosphorylation. Several receptor tyrosine kinases are 
phosphorylated, which then serve as docking sites for signaling proteins [1]. Activated 
FGFR activates multiple pathways, namely PI3K-Akt, PLCγ, and FRS2-Ras-Raf-MAPK 
which includes ERK1/2, p38 and JNK [1, 2]. The lipid-anchored docking protein FGFR 
substrate 2 (FGFS2), which is phosphorylated in response to FGF-2 stimulation, serves as 
the docking site for adaptor protein Grb2 and tyrosine phosphatase Shp2 [3, 4]. GAB1 
docks on FGFS2 which stimulates the PI3K-Akt pathway for cell survival [5]. PI3K 
activation recruits PLCγ, which itself is then activated by FGFR. PLCγ activation leads to 
PKC activation, which subsequently activates Rac [6] to promote cell migration. Grb2 
and nucleotide exchange factor son of sevenless (SOS) (Grbs/SOS-1complex) form a 
complex and activate the Ras-Raf-MAPK pathway [7]. Activated MAP kinase ERK1/2 
leads to cell proliferation while p38/JNK leads to stress response [8]. 
When FGF-2 binds to its receptor, ROS are produced by NADPH oxidases (Nox), 
specifically Nox1 [9]. Nox1 is a member of the Nox family of membrane bound 
enzymes. The Nox complex consists of membrane (gp91phox and p22phox) and 
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cytosolic (p40phox, p47phox, p67phox) components, as well as the GTPase Rac. PI3K, 
PKC and Rac are all involved in Nox1 activation following FGF-2 stimulation [6, 10]. 
Nox catalyze superoxide (O2
-
) production by one electron reduction of oxygen (O2) using 
NADPH as an electron donor [9]. Alternatively, Thannickal et al suggested that O2
-
 
production may occur via the GTP binding protein Ras independent of Nox [11]. The low 
ROS doses produced following FGF-2 stimulation may enhance growth factor binding to 
receptors, induce receptor tyrosine kinase phosphorylation, or act as messengers in 
downstream signaling along growth factor pathways [9, 12-17]. 
ROS produced in response to FGF-2 binding acts as signaling molecules leading 
to cell proliferation and migration. In LNCaP (prostate adenocarcinoma) cells, FGF-2 
stimulated ROS production, followed by ERK1/2 and p38 phosphorylation and AP-1 
activation to increase cell proliferation and migration [18]. Another study in human 
coronary endothelial cells suggested that FGF-2 induced cell proliferation and migration 
involved ROS production by NADPH oxidase [19]. ROS production inhibition using the 
NADPH oxidase inhibitor DPI resulted in decreased cell proliferation. 
FGF-2 stimulation also increases FGF-2 expression in endothelial cells, smooth 
muscle cells and cardiac myocytes. Using an in vitro scrape cell injury model, Ku et al 
showed that scrape-released FGF_2 induced 4-10 fold increase in FGF-2 mRNA levels 
[20]. This process may also be mediated by FGF-2 induced intracellular ROS production 
[20-25]. It is thought that cells that have suffered an injury prepare themselves against 
subsequent injuries by synthesizing additional FGF-2. In pulmonary arterial smooth 
muscle cells (PASMC), FGF-2 expression following exogenous FGF-2 addition was 
associated with increased intracellular ROS via NADPH oxidase activation. FGF-2 
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expression was attenuated by the intracellular ROS scavenger N-acetyl cysteine [2]. FGF-
2 release caused by injury has also been shown to enhance FGF-2 expression in intestinal 
epithelial stem cells and human lens cells [26, 27]. 
We hypothesized that FGF-2 released by DBD plasma treatment contributes to 
increased FGF-2 expression and cell proliferation through intracellular secondary ROS 
production. In this study, we measured intracellular ROS production up to 24 hours after 
DBD plasma treatment and related this to FGF-2 release. We further investigated the role 
of intracellular ROS in promoting cell proliferation and FGF-2 expression. Finally, we 
quantified the effects of multiple plasma treatments on FGF-2 release to begin to identify 
a wound treatment regime. 
5.2 Materials and methods 
5.2.1 Cell culture and DBD plasma treatment 
Porcine aortic endothelial cells (PAEC) were cultured and DBD plasma treated as 
described in Chapter 2. 
5.2.2 ROS measurement in cells 
Intracellular ROS was assessed using the Image-iT LIVE Green ROS Detection 
Kit (Invitrogen) as described in Chapter 2. For long time course, cells treated with 4.2 
J/cm
2
 plasma were incubated in complete medium for 0 – 24 hours. 10 ng/ml FGF-2 was 
used as positive control. Following addition, these samples were incubated in complete 
medium for 0 – 30 hours. 
Amplex red was used to measure H2O2 concentration in the extracellular medium 
following plasma treatment, as described in Chapter 2. Confluent cells were plasma 
treated and incubated in complete medium for 0 – 24 hours at 37 °C. 
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5.2.3 Endothelial cell FGF-2 release after multiple plasma treatment 
Confluent endothelial cells on coverslips were treated with plasma (4.2 J/cm
2
) on 
day 0 (plasma at t=0). Following treatment, cells were incubated in serum-free medium 
for 3 hours at 37°C. FGF-2 release peaked at this time in our previous studies [28]. 
Conditioned medium was then assayed for FGF-2 by FGF ELISA (R&D Systems). 
Another set of samples were treated with 4.2 J/cm
2
 plasma and incubated for 24, 48 and 
72 hours. After incubation, these samples were treated again with 4.2 J/cm
2
 plasma dose 
(plasma at t=0 + plasma at t=24, 48 or 72). Following treatment, cells were incubated in 
serum-free medium for 3 hours at 37 °C. Conditioned medium was assayed for FGF-2 by 
FGF ELISA. 
5.2.4 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) for FGF-2 
expression 
RNA was isolated using an RNeasy
TM
 Mini kit (Qiagen) according to the 
manufacturer’s protocol. 400,000 cells were seeded in 12-well plates in DMEM 
supplemented with 5% FBS. Cells were treated with 4.2 J/cm
2
 plasma as described and 
incubated in complete medium for 24, 48 and 72 hours at 37 °C. Cells were then 
trypsinized, centrifuged at 2000g for 5 minutes, and lysed in 100 µl proteinase K and 200 
µl RNase-free water at 53°C for 20 minutes. 300 μl 70% ethanol was added, and samples 
were then mixed and centrifuged in the RNeasy™ Mini column for 15 seconds at 8000g. 
Flow through was discarded, and the column was washed three times with 700 μl RW1 
buffer for 15 seconds at 8000g followed by two washes with 500 μl RPE buffer at 8000g 
for 15 seconds. Finally, samples were spun dry at 8000g for 2 minutes. The column was 
placed in a sterile 1.5 ml collection tube, and 40 µl warm RNase-free water was pipetted 
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into the column and centrifuged for 1 minute at 8000g. Another 40 µl RNase-free water 
was added and centrifuged for 1 minute at 8000g. Samples were then stored at -80°C 
until further analysis. RNA concentration was quantified by Qubit RNA assay kit. 
The FGF-2 primers (forward: 5´-GAGCGACCCTCACATCAAACTACA-3´; 
reverse: 5´-GGAGTATTTCCTCGACCGGTAAGT-3´) were from Integrated DNA 
Technologies (Coralville, Iowa). A master mix was prepared by adding the following 
components: 2 µl primer/probe mix, 1.3 µl activator, 7.4 µl LightCycler® 480 RNA 
Master Hydrolysis probe and 1.0 µl Enhancer. For each sample, 200 ng total RNA was 
combined with master mix and RNA free water in a 96-well plate to get a 20 µl reaction 
volume. The plate was sealed and centrifuged at 3500 rpm for 2 minutes. Reverse 
transcription was carried out at 63°C for 3 minutes, followed by denaturation at 95°C for 
30 seconds. Samples were amplified for 45 cycles at 95°C for 10 seconds, 60°C for 30 
seconds and 72 °C for 1 second. The samples were then cooled down to 40°C. 
LightCycler® 480 quantification software was used for analysis. 
5.2.5 Statistical analysis 
Statistical analysis was performed with Prism software (Graphpad). Data are 
expressed as mean ± SD. Comparisons between two groups were analyzed using 
Student’s t-test, and comparisons between more than 2 groups were analyzed by 
ANOVA. 
5.3 Results 
5.3.1 FGF-2 induced ROS production – time course 
We previously showed (Chapter 2) that plasma treatment increased intracellular 
oxidative stress immediately after treatment. Depending on plasma dose, the intracellular 
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ROS returned to near baseline levels by 3 hours. To determine longer term plasma 
effects, intracellular ROS were measured up to 24 hours after 4.2 J/cm
2
 plasma. Similar 
to our previous short term results, ROS levels decreased 20% by 3 hours following 
plasma and returned to untreated control levels by 6 – 9 hours. However, at 24 hours, 
intracellular ROS peaked a second time. Plasma-treated samples had 26% more ROS 
compared to control (Figure 66). When cells were incubated with an FGF-neutralizing 
antibody, the initial ROS peak was higher (40% increase), occurred later (3 hours), and 
declined more slowly over time. No secondary ROS increase was observed at 24 hours 
with the FGF-2 antibody (Figure 67). 
 
Figure 66: A second intracellular ROS peak occurred 24 hours following DBD plasma treatment. 
Intracellular ROS were measured using carboxy-H2DCFDA (ex/em: 488/520 nm). Cells were treated 
with 4.2 J/cm
2
 plasma. Confocal microscopy images were quantified using Image J. p<0.0001 with 
ANOVA. *p<0.001 and #p<0.05 compared to control. 
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Figure 67: A neutralizing FGF-2 antibody abrogated secondary ROS production. Intracellular ROS 
were measured using carboxy-H2DCFDA (ex/em: 488/520 nm) in plasma-treated cells (4.2 J/cm
2
) 
incubated with an FGF-2 neutralizing antibody (1 µg/ml). Confocal microscopy images were 
quantified using Image J. p<0.0001 by ANOVA 
Cells stimulated with an FGF-2 bolus (10 ng/ml) also showed increased ROS 
within 1 hour after treatment (+27% compared to control) (Figure 68). An additional 27% 
increase in intracellular ROS was observed within 3 hours and ROS then decreased to 
near control level within 6 hours. A secondary intracellular ROS peak was observed at 21 
hours (+60% compared to control). Intracellular ROS then decreased to the control value 
by 30 hours. 
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Figure 68: Exogenous FGF-2 induced 2 intracellular ROS peaks. Intracellular ROS were measured 
using carboxy-H2DCFDA (ex/em: 488/520 nm) in cells treated with FGF-2 (10 ng/ml). Confocal 
microscopy images were quantified using Image J. p<0.0001. *p<0.001, †p<0.01, #p<0.05 compared 
to control. 
In cells, NADPH oxidases generate O2
-
, which is spontaneously or enzymatically 
converted to H2O2. Since O2
-
 is highly reactive and difficult to measure, we measured 
H2O2. Extracellular H2O2 was used as an approximation of intracellular H2O2 
concentration, since H2O2 reaches equilibrium across the cell membrane. Extracellular 
H2O2 doubled immediately following 4.2 J/cm
2
 plasma (Figure 69). The extracellular 
H2O2 concentration then decreased 23% at 3 hours. H2O2 continued to decrease up to 6 
hours, and this H2O2 level remained up to 18 hours. A secondary increase was observed 
at 24 hours, with H2O2 concentration ~60% higher than control. 
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Figure 69: Extracellular H2O2 showed the primary and secondary ROS peaks. PAEC were plasma 
treated in 100 µl SFM, and H2O2 was detected with Amplex red. p<0.0001 by ANOVA. 
5.3.2 Effect of secondary ROS production on FGF-2 induced cell proliferation 
The intracellular ROS scavenger, N-acetyl cysteine (NAC), was added to plasma 
and FGF-2- treated samples 24 hours following the initial treatment to determine whether 
the secondary ROS peak was related to FGF-2 induced angiogenesis. NAC reduced the 
plasma-induced increase in cell number on day 5 from 10 to 7.6 (Figure 70). Similarly, 
while FGF-2 treated cells had 12 times as many cells on day 5 as on day 1, when NAC 
was added, there were only 9.5 times as many cells. 
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Figure 70: Blocking secondary ROS reduced plasma and FGF-2 induced cell proliferation. PAEC 
were treated with 4.2 J/cm
2
 plasma or 10 ng/ml FGF-2, and NAC was used (10 mM) to block 
secondary ROS. Data are represented as fold change in cell number on day 5 compared to day 1. 
*p<0.001 compare to control, **p<0.001 
5.3.3 FGF-2 induced FGF-2 expression 
FGF-2 expression in plasma treated endothelial cells was analyzed by RT-PCR. 
Increased FGF-2 mRNA expression was observed at 24 hours compared to untreated 
control, but then decreased at 48 hours. Cells treated with 4.2 J/cm
2
 plasma dose had 54% 
increased FGF-2 mRNA expression at 24 hours (Figure 71). By 48 hours, FGF-2 mRNA 
expression returned to control levels. It is not clear whether a secondary increase 
occurred at 72 hours. 
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Figure 71: FGF-2 mRNA expression in plasma treated PAEC increased 24 hours post treatment. 
Cells treated with 4.2 J/cm
2
 plasma were incubated for 24, 48 and 72 hours. FGF-2 mRNA expression 
was analyzed by RT-PCR. #p<0.05 compared to control. 
5.3.4 Effect of initial plasma treatment on subsequent plasma-induced FGF-2 
release 
The effects of initial plasma treatment on subsequent plasma-induced FGF-2 
release must be understood to identify a treatment regime for maximum angiogenesis.  
PAEC were treated a second time 24, 48 and 72 hours (plasma at t=0 + plasma at t=24, 
48 or 72) following the initial plasma treatment (plasma at t=0). FGF-2 release increased 
with the treatment gap between first and second plasma treatment. Cells treated a second 
time at 24 hours released the same FGF-2 quantity as cells treated only once. When the 
second plasma treatment occurred 48 and 72 hours after the first treatment, cell-released 
FGF-2 was 1.7 and 2.4 times higher, respectively, compared to FGF-2 released by cells 
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treated a single time (Figure 72). When an FGF-2 neutralizing antibody was added after 
the initial plasma treatment, cell-released FGF-2 after the second plasma treatment 
decreased significantly. 
 
Figure 72: Cell-released FGF-2 increased with the treatment gap between first and second plasma 
treatment. Confluent PAEC were treated with 4.2 J/cm
2
 plasma at time t=0, and then a second time 
at 24, 48, or 72 hours (plasma at t=0 + plasma at t=24, 48 or 72 hours). FGF-2 was measured in 
conditioned medium 3 hours after plasma by FGF ELISA. *p<0.001, †p<0.01 compared to plasma at 
t=0, **p<0.001, ††p<0.01 compared to without FGFAb 
5.4 Discussion 
Wound healing is a complex process involving growth factors, ROS and multiple 
cell types. To achieve faster and better wound healing with plasma treatment, it is 
important to understand the long terms effects of plasma-induced FGF-2 release. We now 
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show that FGF-2 released by DBD plasma treatment induced secondary intracellular 
ROS production. We also show that this secondary ROS was required for plasma and 
FGF-2 induced endothelial cell proliferation. Finally, we demonstrate through multiple 
plasma treatments that the initial FGF-2 release increased subsequent plasma-induced 
FGF-2 release. 
FGF-2 induced both primary and secondary ROS production, whether the FGF-2 
was released through plasma treatment or added exogenously. Few studies document 
intracellular ROS levels over time following growth factor addition. ROS levels were 
measured either shortly after FGF-2 addition or after 24 hour incubation [2, 29, 30]. 
Increased ROS levels were reported in both these cases. We observed an initial ROS peak 
as well as secondary ROS peak following FGF-2 treatment likely due to different 
mechanisms. The initial peak is related to FGF-2 binding to its receptor on the cell 
surface and activating membrane bound NADPH oxidases [6, 9] The secondary ROS 
production is associated with FGF-2 signaling for cell proliferation and FGF-2 expression 
[2]. The initial FGF-2 ROS peak is likely hidden within the initial DBD plasma ROS 
peak in plasma treated samples. The FGF-2 ROS peak may contribute to the slower 
increase in ROS following low dose plasma treatment. 
NADPH oxidase produces O2
-
 in response to FGF-2 stimulation.  The O2
-
 
generated is rapidly dismutated spontaneously or enzymatically into H2O2. Hence H2O2 
measurement can be considered an indirect method of measuring O2
-
. H2O2 increased in a 
similar trend to intracellular total ROS measurement by carboxy-H2DCFDA. This result 
indicates that O2
-
 and/or H2O2 are involved in the initial ROS increase as well as 
secondary ROS production. 
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Blocking secondary ROS inhibited cell proliferation in both plasma-treated 
samples and FGF-2 samples, which indicates that FGF-2 induced cell proliferation 
proceeds through secondary ROS production. Similar results were obtained by Abid et al 
in human coronary endothelial cells, where ROS inhibition decreased FGF-2 induced cell 
proliferation [19]. Furthermore, increased FGF-2 expression is associated with cell 
proliferation. Adenovirus-mediated FGF-2 expression induced cell proliferation and 
angiogenesis in vitro [31]. FGF-2 expression was associated with cell proliferation in 
balloon injured rat arteries [32]. Yoshimura et al showed that FGF-2 expression enhanced 
injury-induced cell proliferation in dentate gyrus cells [33]. 
An FGF-2 neutralizing antibody inhibited secondary ROS production in plasma-
treated samples. However, it also changed the shape of the initial intracellular ROS peak. 
Intracellular oxidative stress rose up to 3 hours when the FGF-2 antibody was used, 
instead of up to 1 hour in control samples. Elevated ROS compared to control was 
maintained up to 21 hours, indicating sustained oxidative stress in the absence of FGF-2. 
FGF-2 protects against stress-induced cell death in many cell types [20, 21, 26, 34-36]. 
Moderate ROS levels activate PI3K signaling while sustained oxidative stress inhibits 
this pathway leading to apoptosis [37]. Under mild oxidative stress conditions, ERK1/2 
signaling also promotes cell survival [38, 39]. Yang et al showed that growth factors such 
as FGF-2 and VEGF protected against oxidative stress in bovine aortic endothelial cells 
(BAEC) and human umbilical vein endothelial cells (HUVEC) by increasing intracellular 
levels of reduced glutathione, an antioxidant [36]. FGF-2 was also shown to protect 
mouse retinal photoreceptor cells against oxidative damage through protein kinase A 
(PKA) activation [40]. FGF-2 additionally protected against oxidative and radiation stress 
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in human embryonic stem cells, increased intestinal crypt survival following radiation 
damage, and decreased radiation-induced apoptosis in endothelial cells [26, 34, 35]. Thus 
FGF-2 release after plasma treatment may both enhance cell proliferation and increase 
cell survival. 
FGF-2 released by plasma-induced sub-lethal membrane damage increase FGF-2 
mRNA expression in endothelial cells. Damaged cells release FGF-2, which induces its 
own expression to protect against further injury [20-24]. Following radiation injury, 
increased FGF-2 mRNA and protein expression were reported in mouse small intestine 
within 12 hours after irradiation, with peak levels occurring 72 – 96 hours later [26]. 
Another study by Ku et al showed increased FGF-2 mRNA expression following FGF-2 
release by scrape-injured cells [20]. 
Our goal was to understand the long term effects of FGF-2 released by cells sub 
lethally damaged by plasma. However, there were many limitations to this study.  
Amplex red H2O2 measurement provides only an index of intracellular H2O2 
concentration and not the actual concentration, which limits understanding of 
physiologically relevant intracellular ROS concentration. FGF-2 release experiment 
following multiple plasma treatments was compared only to single plasma treatment at 
time 0. However, comparing it with FGF-2 release following single plasma treatment at 
time 24, 48 and 72 hours would be more relevant. Also, we did not specifically optimize 
the secondary plasma time or dose following initial plasma treatment. It may not be 
required to treat samples at the 4.2 J/cm
2
 but perhaps a lower dose may be sufficient for 
secondary FGF-2 release. 
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We now show that long term effects of non-thermal DBD plasma induced FGF-2 
release include secondary intracellular ROS production and enhanced FGF-2 release. 
This study helps to better understand the role of plasma-induced FGF-2 release in cell 
survival, intracellular oxidative stress and angiogenesis in vitro. Since multiple plasma 
treatments released more FGF-2 compared to a single plasma treatment, a treatment 
regimen might contribute to faster and improved wound healing. Better understanding of 
these mechanisms will facilitate development of a treatment regime for non-thermal 
plasma enhanced wound treatment. 
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK 
6.1 Summary of principle findings 
Vascularization is essential for normal wound healing, and successful engineering 
of large organs and tissues in vitro [1]. Insufficient angiogenesis leads to chronic non-
healing wounds [2, 3]. In tissue engineering, the size of tissue or organ that can be 
engineered without vascularization is limited to 100 – 200 µm [4, 5]. Current therapeutic 
angiogenesis techniques such as protein, gene and cell-based therapies involve 
application of growth factors such as FGF-2 and VEGF to wound surface and tissue 
engineering scaffold [6-8]. However, these techniques lack the required clinical efficacy 
primarily due to short serum and tissue half-life of growth factors.  
While high doses of reactive oxygen and nitrogen species cause damage to DNA, 
proteins and lipids [9], low ROS/RNS doses have been shown to promote angiogenesis 
by triggering intracellular signaling pathways [10-12]. But precise dosing of these species 
with the help of donors is difficult to achieve due to their pH and temperature dependent 
release kinetics. Plasma, on the other hand, produces ROS/RNS by electronic collision 
with ambient air. Plasma-produced ROS/RNS can then be transported through liquid into 
cells to generate a physiological response such as angiogenesis. A non-thermal DBD 
plasma has been previously shown to induce FGF-2 release by endothelial cells [13]. We 
hypothesized that ROS produced by a non-thermal dielectric barrier discharge (DBD) 
plasma induce angiogenesis in a dose-dependent manner via FGF-2 release. This FGF-2 
release may also induce further intracellular ROS production and FGF-2 expression. We 
also hypothesized that NO produced by a pin-to-hole spark discharge (PHD) plasma 
induce angiogenesis in a dose-dependent manner.  
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In support of these concepts, this thesis consisted of a series of studies designed to 
elucidate the role of ROS/RNS produced by plasma discharge in angiogenesis.  
In Chapter 2, we identified the various ROS/RNS produced by DBD and PHD 
plasma in liquids and cells with the help of ROS/RNS detection probes, donors and 
scavengers. DBD plasma produced ROS such as hydrogen peroxide, superoxide and 
hydroxyl radicals in PBS and serum-free medium. H2O2 and O2- concentrations were 
higher while OH· concentration was lower in PBS compared to serum-free medium.  
Interestingly, we also detected RNS such as peroxynitrite and nitrite in plasma-treated 
PBS. Of these species, H2O2, OH· and ONOO
-
 were also detected intracellularly 
following DBD plasma treatment. PHD plasma produced RNS such as nitric oxide and 
nitrite in PBS. NO was also detected inside endothelial cells following PHD plasma 
treatment.  
In Chapter 3 we determined the angiogenic effects of DBD plasma on endothelial 
cells, specifically proliferation, 2D and 3D migration, and tube formation, as well the key 
plasma ROS primarily responsible for these effects. Cell counts following DBD plasma 
treatment showed optimum cell proliferation for a plasma dose of 4.2 J/cm
2
. This 
increase in cell proliferation was attributed to ROS-induced FGF-2 release. We also 
showed that ROS produced by plasma also enhanced endothelial cell migration and tube 
formation through FGF-2 release. We also demonstrated that H2O2 and OH∙ are the 
primary plasma ROS responsible for the angiogenic effect.  
In Chapter 4 we quantified the angiogenic effects of PHD plasma on endothelial 
cells such as proliferation, migration, and tube formation. We demonstrated that PHD 
plasma NO can be applied to endothelial cells without causing measurable cell viability 
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loss, while enhancing production of the second messenger, cGMP. PHD plasma also 
enhanced endothelial cell proliferation and migration. However, PHD plasma failed to 
induce endothelial tube formation. 
In Chapter 5 we investigated the long term effects of plasma released FGF-2 on 
endothelial cells. We identified that the long term effects of plasma-induced FGF-2 
release included secondary ROS production, FGF-2 expression, and subsequent FGF-2 
release. DBD plasma induced secondary ROS production via FGF-2 signaling, which 
enhanced endothelial cell proliferation.  
This thesis significantly advanced our understanding of specific DBD plasma-
produced ROS and RNS in liquid and endothelial cells. While attempts to understand 
plasma production of ROS/RNS in gas phase has been done through measurements and 
modeling, no previous attempts have been made to systematically quantify them in liquid 
or cells. With the help of specific detection probes, donors and scavengers, we measured 
specific ROS/RNS production in liquid and in cells. We also investigated the influence of 
cell culture medium in modifying plasma ROS/RNS concentrations. This knowledge may 
be used to develop plasma devices that deliver precise doses of specific ROS or RNS.  
Controlled doses of specific ROS or RNS can be achieved by controlling plasma 
discharge properties, including electron density, temperature, and gas composition. 
However, the composition of the treatment medium should also be taken into 
consideration.  
This study discovered the mechanism by which DBD plasma can be used to 
induce angiogenesis. DBD plasma has previously been used primarily to sterilize tissue 
and surfaces, coagulate blood, treat tissue scaffolds, or kill cancer cells [14-19]. Our data 
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further suggested that DBD plasma may be a useful tool for promoting vascularization. 
This study identified DBD plasma ROS as a potential mechanism for FGF-2 release 
leading to enhanced cell proliferation, migration and tube formation, thus inducing 
angiogenesis.  
We further identified NO-induced angiogenesis as a potential mechanism for 
PHD plasma wound healing. The PHD plasma has been previously reported to stimulate 
wound healing [20-25]. However, the mechanism by which it promotes wound healing 
has never been investigated. We showed that NO produced by PHD plasma is transported 
through liquid into cells to induce cGMP production. cGMP is an intracellular second 
messenger which is primarily responsible for NO-induced angiogenesis. We also showed 
that PHD plasma treatment increased endothelial cell proliferation and migration, which 
are two major steps in the angiogenic process. Hence we believe that plasma NO may be 
primarily responsible for PHD plasma-assisted wound healing.  
We were also able to create a cohesive understanding of the ROS/FGF-2 signaling 
loop. Low ROS doses have been shown to induce sub-lethal membrane damage leading 
to FGF-2 release [13]. Several studies have found that FGF-2 upon binding to its receptor 
induced ROS production (primary ROS) by membrane-bound NADPH oxidase [26, 27]. 
It has also been shown separately that ROS produced by NADPH oxidase further induced 
ROS production (secondary ROS) by up regulating mitochondrial Mn-SOD [28]. This 
primary as well as secondary ROS production is important for FGF-2 induced cell 
proliferation [27, 28]. ROS has also been shown to mediate FGF-2 induced FGF-2 
expression [29]. Taken together, it forms a signaling loop connecting ROS and FGF-2, 
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which has not been described previously. Employing DBD plasma and exogenous FGF-
2, we provided this comprehensive picture of ROS/FGF-2 signaling loop.  
This research may facilitate the development of inexpensive, portable, medical 
devices for wound treatment and tissue-engineering application in the future. 
Conventional methods of inducing ROS or releasing FGF-2 such as ionizing radiation, 
pulsed electromagnetic fields and electrical stimulation cause significant damage to 
surrounding healthy tissue. Plasma, specifically non-thermal plasma, is safe, scalable, 
selective and cheap. Due to these advantages, portable plasma devices can be made to use 
in disaster areas, hospitals and in military. They may be used to apply precise ROS doses 
to wounds to release sufficient FGF-2 concentrations to promote angiogenesis. In order to 
promote vascularization in tissue scaffolds, plasma-treated cells can be added. However, 
angiogenesis is a complex process involving multiple growth factors. Hence plasma may 
be used as an adjuvant to conventional vascularization techniques.  
6.2 Suggested future work 
6.2.1 Effect of primary ROS production on FGF-2 signaling for cell proliferation 
and FGF-2 expression 
In Chapter 5, we investigated the effect of secondary ROS induced by DBD 
plasma treatment on FGF-2 signaling for cell proliferation. We showed that blocking of 
secondary ROS using intracellular ROS scavenger N-acetyl cysteine abrogated plasma as 
well as exogenous FGF-2 induced cell proliferation. However, it was not investigated 
whether the primary ROS production is crucial for plasma and FGF-2 induced cell 
proliferation. Hence, we suggest investigating the effect of this primary ROS on FGF-2 
signaling for cell proliferation. Studies have shown that FGF-2 induced FGF-2 expression 
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involves reactive oxygen species production [29]. The primary ROS may play a role in 
inducing FGF-2 expression following plasma-induced FGF-2 release. Hence it would be 
interesting to investigate whether primary ROS production is required for FGF-2 
expression. 
6.2.2 Effect of secondary ROS production on FGF-2 expression 
We showed that DBD plasma enhanced FGF-2 expression 24 hours following 
treatment. ROS production is associated with FGF-2 induced FGF-2 expression [29]. 
However, it is not clear whether the primary ROS, the secondary ROS or both are crucial 
for FGF-2 expression following FGF-2 release. Hence, in addition to investigating the 
effect of primary ROS on FGF-2 expression, it would be worth understanding the role of 
secondary ROS on FGF-2 expression.  
6.2.3 Effect of FGF-2 produced GSH on primary ROS peak duration 
Besides promoting angiogenesis, FGF-2 is shown to protect cells against 
oxidative stress by enhancing the production of the antioxidant reduced glutathione 
(GSH) [30]. In Chapter 5, we showed that DBD plasma induced a primary ROS peak 1 
hour following plasma treatment. Blocking of released FGF-2 using a neutralizing FGF-2 
antibody resulted in an extension of this primary ROS up to 3 hours following treatment 
which then decreased slowly to control values. We believe that blocking of FGF-2 
resulted in an increase in oxidative stress due to reduced GSH production. As future 
work, we would like to suggest investigating the effect of FGF-2 produced GSH on 
primary ROS peak and its extension upon neutralizing FGF-2. 
Overall, this thesis provided valuable insight into plasma production of ROS/RNS 
in liquid and cells and their effect on endothelial cells, specifically angiogenesis. As this 
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work continues, I hope these discoveries will be translated into medical therapies to 
promote angiogenesis in vitro and in vivo. 
 
References 
1. Folkman, J., Angiogenesis. Annu. Rev. Med., 2006. 57: p. 1-18. 
 
2. Martin, A., M.R. Komada, and D.C. Sane, Abnormal Angiogenesis in Diabetes 
Mellitus. Medicinal Research Reviews, 2003. 23(2): p. 117-145. 
 
3. Mulligan-Kehoe, M.J., et al., Antiangiogenic Plasma Activity in Patients With 
Systemic Sclerosis. Arthritis & Rheumatism, 2007. 56(10): p. 3448-3458. 
 
4. Lovett, M., et al., Vascularization Strategies for Tissue Engineering. Tissue Eng 
Part B Rev., 2009. 15(3): p. 353-370. 
 
5. Rouwkema, J., N.C. Rivron, and C.A. vanBlitterswijk, Vascularizaton in Tissue 
Engineering. Trends Biotechnol., 2008. 26(8): p. 434-441. 
 
6. Takeshita, S., et al., Therapeutic Angiogenesis. A Single Intraarterial Bolus of 
Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit 
Ischemic Hind Limb Model. J. Clin Invest, 1994. 93(2): p. 662-670. 
 
7. Hedman, M., et al., Safety and Feasibility of Catheter-Based Local Intracoronary 
Vascular Endothelial Growth Factor Gene Transfer in the Prevention of 
Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic 
Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT). 
Circulation, 2003. 107(21): p. 2677-2683. 
 
8. Tateishi-Yuyama, E., et al., Therapeutic Angiogenesis for Patients with Limb 
Ischaemia by Autologous Transplantation of Bone-marrow Cells: A Pilot Study 
and a Randomised Controlled Trial. The Lancet, 2002. 360(9331): p. 427-435. 
 
9. Halliwell, B. and J.M.C. Gutteridge, Free Radicals in Biology and Medicine. 4 ed. 
2007, New York: Oxford University Press. 
191 
 
 
10. Ushio-Fukai, M. and R. Alexander, Reactive Oxygen Species as Mediators of 
Angiogenesis Signaling. Role of NAD(P)H oxidase. Molecular and Cellular 
Biochemistry, 2005. 264(1): p. 85-97. 
 
11. Colavitti, R., et al., Reactive Oxygen Species as Downstream Mediators of 
Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR. 
Journal of Biological Chemistry, 2002. 277(5): p. 3101-3108. 
 
12. Martin, K.R. and J.C. Barrett, Reactive Oxygen Species as Double-Edged Swords 
in Cellular Processes: Low-Dose Cell Signaling Versus High-Dose Toxicity. 
Human and Experimental Toxicology, 2002. 21(2): p. 71-75. 
 
13. Kalghatgi, S., et al., Endothelial Cell Proliferation is Enhanced by Low Dose 
Non-Thermal Plasma Through Fibroblast Growth Factor-2 Release. Ann. 
Biomed. Eng., 2010. 38(10): p. 748-757. 
 
14. Fridman, G., et al., Blood Coagulation and Living Tissue Sterilization by 
Floating-Electrode Dielectric Barrier Discharge in Air Plasma Chem. Plasma 
Process., 2006. 26: p. 425-442. 
 
15. Kuo, S.P., et al., Contribution of a Portable Air Plasma Torch to Rapid Blood 
Coagulation as a Method of Preventing Bleeding. New J. Phys., 2009. 11: p. 
115016. 
 
16. Sensenig, R., et al., Non-thermal Plasma Induces Apoptosis in Melanoma Cells 
via Production of Intracellular Reactive Oxygen Species. Annals of Biomedical 
Engineering, 2011. 39(2): p. 674-687. 
 
17. Sladek, R.E.J., et al., Plasma Treatment of Dental Cavities: A Feasibility Study. 
IEEE Trans. Plasma Sci., 2004. 32(4 ): p. 1540-1543. 
 
18. Soloshenko, I.A., et al., Sterilization of Medical Products in Low-Pressure Glow 
Discharges. Plasma Physics Reports, 2000. 26(9): p. 792-800. 
 
192 
 
19. Yildrim, E.D., et al., Effect of Dielectric Barrier Discharge Plasma on the 
Attachment and Proliferation of Osteoblasts Cultured Over Poly(ε-caprolactone) 
Scaffolds Plasma Process Polym., 2008. 5(4): p. 397. 
 
20. Gostev, V. Cold Plasma in Biological Investigations. in NATO Advanced Study 
Institute (ASI): Plasma Assisted Decontamination of Biological and Chemical 
Agents. 2007. Cesme, Turkey. 
 
21. Gostev, V. and D. Dobrynin. Medical Microplasmatron in 3rd International 
Workshop on Microplasmas 2006. Greifswald, Germany. 
 
22. Misyn, F., et al., Experimental Studying of Bactericidal Action of Cold Plasma, in 
Diagnostics and treatment of infectious diseases. 2000: Petrozavodsk, Russia. 
 
23. Misyn, F.A., et al., Experimental Investigation of Bactericidal Influence of 
‘‘Cold’’ Plasma and Its Interaction with Cornea, in Diagnostics and treatment of 
infectious diseases. 2000: Petrozavodsk, Russia. 
 
24. Misyn, F.A., et al., Experimental Curing of Bacterial Ulcerous Keratitis with 
“Cold” Plasma in Diagnostics and treatment of infectious diseases. 2000: 
Petrozavodsk, Russia. 
 
25. Misyn, F.A. and V.A. Gostev, ”Cold” Plasma Application for Curing of Eyelid 
Phlegmon in Diagnostics and treatment of infectious diseases. 2000: 
Petrozavodsk, Russia. 
 
26. Petry, A., M. Weitnauer, and A. Gorlach, Receptor Activation of NADPH 
Oxidases. Antioxidants & Redox Signaling, 2010. 13(4): p. 467-487. 
 
27. Abid, M.R., et al., NADPH Oxidase Activity is Required for Endothelial Cell 
Proliferation and Migration. FEBS Letters, 2000. 486(3): p. 252-256. 
 
28. Ushio-Fukai, M., Redox signaling in angiogenesis: Role of NADPH oxidase. 
Cardiovascular Research, 2006. 71(2): p. 226-235. 
 
193 
 
29. Black, S.M., J.M. DeVol, and S. Wedgwood, Regulation of Fibroblast Growth 
Factor-2 Expression in Pulmonary Arterial Smooth Muscle Cells Involves 
Increased Reactive Oxygen Species Generation. American Journal of Physiology 
- Cell Physiology, 2008. 294(1): p. C345-C354. 
 
30. Yang, W. and D.P. de Bono, A New Role for Vascular Endothelial Growth Factor 
and Fibroblast Growth Factors: Increasing Endothelial Resistance to Oxidative 
Stress. FEBS Letters, 1997. 403(2): p. 139-142. 
  
194 
 
VITA 
 
 
 
 
Krishna Priya Arjunan was born on August 6, 1982 in Kerala, India. She received her Bachelor of 
Technology (B.Tech.) degree in Electronics and Telecommunication Engineering from Lal Bahadur Shastri Institute of 
Technology, Kerala, India in May 2005. Her keen interest in application of engineering techniques in medicine, and her 
penchant for improving the quality of life of people led her to the decision of obtaining an advance degree in 
biomedical engineering. In the fall of 2005, she was admitted into the Masters degree program in Biomedical 
Engineering at Drexel University. Under the guidance of Drs. Alexander Fridman and Alexander Gutsol, she 
investigated the inactivation of microorganisms in water treated with pulsed plasma discharges. To further explore the 
applications of plasma in medicine, specifically plasma-induced angiogenesis, she switched into the doctoral program 
and worked under the supervision of Dr. Alisa Morss Clyne. During her time there, she received several honors 
including Dean’s fellowship, NSF travel grants, Drexel University Student Travel Grant and NAVBO scholarship. She 
has authored several papers, proceedings and given talks at prestigious conferences and meetings. She also held several 
graduate leadership positions including Treasurer of Shor, an Indian a cappella group in Drexel University. She 
received her Ph.D. in Biomedical Engineering from Drexel University in 2011. 
 
Selected publications 
1. Hydroxyl radical and hydrogen peroxide are primarily responsible for dielectric barrier discharge plasma induced 
angiogenesis. K. Arjunan, A. Morss Clyne.  Plasma Process. Polym., Oct 4, 2011. DOI:10.1002/ppap.201100078. 
(Early view) 
2. Non-thermal dielectric barrier discharge plasma induces angiogenesis through reactive oxygen species. K. 
Arjunan, G. Friedman, A. Fridman, A. Morss Clyne. J. R. Soc. Interface, Jun 8, 2011. 
DOI:10.1098/rsif.2011.0220. (Firstcite online) 
3. Direct and controllable nitric oxide delivery into biological media and living cells by a pin-to-hole spark discharge 
(PHD) plasma.  D. Dobrynin*, K. Arjunan*, A. Fridman, G. Friedman, A. Clyne (* Both authors contributed 
equally). J. Phys. D. Appl. Phys., 2010, 44, p.075201. DOI: 10.1088/0022-3727/44/7/075201. 
4. Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species. 
R. Sensing, S. Kalghatgi, E. Cerchar, G. Fridman, A. Shereshevsky, B. Torabi, K. Arjunan, E. Podolsky, A. 
Fridman, G. Friedman, J. Azizkhan Clifford, A. D. Brooks.  Ann Biomed Eng, 2010, 39(2), 674 – 687. DOI: 
10.1007/s10439-010-0197-x. 
 
